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Summary
Phospholipase D (PLD; EC 3.1.4.4) catalyses the hydrolysis of the phosphate 
ester bond of phospholipid molecules, releasing the hydroxyl containing head group 
with the concomitant formation of phosphatidic acid (PtdOH). Evidence now exists 
that PLD catalyses the hydrolysis of membrane phospholipids, particularly PtdCho, in 
an agonist-dependent manner. This may serve as a novel source of the established 
second messenger diacylglycerol with its immediate lipid product, phosphatidic acid, 
functioning as a putative second messenger. The relationship between agonist- 
stimulated PLD activity in vivo and observed in vitro activity remains unclear. This 
study examines the purification and characterisation of membrane-associated PtdCho- 
PLD activity from bovine spleen.
PLD activity was primaiily associated with the membrane compartment of the 
bovine spleen homogenate. Incubation of these freeze-thawed membranes at high pH 
resulted in efficient solubilisation of the membrane-associated PLD activity. 
Purification of the solubilised PLD was subsequently investigated. Use of cation- 
exchange chromatography resolved two PtdCho-hydrolysing PLD activities, the 
major one being further purified by successive chromatographic separation on 
heparin-agarose, hydroxyapatite, cation-exchange and gel-filtration chromatography. 
SDS-PAGE revealed the final protein preparation to be heterogeneous and it was not 
possible to identify a particular protein that co-migrated with the PLD activity on gel- 
filtration which displayed an apparent native molecular weight of 69 kDa. The 
solubilised PLD remains to be purified to homogeneity .
Using mixed micellar methodology the catalytic activity of the partially 
purified enzyme towards PtdCho was characterised. At all substrate concentrations 
the post heparin enzyme displayed pseudo-first order kinetics and values for Vmax 
and Km could not be deteimined by this assay methodology, however, the reaction 
velocity displayed a pH optimum of 7.0 and was independent of Ca^+ and Mg^+. 
Finally, investigation of catalytic activity towards PtdCho, PtdEtn, Ptdlns and PtdSer 
confirmed the partially purified preparation to be a distinct PLD activity that was
X lll
selective between the major phospholipids and displayed substrate specificity towards 
PtdCho.
XIV
Chapter 1 
Introduction.
Chapter 1, Introduction.
Signal tranduction mechanisms provide the cell with a method with which to 
sense and respond to their extracellular enviroment. Thus, in response to a range of 
stimuli various physiological processes such as differentiation and proliferation can be 
both induced and controlled in a co-ordinated manner. The presence of a particular 
extracellular signal in the extracellular enviroment is often detected by a specific cell 
surface membrane receptor. Occupation of this receptor leads to the initiation of a 
signal transduction cascade and the generation of second messenger molecules. Whilst 
there are many extracellular stimuli, there are relatively few second messenger systems 
and this may reflect a degree of evolutionary constriction within signal transduction 
processes. However, it is becoming increasingly apparent that cells respond to multiple 
agents by activating multiple second messenger systems that can act in concert to 
potentiate, synergise or antagonise specific cellular responses (see Malarkey et al, 
1995). The second messenger systems involved have been extensively examined and 
include adenylate cyclase-mediated elevation of intracellular cAMP, activation of 
tyrosine kinases and the hydrolysis of membrane phospholipids (see Billah & Anthes, 
1990; Berridge, 1993; Dennis, 1994; Malarkey et al, 1995). The introduction to this 
thesis will focus upon the regulation of agonist-stimulated membrane phospholipid 
hydrolysis, particularly that of phospholipase D-catalysed hydrolysis of 
phosphatidylcholine and its functional significance.
1.1 Agonist-Stimulated Turnover of Phospholipids.
1.1.1 Regulation of Agonist-Stimulated Hydrolysis of Phosphatidylinositol-4,5 
Bisphosphate.
The early work of Hokin & Hokin in the 50s and the seminal work of Michell, 
Benidge, Irvine and co-workers in the late 70s and early 80s identified the hydrolysis of 
inositol-containing phospholipids as a universal signalling pathway activated in 
response to calcium mobilising agonists (Hokin & Hokin, 1953; Hokin & Hokin,
1958a; Hokin & Hokin, 1958b; Hokin etal,  1958a; Hokin etal,  1958b; Berridge &
Irvine, 1989). Michell (1974) proposed that the receptor-mediated elevation of 
intracellular calcium concentrations ([Ca^+]i)was in fact consequent to agonist- 
stimulated Ptdlns hydrolysis. This resultant elevation of [Ca^+ji as a consequence of 
Ptdlns(4, 5)P% hydrolysis is now recognised as being associated with the initial cellular 
actions of many growth factors, hormones and neurotransmitters upon a variety of cell 
and tissue types (reviewed by Berridge & Irvine, 1989; Whitman & Cantley, 1988, 
Cockcroft & Thomas, 1992; Michell, 1992; Benidge, 1993). Following receptor 
activation, hydrolysis of Ptdlns(4, 5)P2 is catalysed by a phosphoinositide-specific 
phospholipase C (PLC) to generate two second messengers, inositol 1,4,5- 
trisphosphate (Ins(l,4, 5)P3) and sn 1, 2-diacylglycerol (DAG).
Ins(l, 4, 5)P3 has been identified as the molecule responsible for stimulating 
the release of intracellular Ca^+ (Streb et al, 1983) from the hormone-sensitive 
calcium store in the smooth endoplasmic reticulum, by binding to its own intracellular 
receptor (reviewed by Benidge & Imne, 1984; Berridge & Irvine, 1989). In parallel, 
the production oîsn~l,  2-diacylglycerol, acting in concert with phosphatidylserine 
(PtdSer) and Ca^+, activates protein kinase C (PKC) (Nishizuka, 1984, 1986, 1988; 
Parker et al, 1989). Consequently, elevation of sn -1, 2-diacylglycerol is responsible 
for the increase in PKC activity associated with the action of Ca^+-mobilising 
agonists.
As intracellular second messengers both are rapidly removed by metabolism 
involving a number of specific enzymes. Ins(l, 4, 5)P3 is sequentially 
dephosphorylayted by a series of phosphatases to free inositol making it available for 
reincorporation into Ptdlns (see Berridge & Iiwine, 1989). Ins(l,4 ,5)P3 may also be 
phosphorylated to lns(l, 3,4, 5)P4 which itself may play a role in regulating 
intracellular calcium homoestasis. This tetrakisphosphate can be both broken down to 
inositol or further phosphoiylated to higher inositol phosphates (Berridge, 1993).
Coordinate resynthesis of the phosphoiniositides involves a number of 
integrated phosphorylation reactions catalysed by a multitude of kinases. sn~l, 2- 
diacylglycerol is initially phosphorylated to phosphatidic acid by DAG kinase in
readiness for commited incorporation into the resynthetic pathway for 
phosphoinositides (see Berridge & Irvine, 1989). Phosphatidic acid (PtdOH) is then 
condensed with cytidine 5'-triphosphate (CTP) to form cytidine 5'- 
monophosphate(CMP)-PtdOH, catalysed by CMP-PtdOH synthetase. Ptdlns Synthase 
catalyses the reaction of the generated CMP-PtdOH with free inositol derived from 
the inositol phosphate pool to produce Ptdlns. This then serves as the precursor of the 
polyphosphoinositides. The steady state levels of Ptdlns, Ptdlns(4)P and Ptdlns(4,
5)P2 are regulated by the action of specific kinase and phosphatase activities 
including, Ptdlns 4-kinase, PtdIns(4)P 5-kinase, PtdIns(4)P phosphomonoesterase and 
Ptdlns(4, 5)P2 phosphomonoesterase (see Majerus eta l,  1986; Benidge & Irvine, 
1989; Carpenter & Cantley, 1990). The relative sizes of these pools are such that 
approximately 90% of total phosphoinositides is in the form of Ptdlns. The 
equilibrium is transiently disturbed upon agonist stimulation of PLC activities that 
metabolise Ptdlns(4, 5)P2 and detectable decreases in the Ptdlns(4, 5)Ps pool have 
been measured. However, the equilibrium is quickly restored. Therefore, it is apparent 
that hydrolysis and resynthesis of the phosphoinositides occurs by means of an 
integrated cyclical pathway termed the 'Ptdlns-cycle'.
Outwith the 'Ptdlns-cycle', Ptdlns(4, 5)P2 may also be further phosphorylated 
to produce Ptdlns(3, 4, 5)Pg (Whitman eta l,  1988; Auger e ta l,  1989). This reaction 
is catalysed by Ptdlns 3-kinase, primarily a heterodimer consisting of an 85kDa and a 
1 lOkDa subunit; however, several isoforms of this enzymic activity are now known to 
exist (L. Stephens, personal communication). The function of Ptdlns(3, 4, 5)?3 in 
cells is not clear, although a role for this lipid has been reported in the regulation of 
platelet aggregation, histamine secretion, translocation of glucose transporters and 
membrane ruffling (reviewed by Stephens, 1994). These reports perhaps point to a 
general role for this lipid in cytoskeletal regulation.
Several phosphoinositide-specific phospholipase C isoenzymes are present in 
mammalian tissues, as deduced from protein isolation and molecular cloning studies 
(reviewed by Rhee e ta l,  1989; Meldmm e ta l,  1991, Cockcroft, 1992). These
activities have been categorised into four groups: a, p, j  and 5. The a  subfamily 
represents a number of Ptdlns-PLC activities classified by an apparent molecular 
mass of between 60-70 kDa (Rhee et al, 1989). Cloning of a cDNA for one of these 
60kDa acivities has been reported, though its authenticity has been debatable as its 
expression did not encode any functional Ptdlns-PLC activity comparable to the 
expression of cDNA encoding p, y  and ô isoforms (Bennet & Crooke, 1987; Meldrum 
et al, 1991). Further, the PLCa activities possess little sequence or structural
similarity to cloned PLCp, y and 6 (Meldrum et al,  1991). The classification of Rhee 
et al (1989) gave rise to the subdivision of the Ptdlns-PLC activities previously 
purified from bovine brain; the Pi to conespond to the 154 kDa activity, j i  to the 145 
kDa activity and ôi to the 85 kDa activity. Further purification and cloning studies 
resulted in description of more members of these sub-families, designated p2, p3 and 
p4, Y2, Ô2 and 63 based upon analysis of apparent sequence and immunoreactivity. In 
summary, the Ptdlns-PLC isoforms exist as a complex family of inter-related 
activities allowing diverse agonist signalling by means of varied phosphoinositide 
hydrolysis.
For agonists whose receptors comprise seven transmembrane spanning
domains, the signal generated by the agonist receptor complex is well recognised to
be modulated and transduced across the plasma membrane by members of the
heterotrimeric guanine nucleotide binding proteins (G-proteins) (reviewed by
Cockcroft, 1987). This family of proteins, consisting of a, p and y subunits, regulate a
number of intracellular effector molecules (Simon et al, 1991). Further, these
proteins have been airanged into four sub-classes based upon the primary sequence
.identity of their respective a-subunits (Simon etai,  1991). Within this subdivision, :
the Gaq class members were identified as the G-proteins responsible for the 
regulation of the Ptdlns-PLC activity (Gutowski et ai, 1991; Smrcka et al., 1991;
Taylor et al., 1991; Wu et al,  1992a). Partially purified Ptdlns-PLC could be 
activated by a mixture of purified G aq/G an from GTPyS treated bovine liver plasma 
membranes (Taylor et al, 1990). Moreover, when these activators were reconstituted
with individually purified Ptdlns-PLC isoforms, they specifically activated the pi 
isoform, with no effect upon the catalytic rates of Ptdlns-PLCyi nor Ptdlns-PLC ôi 
(Taylor et ai,  1991). Similarly, the Ptdlns-PLCpi homologue purified from turkey 
erythrocytes could be activated by the Gttq (G an) homologue from the same source 
(Waldo e ta i,  1991).
The regulation of catalysed Ptdlns(4, 5)P2 hydrolysis has been refined further 
by the ability of heterotrimeric G-protein py subunits to activate Ptdlns-PLC isoforms 
(see Clapham & Neer, 1993). Activation of an unidentified Ptdlns-PLC isoform was 
first observed in a range of cytosolic extracts from bovine liver, human and bovine 
peripheral neutrophils and HL-60 granulocytes in a similar manner to a PLC purified
from turkey erythrocytes (Blank et ai, 1992; Boyer et al, 1992; Camps et al, 1992).
:Moreover, Park et al (1993) described ordered activation of individual purified !
Ptdlns-PLC isofonns upon reconstitution with Py subunits in lipid vesicles containing 
Ptdlns(4, 5)P2- PLCp2 and PLCps were activated whilst PLCPi was activated to a 
lesser extent. Efforts to demonstrate the activation of mammalian Ptdlns-PLC activity 
by pertussis toxin-sensitive a  subunits has been unsuccessful (Blank et al, 1992;
Camps et al, 1992). Further, agonist-mediated initiation of PLCpg activity has been 
reported in Cos cells transfected with muscarinic receptors, but only if py subunits 
were co-expressed (Katz et al, 1992). The fourth member of the mammalian p-type 
Ptdlns-PLC family has recently been purified, sequenced and cloned (Lee et al,
1993) and in common with the other three sub-family members is activated by all the 
a  subunits of the Gq class heterotrimeric G-proteins yet is unresponsive to py subunits 
in a similar manner to the Pi isoform (Jiang et al,  1994; Lee et al, 1994). 
Consequently, this may represents the mechanism by which pertussis toxin-sensitive 
heterotrimeric G-proteins regulate catalysed Ptdlns(4, 5)?2 hydrolysis.
Î
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Ptdlns-PLCy activities are regulated by receptor or non-receptor tyrosine 
kinases (reveiwed by Rhee & Choi, 1992). Growth factor receptors (R) (eg. EGFR,
PDGFR & NGFR) bind cognate ligands and thus activate their intrinsic tyrosine 
kinase activités leading to Ptdlns-PLCy phosphorylation and thus enhanced rates of
__
Ptdlns(4, 5)P2 hydrolysis. In a number of cell types EGF-mediated activation of PLCy 
requires the involvement of a pertussis-toxin sensitive Gi protein in an undefined role 
(see Rhee, 1991 and references therein).
Receptors that do not posses intrinsic kinase activity can in a number of 
instances also activate PLCy isoforms. This occurs through the recruitment and 
activation of non-receptor/soluble tyrosine kinases, typified by the Src family, eg. the 
T-cell receptor/CD3 complex. This complex does not posses intrinsic tyrosine kinase 
activity, but upon suitable activation induces tyrosine phosphorylation and activation 
of PLCy (see Rhee, 1991 and references therein)
A number of agonists that utilise G-protein coupled receptors can also 
stimulate the tyrosine phosphorylation and activation of PLCy. In CHO cells 
transfected with the M5 subtype muscarinic receptors, carbachol stimulated the 
tyrosine phosphorylation of PLCy (Gusovsky eta l,  1993). This was inhibited by 
receptor operated Ca^+ channels blockers and implicates receptor-mediated Ca^ "*' 
entry and subsequent tyrosine kinase activity in the activation of PLCy. Similar 
observations have been described in Angiotensin II (All)-stimulated smooth muscle 
cells (Marrero et al, 1994; 1995) and consequently may represent an alternative 
mechanism of activating PLCy-catalysed phosphoinositide hydrolysis.
In contrast to the P and y isoforms, the cellular mechanisms by which Ptdlns- 
PLCÔ isoforms are regulated is less clear. The 6 isoforms contain Ca^+-binding EF- 
hand motifs (Bairoch & Cox, 1990) and therefore the regulation by Ca^+ in vivo has 
been investigated. In CHO cells overexpressing PLCÔ1, thrombin-stimulated 
phosphoinositide hydrolysis was completely inhibited by Ca^+ chelation, while 
addition of calcium ionophore (ionomycin) stimulated phosphoinositide hydrolysis 
(Banno et al, 1994). However, the precise mechanisms by which PLC51 is activated 
remain unclear and the elucidation of this may require further reconstitution 
experiments.
'■«f;
1,2 Receptor-Generated sn -1 ,2-DiacylgIycerol from Non-PtdIns(4, 5)P2 Sources: 
Phosphatidylcholine As A Source of Sustained sn -1 ,2-DiacyIglycerol.
In a number of cell types, including fibroblasts and vascular smooth muscle 
cells, it was recognised that agonist-stimulated formation of Ins(l, 4, 5)?3 did not 
correlate with the formation of DAG. Ins(l, 4, 5)?3 formation was transient whilst 
DAG formation was sustained (Griendling etaL, 1986, Cook etal., 1990; Sunako et ai,
1990; Cook & Wakelam, 1992; Plevin & Wakelam, 1992). The transient nature of the 
Ins(l, 4, 5)P3 signal was not due to enhanced removal of Ins(l, 4, 5)P3 by phosphatase 
or kinase activities but reflected a rapid desensitisation of phosphoinositide hydrolysis 
(eg. Plevin & Wakelam, 1992). This suggested that a lipid source other than 
PtdIns(4 ,5)P2 provided the source of the sustained DAG. Consequently the source of
'this secondaiy DAG phase has been extensively examined.
Initial studies in thrombin-stimulated IIC9 fibroblasts (Wright et ai, 1988) 
revealed biphasic formation of DAG, with only the first phase associated with the 
generation of Ins(l, 4, 5)P3. A similar profile of DAG generation was also reported in 
All- and endothelin-stimulated smooth muscle cells (Griendling e ta l ,  1986; Sunako et 
al,  1989), vasopressin-stimulated fibroblasts (Huang & Cabot, 1990a) and bombesin- 
stimulated Swiss 3T3 fibroblasts (Cook e ta l,  1990). Thus, dissociation of Ins(l, 4,
5)P3 foiTnation from DAG generation has been observed in multiple cell types and has 
questioned the nature and source of the sustained phase of DAG generation.
The measurement of [^H]-water soluble metabolites released from prelabeUed
■phospholipids allowed the identification of PtdCho as the putative source of this DAG 
in a number of cell types upon receptor activation (Besterman et al, 1986a; Cabot et 
al,  1988; Cook & Wakelam, 1989; Martin & Michaelis, 1989). DAG molecular species 
analysis has further pointed to PtdCho as the phospholipid source; however, this did not 
identify unequivocally the mechanism by which the DAG was generated following 
receptor stimulation. Potentially a PLC- or phospholipase D (PLD) could have 
catalysed the reaction.
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By means of combined DAG derivatisation and gas liquid chromatography 
techniques Pessin & Raben (1989) described the acyl chain content of different DAGs 
present at different time points during a-thrombin stimulation in nC9 fibroblasts. The 
DAG generated during the early initial transient phase (at 15 secs) displayed 
molecular species with acyl content similar to that of the phosphoinositides which 
reflected the activation of Ptdlns-PLC following receptor activation. During the 
sustained phase (5min-lh) these appeared to be similar to the acyl chain profile of 
PtdCho in unstimulated cells, consistent with the observed release of [3H]-chohne 
from these cells. Based upon this comparison, these workers proposed that PtdCho 
seiwed as the putative source of this sustained DAG. EGF and PDGF stimulated 
sustained DAG generation also apparently derived from PtdCho (Pessin & Raben,
1989).
In fMet LeuPhe-stimulated neutrophils biphasic DAG generation also occured 
and corresponded to initial phosphoinositide hydrolysis and further sustained 
phospholipid hydrolysis (Thompson et ai, 1990). When measured quantitatively, the 
amount of DAG formed during the sustained secondary phase was similar to the 
amount of free choline generated. This suggested that all of this DAG generated was 
purely PtdCho derived.
Extensive molecular species analysis of DAGs generated upon agonist 
stimulation in a wide variety of cells have been conducted. In general, these have 
concluded that the DAG of the initial early phase contains fatty acids predominantly 
found in the phosphoinositides and the second phase those predominantly found in 
PtdCho (see Besterman et ai, 1986a; Bocckino et ai, 1987a; Kennerly, 1987; Pessin et 
al,  1990; Huang & Cabot, 1990a; Van Blitterswijk et al, 1991; Pettitt & Wakelam, 
1993). Although these studies represent the identification of PtdCho as a major 
alternative source of DAG it is important to emphasise that other phospholipids such as 
PtdEtn have been reported to be sensitive to phospholipase-catalysed hydrolysis (Kiss 
& Anderson, 1990) and may therefore also contribute to the observed sustained phase.
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Fig 1.1 Schematic representation of PtdCho and the potential sites for cleavage 
catalysed by hydrolytic phospholipases PLA2 , PLC and PLD. and R2  
represent the hydrocarbon chains of fatty acids.
1.3 Receptor-Mediated Phosphatidylcholine Hydrolysis Catalysed by 
Phospholipase D.
In mammals, PtdCho can be metabolised by a number of different 
phospholipases including PLA2, PLC and PLD (see Fig 1.1). PLA2 enzymes are 
active against the fatty acid at the n-2 position of the phopholipid glycerol backbone 
PtdCho-specific PLC catalyses the formation of DAG and phosphocholine directly. A 
PLC catalysed hydrolytic event may be the predominant pathway by which sustained 
DAG generation occurs. However, since PtdOH can be rapidly dephosphorylated by 
phosphatidate phosphohydrolase (PAP), this hydrolytic pathway could serve as an 
alternative pathway of sustained DAG formation (Fig 1.1). This has been investigated 
further by examination of the time courses of the foimation of both PtdCho-derived 
lipid molecules and their water soluble co-products. However, as the PtdCho-deiived 
molecules are substrates for PAP, DAG kinase and choline kinase enzymes (see 
Pelech & Vance, 1989) careful interpretation of their formation and interconversion 
must be made. PtdCho-hydrolysis would appear to occur predominantly by means of 
a PLD-catalysed reaction though evidence is apparent for receptor-stimulated 
PtdCho-PLC activation (see below).
■ ' :In neutrophils stimulated with fMetLeuPhe, phorbol 12-myristate 13-acetate 
(PMA) or Ca^+ ionophore it was reported that not only sn-1, 2-diacylglycerol is 
formed, but also l-O-alkyl-2-acylglycerol (Agwu et ai, 1989; Tyagi et a i,  1989).
Examination of the 'parent' PtdCho showed that m-l-O-alkyl-2- 
acylglycerophosphocholine constitutes up to 70% of the total PtdCho pool, a 
characteristic common to other haematopoeitic cells (eosinophils and macrophages,
Mueller et ai, 1982; Ojima-Uchiyama etal., 1988). By labelling of the PtdCho pool 
specifically with l-O-alkyl-2-lyso-p^P]PtdCho without incorporating [32p] into the 
cellular ATP pool the subsequent observation of 1 -0-alkyl[^^P]Ptd0H formation has 
identified agonist-stimulated PLD activation in haematopoetic cells (see Billah et al.,
1989a & b; Agwu et ai, 1989; Billah & Anthes, 1990).
Ï
1 0
Phosphatidylcholine
choline
O"
PLD
choline
Phosphatidyl-ENZYME
(a)
Water
Phosphatidic Acid
Primary alcohol
(b)
Phosphatidylalcohol
Phosphatidic Acid Phos phohydrolas e
1,2-Diradylglycerol
Fig 1.2 Schematic representation of PLD-catalysed hydrolytic and transphosphatidylation reactions: (a) the coupled PLD/phosphatidic acid phosphohydrolase pathway and (b) the transferase pathway responsible for formation of phosphatidylalcohols in the presence of primary aliphatic alcohols.
By direct labelling of cells with [32p]-phosphate, receptor-stimulated PtdOH 
foimation has been observed. The specific activity of the [32p]PtdOH formed upon 
fMetLeuPhe stimulation of neutrophils was significantly less than the cellular ATP
pool (Cockcroft, 1984) and therefore argued against the formation of PtdOH as a 
result of DAG kinase-catalysed reaction. If this was indeed true then the source of 
PtdOH was from PLD catalysed phospholipid hydrolysis. It must be noted in this 
example that the obseiwation of [3^P]PtdOH formation represents total agonist- 
stimulated PLD activity and is not necessarily restricted to PtdCho.
Evidence of receptor-regulated PLD activation has been demonstrated by 
exploitation of a catalytic property unique to this phospholipase. Dawson (1967) 
described the ability of PLD to catalyse the formation of phosphatidylalcohols in the 
presence of short chain aliphatic primary alcohols by means of a reaction termed 
transphosphatidylation. Formation of these molecules in an agonist-dependent manner 
is at the 'expense* of PtdOH, whereby the primaiy alcohols rather than water act as the 
preferential nucleophilic acceptors (see Fig 1.2). This feature of PLD activation was 
utilised in the initial identification of agonist-stimulated PLD activity in mammalian 
cell types (Bocckino et al, 1987a & b; Tetterborn & Mueller, 1988; Liscovitch, 1989; 
Liscovitch & Amsterdam, 1989). Phosphatidylalcohols are poor substrates for PtdOH 
phosphohydrolase (PAP) (Metz & Dunlop, 1991) and therefore accumulate within the 
cell. PLD-catalysed formation of these compounds has been measured by either the 
incorporation of radiolabelled primary alcohols into unlabelled phosphatidyl moeities 
or incorporation of unlabelled primaiy alcohol into previously labelled phosphatidyl 
moeities. This has involved the use of [^HJbutan-l-ol in neutrophils or cell free 
fractions (eg. Randall et al, 1990; Horwitz & Davis, 1993) or metabolic labelling of 
PtdCho with saturated fatty acids such as palmitate (eg. Martin & Michaelis, 1989, 
Cook et a l,  1991). As previously described, cells of haematopoetic origin have also 
been successfully labelled with l-D-alkyl-2-lyso-pH]PtdCho or l-O-alkyl-2-lyso- 
[32p]PtdCho which is preferentially incoiporated into PtdCho. This has allowed 
observation of both pH]- and [^^P]-labelled phosphatidylalcohol formation in the
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presence of ethanol in a number of studies (Pai et al, 1988a & b; Anthes et a l,  1989, 
1991; Billah et al, 1989a & b). Hence, fonnation of these compounds has served as 
both a selective and definitive assay for agonist-dependent PLD activiation in vivo.
The use of primary alcohols to 'trap' phosphatidyl moeties, thereby inhibiting 
PtdOH formation and sequential DAG formation by the PLD/PPH pathway, permits 
the relative contribution of PLD-derived PtdOH to the sustained phase of DAG 
production and a number of physiological responses to be determined. For instance, 
following pretreatment with 30mM butanol, DAG formation in bombesin-stimulated 
Swiss 3T3 fibroblasts and vasopressin-stimulated A10 vascular smooth muscle cells 
DAG formation were inhibited 30 and 40-50% respectively (Cook et al,  1991; Plevin 
& Wakelam, 1992). This has questioned the contribution of PLD-catalysed PtdCho 
hydrolysis to the sustained phase of DAG generation and focused attention upon other 
alternative phospholipid sources of DAG.
1.4 Regulation of Receptor-Mediated Phosphatidylcholine-Phospholipase D 
Activity.
The regulation of agonist-stimulated PLD activation involves multiple 
mechanisms. A number of receptor agonists activate a number of phospholipases 
including Ptdlns-PLC, PLA2 and PLD. In a number of instances observation of PLD 
activity requires activation of Ptdlns-PLC (reviewed by Billah & Anthes, 1990; 
Thompson et al, 1993; Exton, 1994). This has been interpreted as the requirement for 
Ins(l, 4, 5)P3 and DAG generation responsible for concomitant increases in 
intracellular Ca^+ release and PKC activation; both responses are relevant to the 
modulation of PLD activation. Modulation by GTP-binding proteins and a number of 
protein kinases have also been extensively detailed in the regulation of receptor- 
stimulated PLD activation (reviewed by Billah & Anthes, 1990; Exton, 1994) and are 
examined below.
1 2
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1.4.1 Calcium dependence.
The role of Ca^+ ions in the regulation of receptor-mediated PLD activation 
has been examined by the use of Ca^+ ionophores and the chelation of extracellular 
Ca^+. Addition of the Ca^+-ionophore A23187 to a number of cell types results in 
extracellular Ca^+-mediated PLD activation while chelation of extracellular Ca^+ 
could attenuate this to varying degrees (Pai et al, 1988a & b; Billah et al, 1989a;
Cook et al,  1991; Huang et al, 1991, Llahi & Fain, 1992).
Loading of cells with the Ca^+ chelator BAPTA has also demonstrated the 
inhibition of agonist-stimulated PLD activation in a number of cell types; eg PGE2- 
Stimulated HEL cells (Wu et al, 1992b), suggesting that mobilisation of intracellular 
Ca^+ is important in agonist-stimulated PLD activation. Use of BAPTA in 
combination with chelation of extracellular Ca^+ completely inhibited fMetLeuPhe- 
stimulated PLD activity which indicated that modulation of both intracellular and 
extracellular Ca^+ concentrations directly affects receptor-stimulated PLD activation.
The involvement of intracellular Ca^ "*" mobilisation in this role has been examined 
further by the use of the tumour promoter thapsigargin. This acts as a Ca^+-ATPase 
inhibitor (Thastrup et al, 1990) and prevents refilling of the Ins(l, 4, 5)P3-sensitive 
Ca^+-store. However, thapsigargin added at concentration that resulted in the 
elevation of [Ca^+]i did not stimulate PLD activation and had no effect upon the dose 
dependent activation of PLD stimulated by bombesin in Swiss 3T3 fibroblasts (Cook 
et al,  1991).
Therefore, an obvious question that remains to be addressed is whether Ca^+ 
exerts its affect upon PLD itself or plays a contributory role in modulation of the
'upstream activators of PLD. In cell free experiments with neutrophil membrane and 
cytosolic fractions, in vitro PLD activation required Ca^+ concentrations of greater 
than lOOnM (Olson et al, 1991). This is consistent with [Ca^+]i in stimulated cells, 
however, due to the protein heterogeneity of the cellular fractions utilised in this 
study it remains unclear if the effect of Ca^+ is upon the enzyme directly.
In examining the site of Ca^+ ion involvement, A23187-stimulated PLD 
activation in Swiss 3T3 fibroblasts can be partially inhibited by pretreatment with the 
selective PKC inhibitor Ro-31-8220 (Cook et al., 1991). Additionally, the inhibition 
of bombesin-stimulated PLD activation by EGTA and Ro-31-8220 in combination 
were less than additive suggesting they exerted their effects at a common site. This 
may signify that the requirement for Ca^+ in PLD activation is as a cofactor for PKC 
activation, PKC activation being required for bombesin-stimulated PLD activation in 
these cells (Cook e ta i,  1991).
Therefore, the modulation of receptor-stimulated PLD activity by Ca^+ does 
not appear to be by a universal mechanism. PLD activation may be influenced by the 
mobilisation of intracellular Ca^+ and entry of extracellular Ca^+ into the cell. 
However, it remains to be clarified whether Ca^+ activates components of the 
pathway regulating PLD or whether it activates PLD directly.
1.4.2 Regulation by PKC.
It has been extensively reported that addition of phorbol esters esters to a 
variety of cell types results in PLD activation, implicating PKC in enzyme regulation 
(Ben-Av & Liscovitch, 1989; Billah etal., 1989b; Cabot e ta i,  1989; Hii etal,  1989; 
Huang & Cabot, 1990b; Balsinde & Mollinedo, 1991; Cook e ta l ,  1991; Plevin et ai, 
1991; Llahi & Fain, 1992; Plevin & Wakelam, 1992). Consequently, activation of 
PLD by phorbol esters has been demonstrated to be sensitive to a number of 
inhibitors of PKC (Llahi & Fain, 1992; Liscovitch, 1989; Gustavsson & Hansson, 
1990; Metz & Dunlop, 1990; Sandman & Wurtman, 1991; Cook etal., 1991), 
However, in a number of cases agonist-stimulated PLD activation has appeared 
insensitive to these compounds. In HL-60 cells, fMetLeuPhe-stimulated PLD activity 
was only partially inhibited by pretreatment with the PKC inhibitor K252a (Billah et 
al, 1989b), staurosporine did not inhibit endothelin-stimulated PLD activity in rat 
aortic preparations and noradrenaline-stimulated PLD activation in rat cerebral cortex 
(Liu et al, 1992; Llahi & Fain, 1992) and the selective PKC inhibitor, Ro-31-8220,
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failed to inhibit PLD activation in fMetLeuPhe-stimulated neutrophils (Uings et al,  
1992), EGF“Stimulated Swiss 3T3 fibroblasts (Cook & Wakelam, 1992) and aa- 
adrenergic stimulation of fibroblasts (MacNulty eta l,  1992). Thus, the requirement 
for PKC in agonist-stimulated PLD activation is not universal.
The involvement of PKC has been examined further by modulation of cellular 
PKC expression, relying on chronic exposure of cells to high doses of phorbol ester to
downregulate DAG-sensitive PKC isotypes (Ways et al, 1992). This approach has 
illustrated the inhibition of PLD activation in a range of cell types in response to a j
variety of agonists or re-addition of phorbol ester; PMA and endothelin-1 in Rat-1 
fibroblasts (MacNulty etal,  1990); PMA, bombesin, PDGF and vasopressin in Swiss 
3T3 fibroblasts (Cook & Wakelam, 1991; Plevin etal,  1991); bradykinin in bovine 
pulmonary artery endothelial cells (Martin et a l , 1989) and PMA and gonadotrophin- 
releasing hormone in ovarian granulosa cells (Liscovitch & Amsterdam, 1989). By 
use of differential down regulation protocols, individual isotypes of PKC have been 
suggested to regulate PLD activation. Rat renal mesangial cells ti’eated with PMA for 
8h showed no loss of PLD activity upon addition of PMA, despite complete 
downregulation of PKC-a, and ô, but not PKC-e (Huwiler etal,  1991; 1992; 1993).
Stimulated PLD activity could only be blocked by 24h pretreatment with PMA, 
consistent with PKC-e downregulation in these cells (Huwiler et al, 1993). Under 
these conditions, PKC-Ç expression remained unchanged as expected (Ways et a l ,
■■/1992). In view of this, PKC-e was proposed to be the main regulator of PLD 
activation. Further, ATP- and UTP-stimulated PLD activity appeared to be regulated 
by PKC-e in a similar manner (Pfielschifter & Meriiweather, 1993).
The involvement of a PKC typical of the Ca^+-independent isoforms may 
explain the observed insensitivity to a number of the commonly used PKC inhibitors 
described eaiiier. Compounds such as staurosporine and K252a have been reported to 
show selectivity towards Ca^+-dependent isoforms (McGlynn et al, 1992; Gschwendt
■et al, 1989), however, it is still apparent that PLD activation may occur by PKC- ■
independent mechanisms (discussed later). In contrast to rat mesangial cells, PKC-e
--:î
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has been suggested to play only a minor role in the regulation of PLD activity in 
C3H/10T1/2 fibroblasts (Kiss & Anderson, 1994). Selective downregulation of PKC- 
e with carcinogenic compounds over 24 h had no effect upon the expression of the 
other PKC isoforms present in these cells (a, Ô and Ç ). Under these conditions both 
PMA- and PDGF-stimulated PLD activity remained unaltered.
Similar inteiwention at the level of PKC isoforms, demonstrated that 
incubation of mouse epidermal (HEL-37) and human skin (SF 3155) fibroblasts with 
sphingomyelin-derived ceramide specifically inhibited membrane-association of the 
PKC-a isoform and PLD activation in response to bradykinin (Jones & Murray, 
1995). Further, supplementation of a related fibroblastic cell type (SF 3271) with 1- 
D-hexadecylglycerol, increasing membrane ether lipid content and decreasing PKC-a 
translocation, prevented bradykinin-stimulated PLD activation (Clark & Murray, 
1995). Thus, a common role for PKC-a in the regulation of agonist-stimulated PLD 
activation may exist in these fibroblasts.
Regulation of PLD activity has also been examined following the 
overexpression of individual PKC isoforms in a vaiiety of cell types. PMA and 
endothelin-1 stimulated PLD activity in Rat-6 fibroblasts over-expressing PKC-pi 
was observed to be markedly elevated (Pai et al, 1991a & b). The effect of PKC-a 
overexpression upon PLD activation in Swiss 3T3 fibroblasts has been examined and 
the authors concluded that while acute PLD activation was not affected, the actual 
expression of PLD itself may be upregulated by PKC-a overexpression (Eldar et al,
1993). Further, they proposed PKC-e may mediate PLD activation in these ceils as 
PKC-pi is not normally expressed in mouse fibroblasts. This suggestion contrasts
with the minor 1.5-fold increase in PMA-induced PLD activation in NIH3T3 
fibroblasts overexpressing PKC-e some 15-fold (Kiss & Garamszegi, 1993).
Regulation of PLD activation by PKC has also been investigated by addition 
of cytosolic extracts and individually purified isoforms of PKC to isolated membrane 
preparations. Conricode etal. (1992) originally described PMA-stimulated PLD 
activity in CCL39 fibroblast membranes, but only in the presence of cytosol, partially
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purified PKC or purified PKC from this fraction. In contrast to a number of other cell 
types (see Section 1.4.2), this activation did not require ATP-dependent 
phosphorylation, as apyrase-catalysed ATP depletion was without effect. This 
suggested that PKC may interact with PLD directly and potentially activate it by an 
allosteric mechanism. Consequently, these workers described the ability of the :
conventional PKC's, a  and P, purified from rat brain to activate PLD in these 
membranes, in either a PMA-or Ca^+-dependent manner (Conricode et al, 1994).
Moreover, rat brain PKC-v and recombinant PKC- 5, e and Ç were all ineffective at 
substituting in this role. Immunoblot analysis of the soluble fraction confiimed the 
presence of only a  and Ç isoforms, however, recombinant PKC-pi was also able to 
activate PLD in these membranes. Therefore, PKC's a  and p were identified as 
activators of PLD.
It would appear that both Ca^+-dependent and independent isoforms of PKC 
are involved in the regulation of PLD activation. Agonists that stimulate Ptdlns(4,
5)P2 hydrolysis prior to PLD activation may utilise Ca^'^-dependent PKC isoforms 
activated by Ptdlns(4, 5)P2-derived DAG and concomitant intracellular Ca^+ release.
In addition, multiple PLD isoforms may exist and their activities may be modulated 
by different PKC isoforms in an agonist and cell specific manner. It remains to be 
determined if activation occurs by phosphorylation-dependent and/or independent 
mechanisms, as inhibitors of PKC that are active competitors at the enzyme ATP 
binding site, are known to inhibit PLD activation (see earlier text).
1.4.3 Involvement of GTP-Binding Proteins.
G-protein involvement in the regulation of stimulated PLD activity were 
illustrated by the differing sensitivity to pertussis-toxin pretreatment and activation of 
PLD with non-hydrolysable GTP analogues.
Pertussis-toxin pretreatment has been shown to completely block PLD activity 
in stimulated granulocytes (Pai e ta l,  1988b; Kanaho et al, 1991; Agwu et al, 1989) 
and preti'eatment also inhibited a 2-stimulated PLD activation in a 2~adrenoceptor
i t
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.transfected fibroblasts (MacNulty et al,  1992). In the latter study ADP-ribosylation 
of both Gi2 and Gig by toxin pre-treatment corresponded with impaired receptor 
stimulated GTPase activity and PLD activity. In this instance, it was also reported that 
no significant a 2-stimulated Ins(l, 4, 5)Pg generation occured and suggested that PLD 
activation was regulated by direct G-protein/PLD effector coupling and not as a 
downsti'eam consequence of PLC activation. This mechanism of regulation is 
discounted in granulocytes as PLC, like PLD, is sensitive to toxin pretreatment 
(Verghese et al, 1985). In hepatocytes, Bocckino et al (1987a & b) reported that 
activation of PLD was not impaired by pertussis toxin pre-treatment and could be 
obseiwed upon addition of GTPyS to membrane fractions prepared from these cells, 
suggesting the possible involvement of a G-protein not of the pertussis-sensitive Gi or 
Go class and distinct from that in fibroblasts.
Extensive evidence for G-protein involvement in PLD activation has been 
based upon permeabilised cell sytems or broken cell fractions and the introduction of 
non-hydrolysable GTP and GDP analogues. In electropermeabilised HL-60 cells, 
sustained PLD activation and phosphatidylethanol accumulation was observed upon 
addition of GTPyS. Further, this accumulation displayed Mg^+-dependence and also 
required ATP, though ATP could not substitute for GTPyS (Xie & Dubyalc, 1991). 
Similar potentiation of GTPyS-stimulated PLD activity has been observed in 
permeabilised NG108-15 hybridoma cells (Liscovitch & Eli, 1991). Moreover, 
adenine nucleotide-stimulated hydrolysis of PtdEtn in isolated membranes of NIH 
3T3 fibroblasts was potentiated by the addition of GTPyS, while nonhydrolysable 
analogues of ATP failed to activate PLD even in the presence of GTP (Kiss & 
Anderson, 1990). In broken cell fractions, particularly membrane preparations,
GTPyS also stimulates PLD activity; this has been documented in synaptosomes and 
microsomal membranes from canine brain (Qian & Drewes, 1989; Qian et al, 1990), 
hepatocyte plasma membranes as described above, rabbit platelet plasma membranes 
(Van Der Meulen & Haslam, 1990) and neutrophil preparations (Anthes et al, 1989, 
Olson era/., 1990).
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In addition the activation of the PLCp2 isoform by py subunits of pertussis- 
toxin sensitive heterotrimeric G-proteins (Camps et at, 1992; Katz et a l,  1992; see 
Section 1.1) may indicate a possible means of PLD regulation and activation. This has 
been examined, whereby both a  and py subunits were added to neutrophil subcellular 
fractions (Bowman et al, 1993). No modulation of PLD activity was noted; however, 
it still remains a possible means of activation in other cell types and requires further 
investigation.
1.4.4 PKC-Independent Mechanisms.
An observed potentiation of GTPyS-stimulated PLD activity in the presence of 
ATP has been described in a number of peimeabilised cell systems (see earlier text). 
Although ATP may interact and mediate a number of signalling events via interaction 
with its own receptor it has been suggested that provision of ATP allows the 
completion of a kinase event required for PLD activation. The involvement of both 
Ca^+ and particularly PKC (see above) in the regulation of receptor-stimulated PLD 
activation has suggested that the upstream activation of PLC is obligatory. However, 
in a number of studies PLD activation occurs in the absence of PLC-catalysed 
Ptdlns(4, 5)P2 hydrolysis (Cook & Wakelam, 1992; MacNulty et ai, 1992; Ahmed ét­
al, 1994). The pathways by which PLD activation occurs in the absence of Ptdlns- 
PLC activity have been partly elucidated. Involvement of receptor tyrosine kinases 
has been suggested in EGF-stimulated Swiss 3T3 fibroblasts and basic FGF- 
stimulated vascular endothelial cells (Cook & Wakelam, 1992; Ahmed e ta l,  1994), 
where agonist-stimulated PLD activation was sensitive to tyrosine kinase inhibitor 
compounds. In fMetLeuPhe-stimulated human neutrophils, PLD activation was also 
sensitive to tyrosine kinase inhibitors though the structural nature of the fMetLeuPhe 
receptor would suggest the involvement of non-receptor tyrosine kinases (Uings et 
al, 1992). Additionally, tyrosine kinase inhibitors were ineffective against phorbol 
ester-stimulated PLD activation suggesting they act proximal to PLD itself.
Moreover, fMetLeuPhe-stimulated tyrosine phosphoiylation of target proteins was
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attenuated while fMetLeuPhe-stimulated PLC activation was unaffected and was 
clearly dissociated from PLD activation (Uings et al, 1992). Consequently, an 
alternative pathway to PLD activation must exist and is not simply as a result of 
Ptdlns(4, 5)P% hydrolysis. Similar observations have been made in endothelin- 
stimulated AlO vascular smooth muscle cells (Wilkes eta l,  1993) and the putative 
involvement of tyrosine kinase activity has been strengthened by the observed parallel 
increases in tyrosine phosphorylation and PLD activation upon treatment of cells with 
tyrosine phosphatase inhibitor pervanadate (Bourgoin & Grinstein, 1992; Uings et al\ 
1992; Dubyak et al, 1993). In contrast, the role of receptor stimulated tyrosine kinase 
activity in the regulation of PLD activity in Swiss 3T3 cells is only a minor one 
(Briscoe etal,  1995). Therefore, the involvement and relative contributions of 
tyrosine kinases in the regulation of PLD activation may be cell type specific.
The regulation of PLD activation by the c AMP-dependent protein kinase 
(PKA) pathway has been reported; however, this varied in a cell type specific manner. 
Attenuation of fMetLeuPhe-stimulated PLD activity occurs in human neutrophils 
pretreated with cAMP-elevating agents (Agwu et al, 1991a; Tyagi etal,  1991). In 
contrast, human endothelial cells treated with similar agents display enhanced 
thrombin-stimulated PLD activity consistent with cholera toxin pretreatment of the 
same cells (Garcia et al, 1992). However, modulation of the PKA pathway has no 
effect upon bombesin-stimulated PLD activity in Swiss 3T3 fibroblasts (Cook et a l , 
1991). Therefore, there is no clear universal mechanism for regulation of the PLD 
pathway by PKA, though, in neutrophils intervention with the agents described above 
did not affect phorbol ester-stimulated PLD activity. Hence, PKA regulation in this 
situation may function as part of another converging pathway or be distal to the 
activation of PKC.
Thus, the identification of the multiple kinases involved and tlieir spatial 
placement in the signalling cascades responsible for PLD activation are unknown and 
requires further investigation. This may rely upon reconstitution studies with purified 
proteins.
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1.5 A Summary of The Regulation of Receptor-Mediated Phospholipase D 
Activation.
Evidence now exists for the involvement of multiple effector molecules in the 
regulation of receptor-stimulated PLD activity. Further clarification of G-protein 
involvement in PLD activation is required and whether it is purely restricted to 
Ptdlns(4, 5)P2 hydrolysis as a prerequisite to PLD activation by defined agonists in 
defined cell types. PKC and Ca^+ ions also differentially contribute to the regulation of 
stimulated PLD activation, however, no universal mechanism is apparent. PLD 
activities, in common with PLC and PKC isoforms, displays varied cytosolic and 
membrane localisation (see Section 1.11.1). It is unclear whether receptor-mediated 
activation involves the translocation of cytosolic PLD to a membrane location for full 
activation or if it is already membrane-associated for activation and requires the 
translocation of other regulatory components such as PKC and/or protein kinases. PLD 
activities may display characteristics similar to other phospholipases such as Ptdlns- 
PLC or PtdCho-PLÀ2 which are known to associate with the plasma membrane in a 
Ca^+-dependent fashion (Channon & Leslie, 1990; Clark et al, 1991). Elucidation of 
the contribution of these various effector molecules may rely upon reconstitution 
studies with purified proteins. In addition the generation of specific aiiti-PLD antisera 
may allow immunological examination of agonist specific changes in PLD subcellular 
localisation in both non-activated and activated cells.
1.6 Phospholipase C Catalysed Hydrolysis of Phosphatidylcholine.
Where PtdCho-PLD activation is rapidly desensitized it has been documented 
that prolonged phosphocholine production is observed (Cook et al,  1991; McKenzie et 
al, 1992; Plevin & Wakelam, 1992; Briscoe eta l,  1994). This has implicated a 
PtdCho-PLC pathway as contributing to sustained generation of DAG. Indeed, in a 
number of cell types the contribution of this pathway may be the major source of DAG 
(Bestennan et al, 1986a; Cook eta l,  1991; Purkiss et al, 1991; Schutze et al, 1992). 
More recent studies of the PtdCho-derived DAG species from EGF-stimulated Swiss
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3T3 fibroblasts has suggested the presence of a potential PtdCho-PLC catalysed 
pathway (Pettitt & Wakelam, 1994).
For many growth factors and G-protein-coupled agonists, generated water
'soluble metabolites of PtdCho have been examined. PLD activation and subsequent 
choline generation were obseiwed to precede phosphocholine production (eg Cook &
Wakelam, 1991; Plevin & Wakelam, 1992; see Billah & Anthes, 1990; Thompson et 
at., 1993). This may reflect metabolism of choline by choline kinase as part of PtdCho 
resynthesis. The proposal of agonist-stimulated PtdCho-PLC activity has relied upon 
the elucidation of the temporal relationship between the production of these two water- 
soluble PtdCho metabolites.
The observed stimulation of prolonged phosphocholine production in PDGF- 
stimulated Swiss 3T3 fibroblasts (Larrodera etal,  1990) instigated a series of studies 
by Moscat and co-workers investigating the contribution of a putative PtdCho-PLC 
catalysed hydrolytic pathway to mitogenic signalling (Cai et a l , 1993 and references 
therein). This utilised either the addition of an exogenous bacterially-derived PtdCho- 
PLC from Bacillus cereus directly to cells or transfection of these cells with an 
expression plasmid containing the phospholipase. Although sustained DAG and 
phosphocholine generation and a number of cellular effects were observed it remains 
debatable what relevance these results have to the elucidation of mammalian signal
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transduction cascades. It remains unclear what similarities, if any, the bacterial protein 
shares with the putative mammalian form(s).
Despite this, PtdCho-PLC activities have been identified and isolated from a 
number of mammalian sources. Neutral activities displaying PtdCho substrate 
specificity have been partially purified from heart cytosol (Wolf & Gross, 1985), bull 
seminal plasma (Sheikhnejad & Srivastava, 1986) and Ü937 cells (Clark e ta l ,  1986).
The heart cytosol and U937-derived enzymes appeared to be sensitive to millimolar 
concentrations of divalent cations whereas the seminal plasma enzyme appeared to be 
unaffected by divalent cations. This activity was further characterised and displayed an
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apparent molecular weight of 125kDa, consisting of 69 and 55 kDa subunits 
(Sheikhnejad & Srivastava, 1986).
The relationship between these cell free activities and putative agonist- 
stimulated PtdCho-PLC remains unknown. Therefore, the existence of mammalian 
PtdCho-PLC activities intrinsic to signal transduction remains speculative and awaits 
the isolation of an enzyme activity sensitive to agonist stimulation.
1.7 Phospholipase A2  Catalysed Hydrolysis of Phosphatidylcholine.
The hydrolysis of PtdCho can also occur by PLA2 catalysed hydrolysis, 
generating free fatty acid and lysophospholipid (see Fig 1.1). There are presently four 
cellular PLA2 activities which have either been purified or whose corresponding cDNA 
have been cloned and sequenced (Glaser et al, 1993; Dennis, 1994). One activity is a 
30kDa activity and has been characterised as a member of the 14.3.3 protein family 
(Zupan et al, 1992). A 40 kDa Ca^+-independent activity has also been purified from 
canine heart (Hazen & Gross, 1993). However, the two forms of PLA2 activity that 
have been best characterised are the low molecular weight (12-20kDa) secreted 
isoforms of PLA2, designated Groups I-III and the high molecular weight 
(approximately 85kDa) cytosolic activities termed CPLA2 (Group IV) (Dennis, 1994).
The extracellular Group I-in forms are present in secretory granules, snake and 
bee venoms, human synovial fluid and pancreatic secretions (see Dennis, 1994 for 
summary). Cytosolic PLA2 has been purified from a number of sources including and 
human promyolecytic U937 cells (Clark et al, 1990; Kramer et al, 1991; Wijkander & 
Sundler, 1989). The CPLA2 from U937 cells was sequenced and the cDNA 
subsequently cloned (Sharp e ta l,  1991; Clark eta l,  1991). Expression of the cDNA 
for this activity in fibroblastic cells demonstrated that this form that was responsive to 
agonist stimulation of cells (Lin et al., 1992; Lin et al., 1993). The PLA2 been further 
characterised to translocate to membranes in a calcium dependent manner. This is by 
virtue of its N-terminal Ca^+-dependent phospholipid binding domain (Clark et ai.
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1991) common to a number of signal transduction proteins, including isoforms of PKC 
(Hug & Sarre, 1993) and PLCy (see Rhee, 1991).
Growth factor receptors and G-protein coupled receptors have been shown to 
stimulate and regulate CPLA2 (see Dennis, 1994; Exton, 1994). Recently, studies have 
revealed that the regulation of CPLA2 involves changes in [Ca^+]i mediated by PLC 
activation and phosphorylation of the CPLA2 polypeptide. Phospholipase A2 has been 
suggested to be directly coupled and regulated by heterotrimeric G-proteins (Glaser et 
al,  1993). Consistent with this are extensive reports of the ability of GTP analogues to 
stimulate arachidonic acid release or enhance agonist-stimulated release in a wide 
variety of cells (see Exton, 1994). These events can also be inhibited by GDP analogues 
and, in some cases, blocked by pertussis toxin (see Exton, 1994). The py subunit of 
heterotrimeric G-proteins has also been proposed to regulate CPLA2. When the py 
subunits of transducin where added to membranes CPLA2 activity was markedly 
stimulated (Jelsema & Axelrod, 1987). Similarly, the use of antiserum against py 
subunits have been shown to inhibit CPLA2 activation by histamine and thrombin in 
permeabilised platelets (Murayama et al, 1990). However, antisera raised against Gj 
and Go inhibited both agonist-stimulated events. Differential involvement of 
heterotrimeric G-proteins in agonist-stimulated CPLA2 activiation has been suggested 
by studies utilising antisera raised against different heterotrimeric G-proteins and their 
constituent subunits. Antiserum against a  and p subunits of Gq inhibited agonist 
stimulated CPLA2 activity in platelet membranes (Kajiyama eta l,  1990). However, 
antiserum to Gi inhibited noradrenaline-stimulated activity but not that of thrombin 
stimulation (Kajiyama eta l ,  1990). Further re-addition of Go and Gi proteins to 
isolated pertussis toxin pretreated platelet membranes restored thrombin and 
noradrenaline responses respectively (Kajiyama et al, 1990). The precise nature of G~ 
protein regulation of agonist-stimulated CPLA2 activation has remained controversial as 
the specificity and purity of the tools described above remain unclear.
Expression of a dominant negative heterotrimeric G-protein chimera, consisting 
of the a  subunit of Gg with its C-terminal 38 residues replaced with those of Gi(%2, in
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CHO cells has demonstrated inhibition of both thrombin and ATP-stimulated CPLA2 
activation (Gupta et al, 1990). This suggests the involvement of Gi2 in the regulation of 
the enzyme by these agonists. A similar involvement of G12 may be apparent from 
studies of NIH3T3 fibroblasts transfected with wild type Gia2 and a mutant Gia2 
whereby the mutated G« possessed a lower intrinsic GTPase activity, resulting in 
enhanced arachidonic acid generation in the presence of seram (Xu e ta l ,  1993). 
Although these results predict G-protein regulation of agonist-stimulated CPLA2 
activation, this does not appear to be restricted to the involvement of heterotrimeric G- 
proteins. Recent studies have also implicated a regulatory role for low molecular weight 
monomeric G-proteins in growth factor-stimulated activation of CPLA2. The Rac and 
Rho proteins and the generation of leukotrienes are well characterised to be involved in 
the regulation of growth factor induced actin stress-fibre formation (Ridley & Hall, 
1992; Peppelenbosch etal,  1993). In investigating the relationship between these 
effector molecules and their relative contribution to stress fibre formation, it was 
recently reported that Rac was essential for EGF-stimulated arachidonic acid 
production and subsequent generation of leukotrienes (Peppelenbosch eta l,  1995). 
Cellular expression of a constitutively active Rac mutant (RacV12) resulted in 
arachidonic acid generation and leukotriene production independent of growth factor 
stimulation. The mechanism by which Rac mediates CPLA2 activation remains unclear, 
though this does not appear to be by means of direct interaction of the Rac and CPLA2 
polypeptides (Peppelenbosch et al, 1995).
Inteimediate roles for various protein kinases, including protein kinase A 
(PKA), PKC and mitogen-activated protein (MAP) kinase, have been proposed to 
mediate in part PLA2 activation involving G-proteins. Direct phosphorylation of CPLA2 
at serine residue 505 (Ser-505) by MAP kinase has been demonstrated m vitro (Lin et 
al, 1993). Mutation of this residue to alanine abolished phosphorylation and 
dramatically decreased agonist-stimulated CPLA2 activation and arachidonic acid 
generation in cells transfected with the mutated CPLA2 protein (Lin e ta l ,  1993). PKC 
is well known to participate in the regulation of MAP kinase (Malarkey et al, 1995)
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and PMA treatment of intact cells leads to phosphorylation of PLA2 at Ser-505 (Lin et 
al,  1993). However, the role of MAP kinase in the serine phosphorylation and 
activation of CPLA2 does not appear to be an exclusive, as phosphorylation of CPLA2 
by MAP kinase remains to be demonstrated in vivo. MAP kinase independent 
activation of CPLA2 has also been reported. The expression of a mutant Gia2 subunit in 
CHO cells, where glycine-203 was mutated to threonine, inhibited thrombin and ATP- 
stimulated arachidonic acid release without effects upon adenylyl cyclase inhibition, 
mobilisation of inti'acellular Ca^+ or MAP kinase activation (Winitz et al, 1994). 
Overexpression of wild type Gja2 subunit or an inactive mutant polypeptide had no 
effect upon agonist-stimulated arachidonic acid release (Winitz e ta l ,  1994). Therefore, 
these studies demonstrated a role for Gia2 hi the regulation of CPLA2 activation 
dissociated from the roles of Ca^ "^  and MAP kinase. Very recently, the stimulation of 
platelets with thrombin receptor agonist peptide has demonstrated differential activation 
of CPLA2 relative to thrombin itself (Ki-amer eta l,  1995). While thrombin stimulated 
Ca^ "*" mobilisation and activation of MAP kinase, the receptor agonist peptide evoked a 
weaker and less sustained Ca^+ response and failed to activate the MAP kinases. 
However, the 'activating' phosphorylation of CPLA2, though weaker than that 
stimulated by thrombin, was obseiwed and suggested the involvement of a proline- 
directed kinase distinct from the MAP kinases.
The functional significance of CPLA2 activation is generally accepted to be its
participation in the generation of arachidonic acid for production of leukotrienes, 
prostaglandins and thromboxanes. The physiological function of these compounds has
been extensively detailed elsewhere (Needleman eta l,  1986). Generation of 
arachidonic acid is rate limiting for these synthetic pathways and therefore dependent 
upon activation of CPLA2.
Ar achidonic acid itself may have a number of putative second messenger 
functions and directly interact with a number of cellular proteins affecting their physical 
or activation status. This has developed primarily from in vitro studies. Activation of a, 
p, y, e and Ç isoforms of PKC in the absence of Ca^+, DAG and phospholipid have been
described (Murakami & Routtenberg, 1985; Sekiguchi et al, 1987) and this may be 
further enhanced in the presence of Ca^+, DAG and PtdSer, depending on PKC isoform 
(Shinomura et al, 1991; Chen & Murakami, 1992). In common with other fatty acids, 
arachidonic acid can activate cell free preparations of PtdCho-PLD (eg Chalifour & 
Kanfer, 1982; Chalifa et al, 1990) and PAP (Gomez-Munoz et al,  1992a). 
Consequently, arachidonic acid may have distinct cellular protein targets, however, 
these effects remain to be demonstrated in intact cells and in an agonist dependent 
manner.
Cytosolic PLA2-catalysed hydrolysis of PtdCho also results in the production of 
lysoPtdCho and this too has been suggested to have signalling functionality. 
LysoPtdCho, like arachidonic acid, potentiated DAG-induced activation of the a, p and 
Y isoforms of PKC in vitro (Sasaki et al, 1993). Exogenously added lysoPtdCho in 
combination with cell peimeable DAG and Ca^+-ionophore activated T-lymphocytes as 
assesed by the upregulation of cell surface expression of Interleukin-2 receptors and the 
initiation of DNA synthesis (Asaoka et al, 1992). Similarly, exogenous lysoPtdCho 
also potentiated phorbol ester or DAG-induced differentiation of HL-60 cells to the 
macrophage-like lineage (Asaoka etal,  1993).
1,8 Other Glycerophospholipids Are Substrates For Phospholipase D.
Although PtdCho appears to be the major phospholipid substi'ate for receptor- 
coupled PLD, other glycerophospholipids may seiwe as substrates for PLD enzymes.
By specific labelling of individual membrane phospholipids, hydrolysis of other 
glycerophospholipids has been demonstrated. PtdEtn hydrolysis in response to 
phorbol esters has been documented in NIH 3T3 fibroblasts, HL-60 and HeLa cells 
(Kiss & Anderson, 1990; Kiss & Anderson, 1991). Similarly, labelling of the 
endogenous Ptdlns pool has demonstrated bradykinin-stimulated Ptdlns-PLD 
activities in Madin-Darby canine kidney cells (Huang & Cabot, 1992).
The consequences of these hydrolytic events remain unclear. Generation of 
PtdOH from these distinct phospholipid pools may have separate putative second
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messenger functions to those PtdOH species derived from PtdCho. Further, hydrolysis 
of PtdEtn and Ptdlns may contribute to sustained DAG generation observed in response 
to a number of agonists.
This may be consistent with the predicted hydrolysis of an alternative inositol 
lipid in thrombin-stimulated platelets (Wilson et al, 1985), All-stimulated vascular 
smooth muscle cells (Griendling et al, 1986, 1987), TRH-stimulated pituitary cells 
(Imai & Gershengorn, 1986), bombesin-stimulated Swiss 3T3 fibroblasts (Cook et al, 
1991) and vasopressin-stimulated AlO vascular smooth muscle cells (Plevin & 
Wakelam, 1992). However, the contribution of a PLD-catalysed hydrolytic pathway 
in this context remains debatable. Hydrolysis could simply occur as a result of 
sustained Ptdlns-PLC hydrolysis. This could be assessed by specific labelling of 
cellular PtdEtn and Ptdlns and incubation of cells in the presence of primary alcohols 
during stimulation. This approach, as previously described, has been utilised in the 
assessment of the contribution PtdCho-PLD activation to sustained DAG production 
in bombesin-stimulated Swiss 3T3 fibroblasts and vasopressin-stimulated AlO 
vascular smooth muscle cells (Cook etal,  1991; Plevin & Wakelam, 1992).
1.9 Functional Significance of Phospholipase D Activation.
1.9.1 Does Diacylglycerol Derived From Phosphatidylcholine-PLD Activate Protein 
Kinases C ?
The fate of PtdOH, by its conversion to DAG, has questioned whether PtdCho 
hydrolysis serves as an alternative means of PKC activation distinct from that 
subsequent to Ptdlns(4, 5)P2 hydrolysis. The lipid product of phosphoinositide 
hydrolysis, sn-l, 2-DAG, is recognised to be the main physiological activator of a 
family of phosphatidyl serine-dependent serine/threonine-directed kinases collectively 
called protein kinase C. Since their discovery by Nishizuka and co-workers, at least 
eleven isoforms have been identified by purification and molecular cloning and these 
can be divided into two main groupings based upon structural and regulatoiy properties 
(Nishizuka, 1988; Parker et al, 1989; Hug & Sarre, 1993). Group 1 consisting of a , (3i,
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Pn and Y isoforms are activated by both DAG and Ca^+. Group 2 isoforms consisting of 
Ô, e and 0 lack the Ca^+-binding domain and though activated by DAG are Ca '^*'- 
iiidependent Isoforms from both groups are known to translocate to the plasma 
membrane following agonist stimulation (Hug & Sane, 1993). A third group, that 
possesses only one rather than two cysteine-rich regions and lacks a Ca^+-binding 
domain has recently been identified (Hug & Sarre 1993). This consists of the X, ft and Ç 
isoforms. They are not activated by DAG or Ca^+ and they have been shown not to 
undergo translocation to the plasma membrane following agonist stimulation (Ways et 
al., 1992; Olivier et al, 1994). These PKC isfoims are phorbol ester insensitive and do 
not appear to undergo down regulation following chronic PM A pretreatment (Ways et 
al, 1992).
Upon receptor stimulation, DAGs with different fatty acid compositions are 
generated. Ptdlns(4, 5)P2-derived DAG contains predominantly unsaturated carbon 
chains while PtdCho-derived species are predominantly saturated. The production of 
divergent DAG, including l-O-alkyl-2-acyl species in some cells (see Billah et al, 
1989a & b), has suggested that selective PKC isoform activation may be initiated. 
Evidence in support of this has been based upon the observed effects of 1, 2-diacyl, 1- 
(9-alky 1-2-acyl and 1-0-alkeny 1-2-acyl glycerol species upon PKC activity in vitro 
(see Stabel & Parker, 1991). The potential correlation between sutained generation of 
PtdCho-derived DAG and the activation of PKC has involved assessment of PKC 
activation by isoform translocation to the membrane compartment in conjunction with 
the phosphorylation of the 80kDa MARCKS protein, an endogenous PKC substrate 
(Aderem, 1992).
In a-thrombin (500ng/ml)-stimulated nC9 fibroblasts, translocation of the a  
form of PKC occured occur in parallel with the generation of early Ptdlns(4, 5)P2- 
derived DAG and correlated with phosphorylation of the 80kDa MARCKS protein 
(Leach et al, 1991). Translocation of PKC a  nor phosphorylation of the 80kDa 
MARCKS protein did not coirelate with the generation of PtdCho derived DAG 
(Leach e ta l,  1991). At lower concentrations of a-thrombin (lOOpg/ml) PtdCho
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hydrolysis was observed in the absence of Ptdlns(4, 5)P2 hydrolysis.
Correspondingly, no PKCa translocation was observed (Leach et al, 1991). Despite 
the lack of PtdCho-derived DAG activation of PKC in whole cell stimulations, it was 
reported that a PKC activity from these cells could be activated in vitro by DAG 
derived from exogenous PLC catalysed hydrolysis of PtdCho extracted from these 
cells (Leach et al, 1991). Therefore, as PtdCho-derived DAG can activate PKC in 
vitro, PKC may not be exposed to these species in vivo. This theory has been 
confirmed in TRH-stimulated GH3 pituitary cells, whereby the observed biphasic 
generation of DAG consisted of an early transient Ptdlns(4, 5)P2-derived phase 
localised to the plasma membrane and a sustained PtdCho-derived phase at the 
intracellular membranes (Martin et al,  1990). Physical separation of generated DAG 
and the various PKC isoforms, each having varied subcellular localisation, may 
account for this. Moreover, the initial phase of generation corresponded to the 
observed translocation of the Ca^+-dependent a , p and j  PKC isoforms, whilst the 
latter phase showed no coiTelation with PKC translocation.
Although PtdCho-derived DAG did not appear to activate PKC in the above 
studies, three points regarding the assessment of PKC activity must be taken into 
account. Firstly, assessment of translocation of Ca^+-dependent isoforms, at time 
points when intracellular Ca^+ levels will be near basal, may not reflect PKC activity 
induced by the foitnation of PtdCho-derived DAG. Therefore, translocation of these 
isoforms is only pertinent to the generation of Ptdlns(4, 5)P2-derived DAGs. 
Secondly, if PtdCho-derived DAG activates a Ca^+-independent isoform then 80kDa 
protein phosphorylation may not serve as a means of assessment of PKC activation as 
it has been reported that this protein is not an endogenous substrate for these isoforms 
(see Olivier & Parker, 1991). Thirdly, it is apparent that the redistribution of Ca^+- 
dependent PKC isoforms can be dissociated from the phosphorylation of their 
substrates and that phosphorylation can be maintained after translocation events have 
ceased (Trilivas eta l,  1991).
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With the isolation of further PKC isoforms, activation of Ca^+-independent 
sub-family members by PtdCho-derived DAG has been investigated. Subsequent 
work upon IIC9 fibroblasts described above illustrated that a-thrombin (500ng/ml)- ■
stimulated PKCa translocation lasted for approximately 1 minute, however, the 
addition of a Ca^+ ionophore at 5 min, could re-induce PKCa translocation after it 
had returned to the cytosol (Ha & Exton, 1993). Translocation of PKCa could also be 
induced by addition of both dioctanoylglycerol and ionomycin, but not each alone.
Therefore, the availability of Ca^+ and not the species of DAG present in the 
membrane appeared to confer translocation. The reported lack of translocation of this 
isoform upon stimulation with lOOpg/ml a-thrombin in the presence of ionomycin 
remains to be resolved. However, in parallel to sustained DAG generation, PKCe was 
observed to translocate and remain membrane associated for up to 1 h. This was 
consistent with the proposed activation of Ca^+-independent PKC isoforms by 
sustained PtdCho-derived DAG. Similarly, in GH4C1 cells, TRH-stimulated biphasic 
DAG generation conesponded to early and transient PKC a  and p translocation 
whilst that of PKCe occurred in parallel with the sustained phase of DAG generation 
(Akita era/., 1990).
In the absence of inositol lipid hydrolysis, interferon-a stimulated HeLa cells 
display PKCp translocation in association with PtdCho hydrolysis (Pfeffer et al,
1990). It remains unclear whether PtdCho hydrolysis was catalysed by a PLC or PLD 
mechanism, however, these investigations illustrated that activation of PKC isoforms 
by PtdCho-derived DAG may not be restricted to Ca^+-independent sub-family 
members as described earlier. This may reflect agonist specificity of activation,
Interferon-y was also reported to activated an unidentified PKC family member in 
endothelial cells in a triphasic manner (Mattila & Renkonen, 1992). PKC activition 
was induced by PLD-derived DAG produced after concomitant PtdOH and choline 
generation.
Thus, no clear consensus is evident for the relationship between the generation 
of PtdCho-derived DAG and the activation of distinct PKC isoforms. The
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contribution of the PLD pathway to the generation of sustained DAG still remains 
unclear and therefore the activation of PKC may be an agonist specific phenomena. 
Further, as a number of DAG molecules with diverse fatty acid content do not appear 
to discriminate in their activation of individual PKC isoforms in vitro, physiological 
activation may be agonist specific requiring appropriate membrane localisation of 
both DAG generation and PKC isoforms. These points remain to be clarified by 
further study.
1.9.2 Phosphatidic Acid As A Disinct Second Messenger In Whole Cells.
The transient generation of PtdOH and the associated rapid desensitisation of 
agonist-stimulated PLD activity in a number of cells (McKenzie et al, 1992; Plevin 
& Wakelam, 1992; Briscoe etal, 1994) have suggested that PtdOH itself may 
mediate acute responses rather than sustained ones. Therefore the potential role of 
PtdOH as a putative second messenger has been studied.
Investigations of the cellular responses initiated by PtdOH have involved its 
addition directly to whole cells and observed effects have included hydrolysis of 
Ptdlns(4, 5)P2, inhibition of adenylate cyclase (Murayama & Ui, 1987), elevation of 
intracellular Ca^+ and DNA synthesis (Moolenar eta l,  1986), enhancement of cPLA2 
activation (Sato et al, 1993) and contraction of smooth muscle (Salmon &
Honeyman, 1980). However, the reported contamination of commercial preparations 
of PtdOH with lysoPtdOH (Jalink et al,  1990) and the recent identification of a 
putative lysoPtdOH receptor (Van der Bend, 1992a) questions to what extent these 
obseiwed cellular responses are in fact attributable to lysoPtdOH. This is primarily 
due to lyso PtdOH, but not PtdOH, being a potent Ca^+-mobilising stimulus for 
fibroblasts Qdlink et al, 1990).
PtdOH has been shown to have a number of actions in vitro that may suggest 
it could function as a distinct second messenger. Studies of PtdOH action suggested it 
could act as a potent Ca^+-ionophore (Putney et al, 1980) and to transfer across 
artificial phospholipid membranes (Serhan etal,  1981) though this was not
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confimied by a further study (Holmes & Yoss, 1983). More direct effects of PtdOH 
upon Ptdlns(4, 5)?% hydrolysis have been described. Jackowski & Rock (1989) 
observed PtdOH activation of Ptdlns-PLC in both membrane and soluble platelet 
extracts which was attributed to either an allosteric effect upon the enzyme or due to 
structural modification of the enzyme's lipid enviroment. PtdOH was also reported to 
mediate up to 20-fold enhanced in vitro catalytic activity of Ptdlns(4)P 5-kinase 
(Moritz et al,  1992). This occured in a concentration dependent manner and 
suggested PtdIns(4)P 5-kinase was sensitive to PtdOH intercalated in cellular 
membranes. This has been suggested to play a role in the maintenance of PLD 
activity in vivo (Liscovitch et ai, 1994) by stimulating the resynthesis of Ptdlns(4,
5)P2 as a cofactor for PLD activation (discussed further in section 1.11.3). Similarly, 
the activity status of a number of small molecular weight G-proteins and their 
associated protein regulators has been proposed to be modulated by PtdOH directly 
(Chuang et al, 1993). In addition to these, the proto-oncogene product, p2P'^-^, may 
be influenced by PtdOH-mediated inhibition of its GTPase-activating protein (Tsai et 
al,  1988) and activation of its GTPase inhibitory protein (Tsai et al, 1990).
Functionally, this would predict that proportionally more Ras would exist in the GTP- 
bound and active state, leading to activation of the ras-signal transduction pathways 
and cellular proliferation (see Mulcahy et al, 1985). This is consistent with the
,observed inhibition of PtdOH-mediated proliferation in fibroblasts by anti-Ras 
antibodies (Yu et al, 1988). However, this may not reflect the effects of PtdOH 
directly, but the contaminating effects of lysoPtdOH. LysoPtdOH is now known to 
utilise and activate Ras-dependentpathways (Hordijk eta l,  1994). Additionally, the 
abrogation of agonist-stimulated PLD activation and its effect upon Ras status has not 
been investigated in whole cells and therefore the direct modulation of Ras by PtdOH 
remains speculative.
PtdOH-mediated initiation of protein phosphorylation in cytosolic extracts 
from a number of rat tissues (Bocckino et al, 1991) has suggested the existence of a 
distinct PtdOH-sensitive kinase. The observed pattern of target protein
phosphorylation was distinct from those initiated by PtdSer in combination with 1, 2- 
dioleoylglycerol, excluding the involvement of classical PKC isoforms. Existence of 
a such a protein, biochemically and immunologically distinct from PKC, has been 
confirmed by the partially purification of a phospholipid-dependent and fatty acid- 
activated kinase from platelets (Khan et al, 1994). This kinase was selectively 
dependent upon PtdOH and may represent the identification of a novel kinase 
signalling cascade.
It would appear that the generation of PtdOH as a consequence of receptor- 
stimulated PLD activation may initiate a number of diverse signalling events and be 
regarded as a distinct second messenger in its own right. However, there is no 
identified universal mechanism to explain all its effects. This may involve both the 
structural effects of PtdOH generation in a membrane enviroment or its interaction 
with distinct protein taigets. These aspects and their physiological relevance in vivo 
remain to be investigated further.
1.9.3 Regulation of Agonist-stimulated Superoxide Generation in Heamatopoeitic 
Cells.
There are a number of reports that have coixelated PtdOH production with 
agonist-stimulated respiratory burst in neutrophils (Bonser et al, 1989; Koenderman
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et a l,  1989; Rossi eta l,  1990; Agwu etal,  1991b; English & Taylor, 1991; Gay & 
Murray, 1991; Bauldry e ta l,  1992). Activation of a membrane-bound multiprotein 
NADPH oxidase complex catalyses the conversion of O2 to a reactive superoxide 
(O2") species (Heyworth e ta l,  1992). These products are active in the killing of 
bacteria and are mediators of inflammation.
The evidence for the involvement of PtdOH in the regulation of NADPH 
oxidase activation has relied upon two approaches. Firstly, stimulation of intact cells 
in the presence of primary alcohols, which results in the accumulation of 
phosphatidylalcohols at the expense of PtdOH, inhibited oxidase activation (Bonser et 
al, 1989; Rossi et al, 1990; Bauldry et al, 1992). Secondly, a number of workers
'n:':
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have utilised propranolol as an inhibitor of PAP to suppress PAP-catalysed 
dephosphorylation of PtdOH. This approach led to sustained PtdOH levels and 
enhanced superoxide production (Rossi et ai, 1990; Bauldry et al., 1991; English & 
Taylor, 1991). The close relationship between PtdOH production and NADPH 
oxidase activation is further illustrated in neutrophils primed with tumour necrosis 
factor a  (TNFoc) and stimulated with fMLP (Bauldiy et ai, 1991). This protocol 
resulted in enhanced PtdOH generation and superoxide production, in the absence of 
DAG formation (Bauldiy et ai, 1991).
The precise role PtdOH plays in the regulation of NADPH oxidase activity 
remains to be elucidated. This may involve modulation of the assembly of the 
NADPH oxidase complex itself or changes in the membrane envkonment required for 
activation of this complex. The NADPH oxidase complex contains, and is regulated 
by, low molecular weight G-proteins of the Rho subfamily (Racl/2; Hey worth et al.
1992). Rho is regulated by Rho-associated GTP Dissociation Inhibitor (GDI) that
binds to Rho family members to prevent GDP to GTP exchange and consequently 
their activation (Downward, 1992; Takai etal,  1995). The dissociation of Rho family 
members from GDI is regulated by phospholipids, in particular PtdOH (Chuang et a l ,
1993). Therefore, agonist-stimulated generation of PtdOH may regulate Rho/Rac 
status and hence the activation of the respiratory burst complex.
A temporal relationship between the formation of PtdOH, rather than DAG, 
has also been observed in other physiological settings such as insulin secretion in 
pancreatic islets (Dunlop & Metz, 1989; Konrad etal,  1991), proliferation in 
fibroblasts (Zhang etal,  1990) and smooth muscle contraction (Salmon &
Honeyman, 1980).
1.9.4 Regulation of Cellular Cytoskeleton Assembly.
Another function of PtdOH generation may be in mediating agonist-stimulated 
cy to skeletal rearrangements. Stimulation of IIC9 fibroblasts with a-thrombin and 
lysoPtdOH induced changes in cell morphology, from rounded to elongated cells,
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consistent with actin-stress fibre formation (Ha & Exton, 1994; Ha et al, 1994). This 
correlated with increased PtdOH formation and F-actin content. These agonist specific 
events could be mimicked by addition of exogenous PtdCho-PLD from bacteria or 
PtdOH micelles (Ha & Exton, 1994). However, addition of PtdCho-PLC or cell 
permeable diglycerides or inhibition of PKC had no effect upon stress fibre formation 
(Ha & Exton, 1994). Similar studies in Swiss 3T3 fibroblasts have also implicated 
lysoPtdOH in regulation of actin-stress fibre formation (Ridley & Hall, 1992), In 
addition, PtdOH, thrombin and bombesin also stimulated small changes in actin 
polymerisation, whereas growth factors appeared ineffective or stimulated alternative 
changes in cell morphology, particularly membrane naffiing (Ridley & Hall, 1992; 
Ridley et al, 1992). The effects of lysoPtdOH were suggested to be regulated by a 
mechanism dependent on the activation of the low molecular weight G-protein Rho 
(Ridley & Hall, 1992). This was based upon the inhibition of rho following 
microinjection of C3 ADP-ribosyl transferase which inactivated Rho by ribosylation 
(Ridley & Hall, 1992) and lowered stress fibre formation.
The mechanism(s) that regulate lysoPtdOH-stimulated actin polymerisation and 
the role of Rho within this have been developed further during recent studies upon 
porcine aortic endothelial (PAE) cells. In tliis cell type lysoPtdOH stimulated actin 
polymerisation and stress fibre formation (Cross etal,  1995) in the absence of PLC, 
PLA2 and Ptdlns 3-kinase activation and suggested a critical functional role for PtdOH 
formation in this cell type. Consistent with PLD activation playing a central role in the 
regulation of stress fibre formation, was the observed inhibition of lyso PtdOH- 
stimulated stress fibre formation in the presence of butan-l-ol, which resulted in the 
accumulation of phosphatidylbutanol at the expense of PtdOH. Further, direct addition 
of PtdOH stimulated stress fibre fonnation which was not susceptible to butanol 
preincubation (Cross et al, 1995). A functional role for Rho was suggested by the 
inhibition of both lysoPtdOH and PtdOH-stimulated stress fibre formation by C3 ADP- 
ribosyl transferase-catalysed ribosylation of Rho and microinjection of ADP- 
ribosylated Rho protein (Cross et al, 1995). Therefore, Rho may function as a
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component of this signalling cascade downstream of PLD activation, however it 
remains to be elucidated if PtdOH directly activates Rho itself or an intermediate factor 
required for Rho activation. Potential candidates include the Rho-associated GDI 
proteins as previously described (see previous section). Again, the dissociation of these 
proteins from Rho family members may be regulated by PtdOH (Chuang et al., 1993) 
and therefore agonist-stimulated generation of this bioactive lipid may regulate Rho 
status and hence cytoskeletal assembly in a manner similar to that proposed for the 
NADPH oxidase complex.
1.9.5 A Potential Role for Phospholipase D in Mitogenesis.
In addition to a number of putative second messenger functions for PtdOH 
(see previous sections) its proposed involvement as a causal factor in the stimulation 
of mitogenesis has been closely considered (reviewed by Boarder, 1994). It has been 
reported that PDGF-stimulated mitogenesis in Balb/c 3T3 fibroblasts coiTelated with 
PtdOH generation (Fukami & Takenawa, 1992) in the absence of DAG formation. 
PtdOH also stimulated DNA synthesis. This could be mimicked by exogenous 
addition of PLD derived from the fungi Streptomyces chromofiiscas, yet addition of 
exogenous bacterial PtdCho-PLC from Bacillus cereus had no effect. The observed 
correlation between PtdOH generation and mitogenesis in the absence of other growth 
factors would suggest PLD activation and PtdOH formation to be a causal factor 
involved in mitogenesis in these cells.
Investigations in CCL39 fibroblasts transfected with the Ml subtype of 
muscarinic receptor demonstrated that carbachol could elicit strong phosphoinositide 
hydrolysis also stimulated by a-thrombin, however, only a-thrombin stimulation was 
mitogenic (Senwen et al, 1990). Therefore, these workers concluded that strong and 
persistent inositol lipid hydrolysis may initiate a number of early mitogenic signals 
but was not sufficient to maintain cellular proliferation. It was proposed however, that 
these events induced a state of 'competence' in readiness for other 'progression* factors 
required for successful mitogenesis. In subsequent studies on the same transfectants.
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carbachol stimulated substantial activation of PLD with a negligble mitogenic 
response while the reverse was apparent for a-thrombin (McKenzie et al,  1992) 
again suggesting that receptor-mediated phospholipid hyrolysis was not the causal 
factor in the mitogenic response. ET-1 activation of PtdCho hydrolysis in Rat-1 
fibroblasts was large though did not elicit a mitogenic response (Van der Bend et al, 
1992b). Therefore, these data suggested that although a number of G-protein coupled 
receptor agonists could induce robust PtdCho hydrolysis, they did not appear to 
function as full mitogens in a variety of cell types.
It is also well established that growth factors also activate PLD (see Cook & 
Wakelam, 1992; Plevin et al, 1992), however, relative to the G-protein coupled 
receptor agonists described above they are less efficacious (McKenzie et al, 1992). In 
a number of cases, particularly PDGF, PLD activation is regulated by PLCy activity
(Plevin et al, 1992; Yeo et al, 1994) and additionally dependent upon the expressed
levels of PLCyi (Lee e ta l,  1994). Molecular studies of growth factor receptors have 
demonsti’ated that mutation of the intracellular binding site for PLCy abrogates PLCy- 
catalysed inositol lipid hydrolysis yet shows no impaiiTuent of mitogenesis in 
response to growth factor (Peters et al, 1992; Mohammadi et al, 1992). Additionally, 
overexpression of the Y isoform of Ptdlns-PLC in NIH 3T3 fibroblasts does not alter 
the effect of PDGF-induced mitogenesis and once again indicates that inositol lipid
hydrolysis and mitogenesis can be dissociated (Margolis et al, 1990).
:The involvement of PLD-catalysed PtdOH generation has been addressed 
more directly in smooth muscle cells (Kondo eta l,  1992). Exogenous addition of
PLD from S.chromofuscus and subsequent generation of PtdOH appeared to elicit a 
mitogenic response and function in a similar manner as the addition of PDGF.
However, these experiments were conducted in the presence of insulin, a Icnown 
mitogen and non-activator of PLD in smooth muscle cells. The abrogation of ET-1- 
stimulated PLD activity in AlO vascular smooth muscle cells by addition of primary 
alcohols and the preferential formation of phosphatidylalcohols at the expense of 
PtdOH has also suggested a potential role for this putative lipid messenger in the
' :
38
mitogenic response. However, in these experiments as above, the presence of insulin 
was required for the observation of a mitogenic response (Wilkes et ai, 1993). Both 
studies may suggest PLD activation functions as a competence factor yet cell cycle 
progression and mitogenesis only occurs in the presence of growth factors.
Down regulation of PKC isoforms by chronic PMA pretreatment reduced 
PDGF-stimulated mitogenesis by 50% but PLD activation was completely abolished 
(Leach et ai, 1991), suggesting pathways other than PLD activation are required for 
mitogenesis. Similarly, Sharma & Bhalla (1993) reported that subsequent to chronic 
phorbol ester pretreatment and PKC isofoim down regulation, PKC-dependent 
pathways were not involved in PDGF-stimulated mitogenesis in rat aortic vascular 
smooth muscle cells. As PDGF-stimulated activation of PLD is regulated by PKC in a 
number of cell types (see above) this again questions the proposed role for PLD in the 
mitogenic réponse. Therefore, conflicting evidence as to the role of PLD activation in 
mitogenic responses is apparent. The observed effects of PtdOH generation in Balb/c 
3T3 fibroblasts (Fukami & Takenawa, 1992) remains unresolved relative to other cell 
types. In some cases PLD activation may function in a capacity similar to competence 
factors but true mitogenesis requires the presence of synergising peptide growth 
factors. However, as described above this may be cell type specific. Thus, the 
proposed causal relationship between PLD activation and mitogenesis requires further 
investigation.
1.9.6 Choline As A Second Messenger.
To date no evidence exists to indicate a distinct second messenger role for 
choline. However, the release of choline as a consequence of PLD activity has been 
suggested to be functionally coupled to the resynthesis of acetylcholine in the brain 
(Corradetti etal., 1983; Hatton & Kanfer, 1985). As PLD activation has been 
identified in cultured neuronal cells stimulated with muscarinic agonists (Liscovitch, 
1989; Martinson et ai, 1989) it may provide a source of PtdCho-derived lipid
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messengers involved in the release of acetylcholine but also mediate the 
replenishment of neurotransmitter stores.
1.10 Metabolism of Phosphatidic Acid and Choline.
1.10.1 Metabolism of PtdOH by Phosphatidic Acid Phosphohydrolase.
Phosphatidic Acid Phosphohydrolase (PAP) catalyses the hydrolysis of 
PtdOH to DAG and Pi. This may be relevant to the transient production of PtdOH that 
is observed in cells stimulated by a number of receptor agonists. Furthermore the 
rapid removal of this bioactive lipid is consistent with its putative role as a second 
messenger. In addition, PAP plays a fundamental role in the biosynthesis of 
glycerophospholipids (Brindley, 1988). To date, two distinct PAP activities have been 
described, teimed PAP-1 and PAP-2 (Brindley, 1988, Jamal e ta l,  1991). These 
activities can be distinguished by their sensitivity to divalent cations and the 
sulphydryl-modifying agent, A-ethylmaleimide (NEM). PAP-1 was dependent on the 
presence of Mg^+ for activity and inhibited by NEM (Brindley, 1988), whereas PAP- 
2 was independent of Mg^+ and insensitive to NEM (Jamal et al,  1991).
PAP-1 exists as an inactive pool in the cytosol and upon translocation to the 
endoplasmic reticulum becomes active (Brindley, 1988). This can be stimulated by 
free fatty acid, particularly oleic acid and specificity for long chain unsaturated fatty 
acid has been described (Aridor-Piterman e ta l,  1992; Cascales etal,  1984; Gomez- 
Munoz et al, 1992a). PAP-2 is predominantly plasma membrane bound (Jamal et al, 
1991) which is consistent with its proposed involvement in signal transduction events.
In common with a number of other signal transduction proteins, particularly 
PKC, PAP activity can be regulated by a number of lipids. These include sphingosine, 
derived from sphingomyelin, which can block oleate-stimulated PAP-1 translocation 
to the endoplasmic reticulum and inhibit activity (Aridor-Piterman et al, 1992; 
Gomez-Munoz et al, 1992a). Sphingosine was proposed to interact with PtdOH 
intercalated in the endoplasmic reticulum membranes rather than having a direct 
effect upon PAP-1 (Gomez-Munoz eta l,  1992a). The translocation of PAP-1 to the
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endoplasmic reticulum has been described to be subject to agonist regulation. 
Translocation was inhibited by the presence of cAMP or agonists that elevate cAMP, 
such as glucagon (Butterwith et al, 1984; Pittner et al, 1985). This may suggest that 
regulation is mediated by phosphorylation events; in this instance PKA may be 
responsible. Consistent with this mechanism of regulation, it has been reported that 
okadaic acid, a protein phosphatase 2/2A inhibitor, inhibited oleate-stimulated 
translocation of the enzyme and displaced PAP-1 activity from microsomal 
membranes (Gomez-Munoz e ta l,  1992b).
Similar investigations relevant to the regulation of PAP-2 have also been 
conducted. Inclusion of protein tyrosine-phosphate phosphatase inhibitors such as 
vanadate and Zn^+ during membrane preparation increased the PAP-2 activity 
recovered from rat fibroblasts (Martin et al, 1993). This may infer that in vivo PAP-2 
is subject to regulation by tyrosine phosphorylation. In contrast to PAP-1 activity, 
inclusion of okadaic acid had no effect upon recoverable PAP-2 activity (Gomez- 
Munoz et al, 1992b) and suggested serine/threonine phosphoiylalion and 
déphosphorylation did not contribute to enzyme regulation.
Further insight into PAP enzymology and regulation may come from the 
purification of these enzymes. A membrane-associated PAP-2 activity from porcine 
thymus has been partially purified (Kanoh et al, 1992) and a similar activity more 
recently has been purified to homogeneity from rat liver (Waggoner et al, 1995).
1.10.2 Removal of Choline and the Phosphatidylcholine Biosynthetic Pathway.
As previously described agonist stimulation of a number of cell types results in 
the generation of water soluble PtdCho metabolites. Free choline generated by receptor
Stimulated PLD activation may have second messenger functions, though these may be 
limited (see Section 1.9.6). Alternatively, free choline can be utilised in the resynthesis 
of cellular PtdCho in whole cells. Such a relationship between PtdCho hydrolysis and 
resynthesis was proposed to foim a 'phosphatidylcholine cycle' by Pelech & Vance,
I
(1989). Within this cycle, the predominant route of PtdCho biosynthesis in eukaryotic
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Fig 1.3 Schematic representation of the biosynthesis of phosphatidylcholine via 
the CDP-choline (Kennedy) pathway and its relationship to agonist-stimulated 
PLD-activation.
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cells occurs via the CDP-choline or 'Kennedy' pathway (Bishop & Bell, 1988; Pelech &
Vance, 1989; Tronchere eta l,  1994). This relies upon incorporation of choline into 
PtdCho mediated by the sequential action of choline kinase, CTP:phosphocholine 
cytidylyltransferase and choline phosphotransferase (see Fig 1.3).
Cytosolic choline kinase activity represents the first step in PtdCho resynthesis 
and enzyme activation by mitogenic growth factors in cultured fibroblasts has been 
described (Warden & Freidkin, 1985). Consistent with this, the isolation of a 
fibroblastic mutant cell type with an approxiate 3-fold decrease in choline kinase 
activity displayed a similar 3-fold decrease in PtdCho synthesis (Nishijima et al., 1984) 
and highlights its requirement as the initial step to PtdCho synthesis.
The second step is catalysed by key regulatory enzyme CTPiphosphocholine 
cytidylyltransferase. This catalyses the rate limiting step in the pathway (Wright et al,
1985). The enzyme has been purified from rat liver cytosol and exists as a heterodimer 
of 38 and 45kDa polypeptides, with the 45kDa polypeptide representing the catalytic 
subunit (Feldman & Weinhold, 1987). Similar to PAP (see previous section) 
cytidylyltransferase appears to be localised to both cytosolic and microsomal 
compartments. The cytosolic form has been described as an inactive pool of the enzyme 
and upon translocation to and association with microsomal membranes becomes active.
This occurs under conditions that stimulate PtdCho synthesis including regulation by 
addition of free fatty acids (Pelech & Vance, 1984; Weinhold e ta l,  1991), stimulation
,with phorbol esters that stimulate DAG generation (Pelech & Vance, 1984), treatment :
'of cells with exogenous PLC (Wright et al, 1985) and by phosphorylation and 
dephosphorylation dependent mechanisms (Hatch eta l,  1990; Utal e ta l,  1991; Jamil 
e ta l ,  1992).
The final step is catalysed by choline phosphotransferase localised to the
microsomal compartment (Bishop & Bell, 1988). Multiple forms of this enzyme have
been isolated which catalyse the synthesis of distinct species of PtdCho, one is
.responsible for the synthesis of diacyl and alkylalkyl forms and another appears to be 
specific for de novo synthesis of platelet activating factor (PAF) (Woodard et al, 1987).
__
Homologous enzymes have also been studied in yeast {Saccromyces cerevisiae) and 
mutant strains have been isolated with defects in choline phosphotransferase and 
consequently PtdCho synthesis (Hjelmstad & Bell, 1987). This enzyme is specific for 
choline and distinct from the analogous protein required for PtdEtn synthesis. However, 
yeast exhibiting mutations in both transferase enzymes were viable and highlighted the 
ability of other pathways to support PtdCho and PtdEtn synthesis (Bishop & Bell,
1988). Alternative pathways may include the successive transfer of methyl groups to 
PtdEtn from S-adenosyl methionine to generate PtdCho (Ridgeway & Vance, 1987).
More recently attention has focused directly upon the relationship between 
receptor-stimulated hydrolysis and synthesis of PtdCho. In human neutrophils both 
IMetLeuPhe and PMA stimulate PtdCho hydrolysis catalysed by PLD (eg Thompson et 
al, 1990). Tronchere et al, (1995) reported that fMLP alone stimulated PtdOH 
production but not PtdCho synthesis. However, addition of fMLP in combination with 
cytochalasin B led to stimulated PtdOH formation, its conversion to DAG and resulted 
in choline incorporation into PtdCho. This was mediated by the CDP-choline pathway 
and relied upon membrane-association and activation of CTP:phosphocholine 
cytidylyltransferase (Tronchere et al, 1995). Therefore, PtdCho-derived DAG and not 
formed PtdOH appeared to regulate the activity status of the transferase and the 
synthesis of PtdCho. PMA also stimulated the generation of DAG from PtdCho and 
caused similar effects upon cytidylyltransferase membrane association. This too 
resulted in PtdCho synthesis (Tronchere e ta l,  1995). Therefore, this study 
demonsti’ated that only DAG derived from PtdCho, catalysed by the PLD/PAP 
pathway, was involved in stimulated choline incorporation into PtdCho. This may serve 
as a model demonstrating the close association of PtdCho hydrolysis and its resynthesis 
in a similar manner to that described for the catalysed hydrolysis and resynthesis of the 
phosphoinositides in the extensively described 'Ptdlns cycle' (see Section 1.1). 
Moreover, the relationship between hydrolytic and synthetic pathways in this cell type 
may serve as an example to be extrapolated to others. Further study is obviously
4 3
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.required to elucidate whether this represents a universal mechanism of 'phospholipid 
cycling' common to all mammalian cell types.
1.11 Cell Free Phospholipase D.
1.11.1 Assessment of Cell Free PLD Activity.
The assessment of cell free PLD activity has relied upon the development of 
suitable in vitro assay conditions, such that both hydrolytic and 
transphosphatidylation activities of PLD enzymes can be monitored by presentation 
of substrate to the enzyme in an appropriate manner. This has included investigations 
utilising cell free preparations from cells and tissue whereby endogenous PtdCho 
substrate has been radiochemically labelled prior to cellular fractionation or secondly, 
by the presentation of exogenous substrate in a lipid/detergent micelle or as a 
dispersion.
Metabolic labelling of endogenous membrane glycerophospholipids (PtdCho 
& PtdEtn) by preferential incorportion of labelled fatty acids, choline or ethanolamine 
prior to cell fractionation has facilitated the identification of PLD activities in 
membrane fractions of rat brain (Chalifour & Kanfer, 1979; Mohn etal., 1992;
Horvitz & Davis, 1993) CCL39 fibroblasts (Coniicode etal., 1992; Conricode et al.,
1994) Swiss 3T3 fibroblasts (Eldar etal, 1993) and leukemic HL-60 granulocytes 
(Kiss & Anderson, 1989). PLD enzymes active against exogenously presented 
substrate have also been widely documented, however, the technical approach to 
these assay protocols was diverse. Presentation of exogenous substrate has been 
performed in three main ways.
'■ 'V
1; PtdCho substrate in a mixed micellar assay system with the non-ionic 
detergent Triton X-100 (TX-lOO) (see Martin, 1988; Kanoh et ai, 1991) 
2; A dispersion of PtdCho with the free fatty acid oleate (see Chalifour & 
Kanfer, 1982, Chalifa et al, 1990).
;
3a: A dispersion of PtdCho and the non-ionic detergent «-octyl-p, D-
glucopyranoside (see Wang et al, 1991).
3b. Radiolabelled endogenous PtdCho in native cellular membranes.
(Kiss and Anderson, 1990).
Studies utilising assay methodology based upon the above have demonstrated 
that PLD activity in cell free preparations was highly latent and required the presence 
of a suitable activator. In these situations it is likely that TX-lOO, oleate and 
octylglucoside have fulfilled this role. These assays were used in the preliminaiy 
characterisation and purification of various PLD activities. Prior to purifcation of an 
enzyme it is necessary to identify a suitable tissue source and if possible a subcellular 
fraction enriched in the protein of interest. The subcellular distribution of PLD 
activities has been examined in detail. Crude subcellular fractionation by differential 
centrifugation has demonstrated detectable PLD activities in various organelle 
fractions.
Cytosolic PLD activities have been observed upon presentation of lipid 
substrate in the form of a PtdCho/octylglucoside dispersion (Wang et al, 1991). 
Although this approach also demonstrated the existence of membrane-associated PLD 
activities in the same bovine tissues, the cytosolic PLD activities were described to be 
the predominant form of the enzyme under these assay conditions (Wang et al,
1991), A cytosolic Ptdlns-hydrolysing PLD activity in addition to the previously 
described PtdCho-hydrolysing activity present in Madin-Darby kidney cells has also 
been identified (Huang et al, 1992). Detection of this enzyme activity required 
altered detergent conditions to those in the assay of PtdCho-hydrolysing PLD (Huang 
et al, 1992). Again, this suggests not only distinct isoforms of PtdCho hydrolysing 
PLD, but also PLD isoforms active againt other glycerophospholipids may be 
activated in an agonist specific manner.
However, in the majority of studies PLD activity has been described as almost 
exclusively particulate. For example in bovme pulmanory artery endothelial cells,
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PLD activity was present in all fractions recovered (Martin eta l,  1988). An 
intermediate pellet fraction (15,000g) contained the most PLD activity arguing for 
localisation to be in a cellular organelle or plasma membrane fraction. A similar 
PtdCho-selective PLD activity has also been described in Madin-Darby cells (Huang 
et al, 1992). PLD activity in rat ventricular myocaidium was localised primarily to 
particulate fractions, though these were the 40,000 & 100,000g pellets respectively 
suggesting PLD localisation to be in a less dense organelle than plasma membranes 
(Panagia et al, 1991). Studies of rat brain (Kanoh et al, 1991) have demonstrated 
that PLD activity in TX-lOO-solubilised cmde plasma membranes displayed a greater 
specific activity than that of microsomal membranes in a PtdCho/TX-100 micellar 
assay while the reverse relationship is apparent upon assaying these fractions by 
means of a PtdCho/oleate dispersion. This was clarified following the identification 
of distinct PLD isoforms in rat brain, where an oleate-dependent and an ARF- 
activated enzyme were separated from solubilised membranes by column 
chromatography on heparin (Massenburg eta l,  1994).
The membrane bound, or associated, forms of PLD have been most 
successfully characterised in neutrophils and HL-60 granulocytes, where PLD 
specific activity is considerably higher than tissues such as brain and spleen 
(M.Hodgkin, personal communication). Prelabelling of endogenous phospholipids in 
neutrophils and HL-60 cells led to the observation of TP A- and GTPyS-stimulated 
PLD activity. However, this was only detectable if both membrane and cytosolic 
fractions were combined in cell free assays (Olson et al, 1991; Anthes et al,  1991; 
Bowman et al, 1993). Similar observations were made in HL-60 cells depleted of 
their cytosol following streptolysin-0 peiTneabilisation (Geny et al,  1992). Upon re­
addition of cytosol, GTPyS-stimulated PLD activity was restored (Geny etal,  1992). 
This model system allowed the purification and identification of ARF as a component 
required for GTPyS-dependent PLD activation (Cockcroft et al, 1994). A defined in 
vitro assay for PLD activity was developed by Brown et al, (1993) which used 
exogenous lipids. The PtdCho was presented in the form of liposomes composed of
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PtdCho, Ptdlns(4, 5)P% and PtdEtn in specific molar ratios (1:1.4:16). PLD activity in 
the membrane fraction of HL-60 cells could be observed in a GTPyS-dependent 
manner that also required Ptdlns(4, 5)P2. Other acidic phospholipids, such as PtdSer, 
could not replace Ptdlns(4, 5)P2 in the assay. This too served as a pseudo- 
reconsitution assay for the purification and identification of ARF as a PLD activator 
(Brown et al,  1993). Similai'ly, Ptdlns(4, 5)P2 activates rat brain membrane PLD 
activity up to 10-fold in vitro in a specific manner (Liscovitch etal,  1994) which 
could not be fulfilled by PtdIns(4)P, Ptdlns nor other acidic phospholipids. The 
physiological relevance of exogenous lipid addition remains uncleai* and does not 
prove the requirement for Ptdlns(4, 5)P2 as an endogenous cofactor. Estimations of 
Ptdlns(4, 5)P2 concentration in the plasma membranes of cells approaches 2 mol% 
(White, 1973), a concentration at which Liscovitch and coworkers (1994) reported 
near maximal activation of membrane-bound PLD. In the presence of neomycin, 
which binds anionic phospholipids with high affinity (Gabev et al, 1989), inhibition 
of membrane-bound PLD but not solubilised or partially purified PLD was apparent 
(Liscovitch et ai, 1994). This was not due to vaiying detergent/phospholipid 
concentiations as neomycin sensitivity could be restored upon addition of Ptdlns(4, 
5)P2 to the partially purified enzyme (Liscovitch et ai, 1994). Further evidence in 
support of Ptdlns(4, 5)P2 functioning as an endogenous cofactor is the observed 
neomycin-mediated inhibition of GTPyS-stimulated PLD activation in permeabilised 
NG108-15 cells (Liscovitch e ta l,  1991) and may confirm its involvement in the 
activation of membrane-associated PLD activity in whole cells.
1.11.2 Regulation of in vitro PLD Activity By Small Monomeric GTPases.
Recently, attention has focused upon the nature of the regulation of PLD 
activity in fractions of neutrophils and granulocytes. In neutrophil subcellular 
fractions, Olson eta l,  (1991) reported that for optimal GTPyS-stimulated PLD 
activity both plasma membranes and cytosol were required in the presence of Ca^+. 
This was consistent with the previous observation of a requirement for GTP and Ca^+
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for PLD activation in neutrophil homogenates (Anthes et al, 1989). The use of HL- 
60 cells to study PLD and its regulation quickly led to the identification of ARF as a 
GTP-dependent step in PLD activation (see section 1.11.1). ADP-Ribosylation Factor 
(ARF) is a member of the Ras superfamily of small molecular weight GTP-binding 
proteins (Brown etal,  1993; Cockcroft eta l,  1994).
ARF was originally identified as a protein cofactor for cholera toxin-catalysed 
ADP-iibosylation of a  subunit of the heterotrimeric G-protein Gs, responsible for the 
activiation of adenylate cyclase (Kahn & Gilman, 1984; Kahn & Gilman, 1986). The 
ARF proteins (ARF 1, 3, 4, 5, and 6) represent a family of highly conserved and 
ubiquitously expressed GTP-binding proteins related to both the Ras superfamily and 
heterotrimeric G-protein a  subunits (see Moss & Vaughan, 1993). However, the ARF 
proteins are distinct from heterotrimeric GTP-binding proteins in that binding of GTP 
initiates their translocation from a cytosolic to membrane localisation following N- 
terminal myristoylation (Kahn et al,  1988; Huan et al, 1993). Nucleotide exchange 
can be modulated by lipids and detergents (Bobak et al, 1990). It is also apparent that 
ARF binding to Golgi membranes is mediated by both receptor agonists and PKC 
activation (De Matteis etal,  1993). In mammalian cells ARF is localised to the Golgi 
network and plasma membranes upon GTPyS activation (Stearns eta l,  1990; Regazzi 
et al, 1991; Walker et al, 1992). Golgi ti-ansport assays identified ARF as being 
required for a number of GTPyS sensitive-vesicular fusion processes, including 
endoplasmic reticulum-golgi fusion (Balch et al, 1992), endosome-endosome fusion 
and nuclear vesicle fusion (Lenhard et al, 1992; Bom an e ta l,  1992). Thus, the 
identification of ARF as a putative activator of PLD in HL-60 granulocytes suggests a 
potential role for PLD activation and PtdOH generation in the regulation of 
intracellular membrane trafficking (see Khan e ta l,  1993).
Other small molecular weight GTP-binding proteins have also been implicated 
in the regulation of PLD activity in neutrophils (Bowman eta l,  1993) and hepatocyte 
membranes (Malcolm et al, 1994). This is likely to be a member of the Rho family of 
proteins which, like ARF, are also members of the Ras-superfamily. The involvement
4 8
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of Rho, or Rho-like proteins, was suggested based upon the ability of m^GDP
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dissociation stimulator, which stimulates GDP for GTP exchange on Rac and Rho 
(Downward, 1992), to stimulate GTP-dependent PLD activity (Bowman e ta l,  1993). 
The RhoGDP Dissociation Inhibitor (RhoGDI) protein, which binds specifically to 
Rho proteins and maintains their inactive GDP-bound status, was observed to inhibit 
GTPyS-dependent PLD activity (Bowman et al, 1993). In hepatocyte membranes 
treated with RhoGDI, GTPyS-stimulated PLD activity was diminished which 
correlated with the removal of membrane-associated RhoA (Malcolm et al, 1994). 
Readdition of recombinant RhoA fully reconstituted GTPyS-stimulated PLD activity. 
Only partial recovery of PLD activity was observed upon re-addition of R ad , another 
Rho family member and no enhancement was obseiwed upon addition of ARF. These 
data may clarify the previously observed pertussis-toxin insensitivity of GTPyS- 
stimulated PLD activation in hepatocytes membrane fractions (Bocckino e ta l ,  1987a 
& b) as these small molecular weight G-proteins are insensitive to modification by 
pertussis-toxm-catalysed ADP-ribosylation. Therefore, the regulation of PLD 
activation would appear to occur by a G-protein dependent mechanism but the 
individual small moleculai* weight G-proteins involved in the activation of 
membrane-associated PLD may be diverse and cell type specific.
It is also now apparent that PtdOH itself, in common with a number of acidic 
phospholipids may function to modulate the physical association of the Rho proteins, 
particularly Rac, with their GDI proteins (Chuang eta l,  1993). This complex only 
exists in resting cells and thus may be regulated by the generation of lipid molecules 
in an agonist-dependent manner. Therefore, the production of PtdOH may regulate 
further Rho-mediated activation of PLD or allow activated Rho to initiate other 
divergent signalling events. The activity of ARF also appears to be modulated by 
acidic phospholipids (Randazzo & Kahn, 1994). Ptdlns(4, 5)P2 stimulates the ARF 
GTP ase activating protein and GTP-hydrolysis up to 30-fold. However, the
requirement for Ptdlns(4, 5)P2 is reduced or increased in the presence of PtdOH and
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PtdCho respectively. Recently Terui e ta l  (1994) have extended this by showing that
Ptdlns(4, 5)P2 increases GTP binding to ARF and mediates this effect by binding to 
ARF. As ARF functions as an activator of PLD, the finding that substrate for PLD 
(PtdCho) inhibits ARFGAP activity while the product (PtdOH) potentiates it suggests 
a negative feedback loop for the coordinate regulation of PLD and ARF activities 
may exist.
1.11.3 Is PLD Regulated Via Ptdlns(4, 5)?2 Synthesis ?
The formation of Ptdlns(4, 5)P2, catalysed by Ptdlns(4)P 5-kinase activity, 
may influence PLD activation. In this context, PtdIns(4)P 5-kinase activity has been 
suggested to be regulated by GTP-binding proteins (Smith & Chang, 1989) and more 
recently the small monomeric GTPase, Rho, has been identified as fulfilling this role 
(Chong et a l,  1994). This was based upon the use of lavostatin, an inhibitor of small 
molecular weight G-protein isoprenylation, in reducing Ptdlns(4, 5)P2 levels in 
stimulated cells. Further, in cell lysates, botulinum C3 exoenzyme pretreatment, 
which catalyses ADP-ribosylation of Rho and impairs its interaction with effector 
molecules, blocked GTP7S-stimulated PtdIns(4)P 5-kinase activity (Chong etal.,
1994), Conversely, microinjection of GTP-bound Rho into cells, stimulated 
PtdIns(4)P 5-kinase activity, whereas GDP-bound Rho and GTP-bound Rac were 
ineffective. Therefore a Rho family member, regulates PtdIns(4)P 5-kinase activity 
and therefore cellular Ptdlns(4, 5)P2 content. This may potentially influence the 
nature and magnitude of PLD activation and is consistent with the proposed 
regulation of PLD activation by Rho or an alternative member of the Rho subfamily, 
that has been observed in both rat liver plasma membranes (Malcolm et al,  1994) and 
human neutrophils (Bowman e ta l,  1993). However, C3 exoenzyme-catalysed ADP- 
ribosylation of RhoA had no effect upon GTPyS-stimulated PLD activation in either 
study and which suggests that PtdIns(4)P 5-kinase and PLD activity are in fact 
dissociable. It remains to be examined whether C3 exoenzyme-catalysed ADP- 
ribosylation of Rho proteins inhibits agonist-stimulated PLD activation in whole cells.
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1.11.4 A Model for Co-ordinate Regulation of ARF Activity, Phosphoinositide 
Metabolism and PLD Activity: A Potential Role in the Regulation of Receptor- 
mediated Vesicular Membrane Trafficking.
The identification of ARF proteins as activators of PLD has implicated PLD 
itself in vesicular trafficking (see Kahn e ta l,  1993). In addition, 
polyphosphoinositide metabolism has emerged as a candidate mediating membrane 
transport in both yeast and a number of cell types. This is due to the apparent 
association of the enzymatic machineiy of phosphoinositide metabolism with that of 
membrane trafficking. For example, the phosphatidylinositol transfer protein 
(PtdlnsTP), the product of the SEC 14 gene in yeast, is required for constitutive 
secretion in yeast (Cleves etal., 1991; Skinner etal., 1993). Its mammalian 
homologue plays a similar role in neurotransmitter release in PC 12 cells (Hay & 
Martin, 1993). The VSP34 mutant of yeast, deficient in membrane trafficking, has 
been established as a lesion at the level of a Ptdlns 3-kinase enzymatic activity (Schu 
et al., 1993) and Ptdlns 4-kinase activity is localised in secretory granules from 
adrenal chromaffin cells (Husebye & Flatmark, 1988), coated vesicles (Campbell et 
al,  1985) and glucose transporter carrying vesicles (Del Vicchio & Pilch, 1991). This 
therefore suggests that the activation of PLD by ARF and Ptdlns(4, 5)?2 in concert 
coordinately regulates membrane trafficking. This is supported by the stimulation of 
PtdIns(4)P 5-kinase activity by PtdOH, dramatically influencing the synthesis of 
Ptdlns(4, 5)P2 (Moritz e ta l,  1992). Consequently the ability of Ptdlns(4, 5)P2 to 
enhance activation of PLD and the ability of PtdOH to influence the activity of 
PtdIns(4)P 5-kinase has formed the basis for the model, proposed by Liscovitch et al, 
(1994), in which the formation of PtdOH, by PLD, and Ptdlns(4, 5)P2 participate in a 
positive feedback loop regulating cellular vesicular and membrane trafficking (see Fig 
1.4).
Information generated from a number of studies upon the phosphoinositide 
kinases, ARF proteins, PLD and membrane trafficking may be relevant in defining 
this proposed model system. It has been proposed that the GTP-bound form of ARF
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Fig 1.4 A hypothetical model for the co-ordinate regulation of vesicular membrane trafHcking 
involving the activation of ARF, PLD and the phosphoinositide kinases. Abbreviations used: PC, 
phosphatidylcholine; PI4P, phosphatidylinositol 4-phosphate; PI4K, phosphatidylinositol 4-kinase; 
PIP5K, phosphatidylinositol 4-phosphate 5-kinase; PIP2, phosphatidylinositol (4 ,5)-bisphosphate.
initiates the assembly of coated vesicles on donor membranes and their subsequent 
budding off (Orci et al,  1993). These vesicles are likely to contain PtdIiis(4)P due to 
the presence of Ptdlns 4-kinase (Campbell e ta l,  1985; Del Vicchio & Pilch, 1991; 
Husebye & Flatmark, 1988) and their subsequent interaction with acceptor 
membranes would result in the ARF-GTP activating membrane bound PLD (Brown 
et al, 1993; Cockcroft et al, 1994). Activation of PLD would result in an increase in 
local PtdOFI concentration, stimulate PtdIns(4)P 5-kinase activity, putatively co­
localised at acceptor membranes and dramatically increase local Ptdlns(4, 5)P2 
concentrations further augmenting PLD activation. Responsibility for termination of 
such activity may rest with the associated GTPase-activating protein for ARF, 
ARFGAP. This regulatory enzyme is synergistically activated by Ptdlns(4, 5)P2 and 
PtdOH (Randazzo & Kahn, 1994). Therefore, the interaction of ARFGAP with these 
vesicles enriched in Ptdlns(4, 5)P2 and PtdOH may lead to its activation, stimulating 
GTP hydrolysis by ARF converting it to the GDP bound and inactive form. 
Consequently, PLD activity would cease, the positive feedback loop would terminate 
and the coat proteins disassemble and the lipid vesicle fuse with the acceptor 
membranes.
Further evidence in support of such a model has come from investigations 
conducted in peimeabilised U937 myeloma cells where MgATP potentiates GTPyS- 
stimulated PLD activation (Fertile et ai, 1995). This was proposed to represent 
ongoing Ptdlns(4, 5)P2 synthesis, MgATP being required for activity of the 
phosphoinositide kinases and maintenance of both PtdIns(4)P and Ptdlns(4, 5)P2 
levels. Use of an inhibitory antibody directed against Ptdlns 4-kinase completely 
inhibited Ptdlns 4-kinase activity and dramatically reduced cellular Ptdlns(4)P and 
Ptdlns(4, 5)P2 levels in the peimeabilised cells. This coincided with complete 
abrogation of GTPyS-stimulated PLD activity and approximately 60% inhibition of 
PMA-stimulated activation (Fertile et aL y 1995) and again suggests a critical 
functional role for Ptdlns(4, 5)P2 and its synthesis in the initiation and maintenance of 
PLD activation.
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Further support for this proposed model is the inhibition of secretory events in 
varying cell types upon pretreatment with a competing peptide corresponding to the 
N-terminus of ARF. This includes both inhibition of catecholamine release from 
adrenal chromaffin cells (Morgan & Burgoyne, 1993) and exocytotic activity in HL- 
60 cells (Fensome et al. y 1994). Again, ARF activity is both required and fundamental 
to trafficking events. In addition these peptides also inhibit PLD activation (Fensome 
et al y 1994; R. Randall, personal communication) and indicate the potential 
involvement of PLD, in association with ARF, in these vesicular trafficking events.
Therefore, a distinct physiological role for ARF-sensitive PLD activities 
involving the coordinate regulation of ARF, phosphoinositide kinases and PLD may 
be evident. It must be stressed, however, that relationship of such a model to receptor- 
stimulated PLD activation in intact cells remains to be extensively examined. 
Indications of receptor mediated regulation of ARF-activity and status have been 
described. ARF binding to Golgi membranes is mediated by both receptor agonists 
and PKC activation (De Matteis et at, 1993) and may indicate the potential regulation 
of such a system in an agonist-dependent manner. In addition, this does not account 
for the functionality of the sodium oleate-dependent PLD isolated fom porcine lung 
(Okamura & Yamashita, 1994) and the related oleate-activated PLD activity from rat 
brain (Massenburg et at, 1994). Their contribution to agonist-stimulated PLD 
activation, the physiological significance of the PtdOH generated by their activation 
and their relationship to ARF-sensitive activities remains to be elucidated.
1.11.5 PtdCho-PLD Enzymes Are Distinct From Phospholipid Base-Exchange 
Enzymes and the GPI-PLD Enzymes.
The group of enzymes that catalyse phospholipid remodelling are the base- 
exchange enzymes and have previously been confused with PLD activities. They are 
both phosphatidyl transferases. However, despite these similarities base-exchange 
enzymes are not hydrolases and do not produce PtdOH. PLD activities can also utilise 
primary alcohol at millimolar concentrations in the generation of phosphatidylalcohols
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by means of a transphosphatidylation reactions. Base-exchange enzymes are unable to 
catalyse such a reaction and fail to generate phosphatidylalcohols (Gustavsson & 
Ailing, 1987; Siddiqui & Exton, 1992). In addition, noticeable differences in the 
enzymological characteristics of base-exchange and PLD activities have been 
demonstrated by studies in vitro (reviewed by Kanfer, 1980). In one outstanding 
example, the base-exchange and PLD activities associated with subcellular fractions of 
rat liver were described to be clearly dissociated and displayed different subcellular 
localisation and sensitivity to divalent cations (Siddiqui & Exton, 1992). However, it 
was suggested that base-exchange activity, like that of PLD, could be regulated in both 
an agonist and G-protein dependent manner. The relationship of these events to the 
mechanisms that regulate agonist-stimulated PLD activation remains to be clarified, 
though molecular cloning of the mammalian base-exchange and PLD enzymes will 
allow this to be further elucidated.
It is now well established that mammalian plasma contains a PLD activity 
which is able to remove PtdOH from glycosylphosphatidylinositols (GPI), termed GPI- 
PLD (reviewed by Low, 1989). This PLD activity is produced as a secretory protein by 
the Islets of Langerhans (Metz et al, 1991) and a range of myeloid cell types (Xie & 
Low, 1994) and releases GPI-anchored proteins from membranes either at the cell 
surface or in an intracellular compartment (see Low, 1989). This enzyme has been 
purified, cloned and sequenced and demonstrated the existence of at least two distinct 
human cDNAs (see Huang et al,  1990; Low & Huang, 1993). However, this GPI-PLD 
activity can be distinguished from agonist-stimulated PtdCho-PLD and Ptdlns-PLD 
activities as glycerophospholipids do not serve as substrates for the enzyme (Hoener et 
al, 1990). Again, the relationship between the GPI-PLD activities and the signalling 
PtdCho-PLD activities awaits further clarification by molecular studies.
1.11.6 Purification of PLD Isoenzymes.
Information regarding the purification of PLD enzymes initially came from its 
isolation from non-mammalian sources, including plant tissues and bacteria. This is
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best illustrated by the series of investigations in which PLD was purified 680-fold 
from Savoy cabbage (Davidson & Long, 1958; Dawson & Hemington, 1967, Yang et 
al, 1967; Allgyer & Wells, 1979). The enzyme was inactive at high ionic strength, 
displayed pH optima of 7.25 and 6.0 at low and high Ca^+ concentrations respectively 
and displayed both parabolic and hyperbolic kinetics towards substrate at set pH and 
ionic strength conditions (Allgyer & Wells, 1979).
A 31kDa PLD has been directly cloned and sequenced from the bacteria 
Corynebacterium pseudotuberculosis (C.pseudotuberculosis) and expressed in E. 
coli (Hodgson et al, 1990). Comparison of the of protein sequence with the PLA2 
protein of Laticauda laticaudata showed a region of homology confering a putative 
metal ion binding site. As the PLD of C.pseudotuberculosis was Mg^+ dependent, this 
structural motif was proposed to fulfil this role and be required for activity (Hodgson 
et al, 1990). Similar approaches have allowed identification of PLD enzymes in 
Ricinus communis (Wang etal, 1994) and the fungi Streptomyces antibioticus 
(Iwasaki e ta l,  1994). Despite the isolation of these PLD activities it is unknown how 
these relate to mammalian enzymes and their stimulus-dependent activation. As yet, 
none of the molecular information of these non-mammalian enzymes has been 
utilised in novel approaches to purify or clone their mammalian counterparts.
The first partial purification of a mammalian PLD was that of a cytosolic 
activity from human eosinophils (Kater et al, 1976), Following ion-exchange and gel 
filtration the enzyme was characterised and displaying a pH optimum of 4.5-6.0 and a 
molecular weight of 60kDa. These characteristics were directly compared to PLD of 
Savoy cabbage and found to be similar except that upon gel-filtration the cabbage 
enzyme had a molecular weight between 100-200kDa (Kater et al, 1976).
A more extensive purification of a mammalian PLD distinct from base- 
exchange activities was that of a membrane localised activity from rat brain (Tald &
Kanfer, 1979). This involved the partial purification (240-fold) of the microsomal 
enzyme from Miranol H2M-solubilised rat brain that utilised both PtdCho and PtdEtn
as substrates and displayed an acidic pH optima (6.5). The protein had an molecular
weight of 200kDa upon gel filtration. Subsequent studies, identified the unsaturated 
fatty acid oleate as a potent activator of this PLD activity in vitro and allowed 
identification of PLD activity in a range of rat tissues (Chalifour & Kanfer, 1982). A 
similar activity has been identified in rat brain microsomes (Chalifa et al,  1990) and 
partially purified (M. Liscovitch, personal communication), however, this enzyme 
displays a neutral pH optima (7.2). It remains unclear as to whether this represents 
another PLD isoform or reflects variation in tissue preparation and assay techniques.
A PLD activity with characteristics common to the ones identified in the 
above studies has been purified to homogeneity from heptylthioglucoside-solubilised 
pig lung microsomes (Okamura & Yamashita, 1994). The enzyme displayed 
specificity for PtdCho, a pH optimum of 6.6 and molecular weight of 190kDa.
A neutral membrane-associated PLD activity has been partially purified from 
TX-lOO-solubilised crude plasma membranes of rat lung (Martin, 1988). This enzyme 
was dependent upon TX-lOO for hydrolytic activity and its relationship to the 
activities described above remains unresolved since no investigations into the effect 
of oleate upon activity were made. Despite this, further studies illustrated that 
purification of oleate-activated rat brain PLD could also be initiated by solubilisation 
of microsomes with TX-lOO (Kobayashi & Kanfer, 1991; Liscovitch et al, 1994).
Additionally, suitable dilution of TX-lOO during in vitro assay allowed oleate
■
activation of the enzyme to be observed (Kobayashi & Kanfer, 1991). The relative 
effects of TX-lOO and oleate upon each of these enzymes and whether they represent 
a means of distinguishing between individual isoforms remains to be reconciled.
However, the chromatographic separation of two membrane-associated PLD activities 
from solubilised rat brain particulate fraction has demonstrated the presence of an
oleate-activated PLD activity distinct from an additional ARF-regulated PLD activity 
(Massenberg ef a/., 1994).
The partial purification of the previously described ARF-stimulated, 
membrane-associated PLD in HL-60 granulocytes has been described (Brown et al,  
1993). Washing of crude membranes from these cells with hypertonic salt solutions
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generated a solubilised activity and was subsequently partially purified by a number 
of chromatographic steps. This has been further extended to the purification of a 
similar ARF-sensitive membrane-associated PLD from porcine brain (Brown etal.,
1995)
During these studies, the presence of n-octyl-p, D-glucoside was required for 
maintenance of activity and this may infer similarities to the previously described 
membrane-associated and cytosolic activities partially purified 20-fold from bovine 
lung also solubilised and chromatographed in the presence of n-octyl-p, D-glucoside 
(Wang et al, 1991). These enzymes were dependent upon the presence of n-octyl-P, 
D-glucoside for activity, characterised as a membrane-associated PtdCho-specific 
PLD and a cytosolic activity that hydrolysed PtdEtn>PtdCho>PtdIns. Therefore, with 
differences in biochemical characteristics under the same in vitro assay conditions 
these observed cytosolic and membrane bound activities may indeed be distinct 
isoforms as previously described. The relationship of these n-octyl-P, D-glucoside- 
dependent activities to both the ARF-activated and oleate-dependent activities 
remains to be clarified.
Thus, partial purification studies have highlighted the potential existence of 
multiple PLD isoforms, two distinct isoforms being identified in rat brain 
(Massenberg e ta l,  1994) with a comparable oleate-dependent isoform being purified 
to homogeneity from pig lung (Okamura & Yamashita, 1994). The ARF-activated 
PLD activity remains to be purified to homogeneity yet its identification in parallel to 
the oleate-dependent activity may represent the emergence of a multiple PLD enzyme 
family.
1.12 Aim of Project.
Receptor-stimulated phospholipid hydrolysis is a common response to a 
number of hormones and growth factors. Within this, PLD catalysed hydrolysis 
results in the generation of free base and the putative second messenger PtdOH. The 
PLD activity involved appears to preferentially catalyse the hydrolysis of PtdCho,
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however, this substrate specificity is not shared by all the PLD activities monitored in 
crude fractions from a range of cells and tissues. Additionally, the relationship 
between the activities monitored in vitro and in vivo remains unclear.
At the initiation of this work no mammalian PLD enzymes had been purified 
to homogeneity. Therefore, the aim of this project was the purification of a PtdCho- 
specific PLD activity reponsible for agonist-stimulated hydrolysis. Tissue distribution 
studies in a number of mammalian tissues and tissue availability suggested bovine 
spleen to serve as an appropriate source of enzyme.
To purify a PtdCho-specific PLD, PtdCho was to be utilised as substrate for 
monitoring reaction velocities at all stages during the development of the purification 
protocol and allow resolution of this activity from other non-selective PLD isoforms. 
This selectivity would be confirmed by comparison of the purified preparations' 
reaction velocities towards other glycerophospholipids under identical assay 
conditions.
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Chapter 2 
Materials and Methods
_____
2.1 Materials
All reagents were of analytical or similar grade; purchased from the following 
suppliers.
Amersham International pJ.c., Aylesbury, U.K.
11-[3, 4(ii)-3H] butanol.
L-3-Phosphatidyl [N-methyl-3H] choline, 1, 2-dipalmitoyl.
L-3-Phosphatidyl [2-l^C] ethanolamine, 1, 2-dioleoyl.
L-3-Phosphatidyl [2-^H] inositol, mixed acyls.
L-3-Phosphatidyl [3-^ '^ C] serine, 1, 2-dioleoyl.
Donkey anti-rabbit Ig horseradish-peroxidase conjugated antibodies.
Enhanced chemiluminescence (ECL) reagents.
Amicon Ltd., Stonehouse, U.K.
Centriprep 10 microconcentrators.
B.D.H. Ltd. Poole, U.K.
EDTA, formaldehyde and gluteraldehyde.
Bio-Rad Laboratories Ltd., Hemel Hempstead, U.K.
BioGel HTP (hydroxy apatite), Econo-Pac hydroxy apatite cartridges (pre-packed, 
5ml) and Detergent Compatible Protein Assay Kit.
Boehringer Manheim., Lewes, U.K.
DTT and Tris base.
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Lisons Scientific Equipment, Loughborough, U.K.
Absolute alcohol, acetic acid (glacial), acrylamide, chloroform, citric acid, glycine, 
hydrochloric acid, methanol, N, N' -methylenebisacrylamide, MgCl2.6(H20), Mops, 
Na2C0 3 , NaCl, NaOH, Na2HP04 , NaH2P04, sodium acetate and urea.
J anssen Qi inüca, Newton, Hydc^  U.K
Heplau-4-aie and Mes.
Lipid Products, Redhill, U.K.
Lecithin (bovine spinal cord)
May and Baker Ltd., Dagenham, U.K.
Ammonium persulphate.
Scientific Instrument Centre Ltd. Eastleigh, U.K.
Dialysis tubing (Viskiiig).
■I
■ fPharmacia, Milton Keynes, U.K.
Mono-S HR 5/5 FPLC column, Phenyl-Sepharose, Q-Sepharose FF, SR-12 Gel 
Filtration FPLC column, and S-Sepharose FF.
:
Scientific Marketing Associates, Barnet, U.K.
E-64 [L-trans -epoxysuccinyl-leucylamide-(4-guanidino)-butane], leupeptin and 
pepstatin A.
Sigma, Poole, U.K.
Aprotinin (bovine lung), bovine serum albumin (fraction V), broraophenol blue, 
choline chloride, ethanolamine hydrochloride, myo -inositol, heparin-agarose (Type 
I), phosphatidylinositol (soybean), phosphatidylethanolamine (bovine brain),
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phosphatidylserine (bovine brain), PMSF, L-serine, sodium cholate, sodium 
deoxycholate, sodium fluoride, TEMED, sodium tetraphenylboron, Triton X-100 and 
Tween 20.
Whatman LabSales Ltd., Maidstone, U.K.
LK5DF pre-laned TEC plates.
2.2 Methods: Determination of protein concentration.
2.2.1 Detergent Compatible Method.
Protein concentration was determined using the Bio-Rad DC Protein Assay 
Kit based upon the method of Lowry et a l . (1951). Samples (200|j,l) were prepared in 
duplicate and lOOpJ of Solution A (Copper Sulphate solution) and 800|il of Solution 
B (Folin's Reagent) added as described in the manufacturers Micro assay protocol. 
Standards (0-50|ig) constructed from l.Omg/ml bovine serum albumin were prepared 
in the same manner. All samples were incubated for 15 min at room temperature and 
absorbance recorded at 750nm.
2.2.2 U.V. Absorbance Method.
The protein concentration of chromatography column eluants was determined 
by the 'on line' monitors connected in series with the apparatus utilised for routine 
preparative chromatography; UVS II with the Pharmacia Hi-Load system and 
LCC500/UVM with the Pharmacia FPLC system. The absorbance of the eluant was 
monitored at 280nm in a 3mm quartz flow cell and recorded by the connected pen 
recorder.
2.3 SDS-Polyacrylamide Gel Electrophoresis,
Electrophoresis was performed using the method of Laemmli (1970). Slab 
gels were routinely performed employing either 100mm x 140mm x 1.5mm gel plates
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as part of a Bio-Rad Protean system, or as mini-slab gels using a Hoeffer 'Mighty 
Small’ system.
2.3.1 Lower Resolving Gels
Separating gels contained 10% (w/v) acrylamide, and 0.27% (w/v) 
bisacrylamide with 0.375M Tris-HCl pH 8.8, 0.1% (w/v) SDS, 0.033% (w/v) 
glycerol, 0.0003% (v/v) TEMED and 0.0004% (w/v) ammonium persulphate. For 
1.5mm thick slab gel a final volume of 16ml was used and for mini-gels 4.5ml was 
used.
2.3.2 Upper Stacking Gels.
The upper stacking gels contained 3% (w/v) acrylamide and 0.08% (w/v) 
bisacrylamide with 0.125M Tris-HCl pH 6.8, 0.1% (w/v) SDS, 0.0005% (v/v) 
TEMED and 0.001% (w/v) ammonium persulphate. An appropriate volume of the 
stacking gel solution was poured into the electrophoresis apparatus and the well comb 
introduced before polymerisation.
2.3.3 Sample Preparation.
The protein samples for electrophoresis were coirected to 740jil with H2O and 
lOfll 2% (w/v) sodium deoxycholate added. Subsequent to mixing, proteins were 
precipitated by addition of 250p,l of 24% (w/v) trichloroacetic acid and the samples 
incubated at room temperature for 5 min after further vigorous mixing. The 
precipitate was pelleted by centrifugation (18,000 x g, 15 min, 4 °C) and the 
supernatant removed by careful aspiration. Appropriate equal volumes of l.OM Tris 
base and Laemmli buffer were added to the pellet and the samples solubilised by 
incubation in a boiling water bath for 3 min [Laemmli buffer: 30% (w/v) urea, 5% 
(w/v) SDS, 6% (w/v) DTT, 20mM Tris-HCl pH 8.0, 0.2% (w/v) bromophenol blue].
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2.3.4 Electrophoresis Running Buffers.
The running buffer contained 25mM Tris-HCl pH 8.5, 0.192M glycine and 0.1 
% (w/v) SDS. Samples were introduced to the wells of the stacking gel using Gilson 
'Ducktair pipette tips and electrophoresis performed towards the anode at 150V,
i
25mA until the dye front was 0.5cm from the end of the resolving gel.
2.3.5 Silver Staining of SDS-Polyacrylamide Gels .
Upon completion of electrophoresis, gels were silver stained according to the 
method of Morrisey (1981). Gels were prefixed for 30 min in 50% (v/v) methanol,
10% (v/v) acetic acid followed by 5% (v/v) methanol, 7% (v/v) acetic acid again for 
30 min. The fixed gels were placed in 10% (v/v) glutaraldehyde and incubated for 30 
min. The glutaraldehyde was removed by washing the gels with multiple changes of 
distilled water over 3 hours. After washing, the gels were placed in an aqueous 
solution of 5flg/ml DTT for 30 min followed by immersion in 0.1% (w/v) silver 
nitrate for 30 min. Excess silver nitrate solution was removed by aspiration and the 
gels washed briefly in a small volume of developer solution (3% (w/v) Na2C03 
0.019% (v/v) formaldehyde). This was rapidly removed by aspiration and 
development continued by immersion of the gel in 100ml of developer solution.
When the desired level of staining was achieved the reaction was terminated by the 
addition of 12ml of 2.3M citric acid to the developer solution and agitated for 10 min.
The developed gels were then transfeiTed to 10% (v/v) glacial acetic acid and left 
overnight. In preparation for photography, tire gels were rinsed and stored in distilled 
water at 4^0 in the dark.
Ï.72.4 Assay of Phospholipase D Activity.
The reaction velocity of bovine spleen PLD was measured by means of a 
phosphatidylcholine (PtdCho)/Triton X-100 (TX-lOO) mixed micellar assay. This 
methodology was also employed for the kinetic characterisation of the purified PLD.
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The bovine spleen PLD was incubated in a final reaction volume of 120pl 
containing 0.1% (w/v) TX-lOO, 2.8mol % (39]llM) phosphatidylcholine [0.26jiCi 
[^HJPtdCho/nmol PtdCho], 50mM Hepes pH 7.5, 2mM EDTA. An appropriate 
amount of PtdCho and labelled PtdCho were dried under a stream of nitrogen and 
resolubilised in 2mM EDTA pH 7.5, containing an appropriate concentration of TX- 
lOO, by vigorous vortexing and sonication in a bath type sonicator at 4^C for 15 rain. 
The final concentration of the PtdCho in the sonicate was 78jLiM and served as a 2x 
strength substrate for aliquoting to the final assay tubes. Concentrated buffer (600mM 
Hepes pH 7.5, 2mM EDTA) was added in a volume of lOpl. The tubes were 
vortexed, sonicated for 5 min as above and incubated at 37°C for 3 min.
Reactions were then initiated by addition of protein samples and appropriate 
controls in a volume of 50jil. Assay tubes were briefly vortexed and maintained at 
37^C for 45 min. The reactions were terminated by the addition of 750pl of 
CHClgzMeOH (1:2, v/v) and incubated at room temperature for 15 min. Organic and 
aqueous phases were resolved by the addition of 250pl CHCI3 and 330jLil H2O 
followed by brief centrifugation (2500 x g, 5 min). The upper aqueous phase was 
removed to a clear 5ml insert vial and 650|al H2O added. Tritiated choline produced, 
was recovered from the collected aqueous products by means of an ion-pair extraction 
as described by Murray et al „ (1990). One ml of heptan-4-one, containing 
tetraphenylboron (5mg/ml), was added to each insert vial, vigorously vortexed and 
centrifuged (2500 x g, 5 min). The upper heptanone phase, containing 
tetraphenylboron-extracted ^H-choline, was removed and radioactivity determined by 
liquid scintillation counting in 10ml of Optiphase scintillant.
2.5 Preparation of Solubilised PLD.
2.5.1 Preparation of Bovine Spleen Crude Plasma Membrane Fraction.
A fresh bovine spleen obtained from a local abbatoir was rapidly decapsulated 
and finely chopped into ice-cold homogenisation buffer (25mM Hepes pH 7.0, 
154mM NaCl, 2mM EDTA, 5pg/ml leupeptin, 5|ig/ml aprotinin, IpM E-64, 200jiM
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PMSF, IjiM pepstatin A). The buffer was decanted and the chopped tissue 
homogenised in 2-3 volumes of the same buffer; initially by 4 x 30 sec periods in a 
tissue blender, followed by 5 strokes of a teflon pestle in a glass homogenisation 
vessel at approximately SOOrpm, The homogenate was centrifuged (1000 x g, 15 min) 
and the pellet discarded. The supernatant was filtered through cheesecloth and then 
centrifuged (35,000 x g, 45 min) to yield a pellet representing the crude plasma 
membrane fraction and a supernatant representing a crude cytosolic fraction. The 
cytosolic fraction was discarded and the pellet resuspended in an equal volume of the 
homogenisation buffer and washed by centrifugation (35,000 x g, 45 min). The final 
pellet was resuspended in homogenisation buffer at an approximate protein 
concentration of 15mg/ml and stored overnight at -80^C.
«
2.5.2 Solubilisation of Membrane-Associated PLD Activity from the Crude Plasma 
Membrane Fraction of Bovine Spleen.
The stored crude plasma membranes were thawed and pelleted by 
centrifugation (40,000 x g, 45 min), the supernatant collected and termed the 'pre-
spin' activity. The particulate material was resuspended in an equal volume of 50mM 
Na2HP04  pH 12 supplemented with leupeptin, aprotinin, E-64, PMSF and pepstatin
; ■A (at the concentrations described in Section 2.5.1) and incubated at 4°C for 30 min 
with agitation. Generation of soluble PLD activity was achieved by centrifugation 
(40,000 X g, 45 min) of this suspension and collection of the resultant supernatant.
This 'phosphate-extracted' supernatant was pooled with the 'pre-spin' supernatant and 
brought to pH 7.5 by gradual addition of 500mM NaH2P04  and tenned the 
solubilised PLD activity for ammonium sulphate precipitation and further purification 
of the membrane-associated PLD.
2.5.3 Ammonium Sulphate Precipitation of the Solubilised PLD from the Crude 
Plasma Membrane Fraction of Bovine Spleen.
The solubilised PLD activity was maintained at 4<^ C with constant mixing and 
solid ammonium sulphate added gradually (calculated from Dixon, 1953) over 45 min 
until saturation of 50% achieved, pH being maintained by the addition of NH4OH. 
The suspension was mixed for 30 min, and the precipitate collected by centrifugation 
(10,000 X g, 15 min). The supernatant was decanted and the pellet discarded. Further 
solid ammonium sulphate was added to the recovered supernatant over 30 min until 
saturation of 70% achieved. Again, after 30 min mixing the precipitate was recovered 
by centrifugation as described above and the supernatant discarded. The pellet 
containing the PLD activity was resuspended in 20-40ml of homogenisation buffer 
and dialysed against 2 x 5  litres of chromatography equilibration buffer (25mM Mes 
pH 6.0, 2mM EDTA, 0.1% (w/v) TX-lOO, supplemented with leupeptin, aprotinin, E- 
64, PMSF, pepstatin A as described in Section 2.5.1) to remove ammonium sulphate. 
The dialysate was collected and clarified by centrifugation (10,000 x g, 15 min) and 
the supernatant used for further purification of the membrane-associated PLD.
column packing. The column was then equilibrated with 10 volumes of 
chromatography buffer.
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2.6 Preparation of Chromatography Resins: S-Sepharose FF and Heparin- 
Agarose.
The following procedures were performed at 4^C. An appropriate volume of 
each resin was transferred to a clean glass bottle and allowed to settle. The 
supernatant was decanted and the settled gel resuspended in 10 volumes of 250mM 
Mes pH 6.0, IM NaCl. The resin was again allowed to settle and the supernatant 
removed by aspiration. The above procedure was repeated twice and a further three 
times with chromatography equilibration buffer as described in Section 2.5.3. Finally, 
the supernatant was aspirated to generate a resin sluixy of 75% which was used lor
6 8
2.7 Scanning Spectrophotometery.
Continuous scanning spectrophotometry of partially purified enzyme 
preparations was performed between 200 and 600nm in a Shimadzu UV-2101PC UV- 
Visible scanning spectrophotometer. Absorbance profiles were recorded by a Roland 
Sketchmate printer.
2.8 Anti-p47 and p67P*>®^  Iinmunoblotting.
Aliquots of whole cell lysates and partially purified PLD from
:chromatography steps prepared in SDS-sample buffer, as described in Section 2.3.3,
"iwere subjected to SDS-PAGE on 10% polyacrylamide slab gels and then transferred 
onto nitrocellulose. The nitrocellulose membranes were incubated for three hours in
lOmM Hepes, 0.5M NaCl pH 7.4, containing 3% BSA and 10% donkey serum then 
incubated overnight in lOmM Hepes, 0.5M NaCl pH 7.4, containing 1% BSA, 0.2%
(w/v) Tween 20, 3% donkey serum and Ipgmpl of rabbit polyclonal anti-p47 and 
p67P^ °^  ^antibody respectively. Following six washes over 30 min in lOmM Hepes,
0.5M NaCl pH 7.4 containing 0.2% Tween 20 (w/v) the membranes were incubated 
with anti-rabbit Ig-horseradish-peroxidase conjugate (HRP) for 1 hour. The 
membranes were then washed a further 4 times over 20 min and then finally for 5 min 
in 10 mM Hepes, 0.5M NaCl pH 7.4 in the absence of Tween 20 before development 
using the ECL chemiluminescent detection system (Amersham).
: : s
2.9 Miscellaneous Procedures.
2.9.1 Concentration of Protein Solutions.
Pooled chromatography eluants requiring concentration, usually l-5ml, were 
placed in Centriprep 10 microconcentrators and centrifuged (2500 x g, 4^ >C) until the 
desired volume was obtained. ::
t
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2.9.2 Preparation of Dialysis Tubing.
Dialysis tubing was hydrated in distilled H2O and then boiled twice for 30
2.9.3 Critical Micelle Concentrations.
Values for detergent critical micelle concentration (cmc) employed in this 
work were as described by Neugebauer (1990).
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min in lOmM EDTA. Before use, the tubing was allowed to cool and extensively 
rinsed with distilled H2O.
2.9.4 Chromatography Buffers.
Unless otherwise stated the chromatography buffer used was 25mM Mes pH 
6.0, containing 2mM EDTA and 0.1% (w/v) TX-lOO. All buffers throughout the 
purification protocol contained the following protease inhibitors; 5jig/ml leupeptin,
5pg/ml aprotinin, IpM E-64, 200|aM PMSF and l|iM  pepstatin A.
;
2.9.5 Statistical Analysis.
Unless otherwise stated, the results presented within this thesis are
:
representative of at least three experiments.
The PLD activities measured in fractions recovered from chromatography 
columns are single point determinations. Otherwise, values stated are expressed as the 
mean of a triplicate determination and the eiTor expressed as ± Standard Deviation.
Chapter 3
Partial Purification of the Membrane-Associated PLD.
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3.1 Introduction.
3.1.1. Preparation of an Appropriate Source of Enzyme Activity for Purification.
The formation of phosphatidylalcohols in a stimulus-dependent manner has 
allowed the description of agonist-dependent PLD activation in a wide variety of cells 
and tissues (reviewed by Billah & Anthes, 1990; Thompson e ta l,  1993; Exton,
1994). Although the physiological importance and function of PLD is still unclear, 
insight can be gained in understanding enzyme function by the preparation of highly 
purified protein. In order to purify any protein, both assay conditions and the potential 
source of protein must be carefully considered.
Using a variety of in vitro assays PLD activity has been described in 
subcellular fractions from a number of cell types and most commonly in bovine and 
rat tissues (for summary see Thompson et al, 1993). Cytosolic PLD activity in 
bovine tissues varies greatly, with the following order:
lung>brain=spleen>heart=kidney>thymus>liver (Wang e ta l,  1991). Membrane- 
bound and microsomal PLD activity in various rat tissues exhibited a similar 
distribution to the bovine tissues where
.
lung>brain=spleen>heart=kidney>thymus>liver>testis (Martin, 1988; Chalifour &
Kanfer, 1982). From these reports, it was apparent that PLD activity was consistently 
highest in lung, brain and spleen tissues of both rat and bovine tissues even when 
lipid substrates were presented in differing assay environments. Abundant PLD 
activity has also been reported in subcellular fractions of neutrophils and related 
myeloid cell types such as HL-60 granulocytes (see Thompson et a l,  1993). PLD 
activity in membranes from these cell types appeared to be regulated in a GTPyS- 
dependeiit manner by a required cytosolic factor (Anthes et al, 1991; Geny et al,
1992), proposed to be a G-protein (Xie & Dubyak, 1991; Geny & Cockcroft, 1992).
At the initiation of this study, no mammalian PLD enzymes had been purified 
to homogeneity. However, a 30 and 80kDa PLD enzyme had been partially purified 
from bovine lung cytosol using anion-exchange and gel filtration chromatography 
(Wang et al, 1991). Subsequently, a PtdCho-specific PLD was identified in the
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particulate fraction of bovine lung and partially purified by anion-exchange 
chromatography in the presence of n -octyl-p, D-glucopyranoside (Wang et al,  
1991). This was different from the observed 50 kDa activity from human neutrophil 
cytosol (Bowman et al,  1993) and the partially purified rat brain 200 kDa activity 
(Taki & Kanfer, 1978)
In accordance with tissue availability and the apparent abundance of PLD in 
haematopoietic cells, bovine spleen was selected as the source of PLD activity for 
purification of a PtdCho specific enzyme.
3.1.2 Particulate and Cytosolic PLD Activities of Bovine Spleen.
Bovine spleen was homogonised and centrifuged at 35,000 x g to prepare 
crude cytosolic and plasma membrane fractions. Using a PtdCho/TX-100 mixed 
micellar assay (Martin, 1988) PLD activity was found to be approximately equally 
distributed between the two fractions (Table 3.1). The highest specific PLD activity 
was expressed in the membrane fraction.
Table 3.1 PLD Activity in Crude Fractions Prepared from Bovine Spleen.
Specific PLD Fold Total PLD Recove
Activitv Activitv
Ipmol/minl
Homogenate 0.12 1 6083 100
Cytosol 0.21 2 3042 50
Membranes 1.21 10 4594 76
It was also apparent that upon fractionation of the homogenate, the total activity 
recovered in cytosolic and membrane fractions represented a greater amount that in 
the homogenate alone. This may represent the cytosolic localisation of an inhibitory 
factor consistent with the observed fold increase in PLD activity recovered in the 
membrane compartment.
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?Very little PLD activity was recovered from these fractions when assessed by 
the PtdCho/n -octyl-P, D-glucopyranoside mixed micellar method described by Wang 
et al (1991) whereas the use of a PtdCho/oleate dispersion assay (Chalifour &
Kanfer, 1982) resulted in specific activities of up to 10-fold higher than those shown 
here. However, the dispersion assay was not detergent compatible (data not shown) 
and it was therefore considered to be of limited use in this study. In accordance with 
the aim of purifying a PtdCho-hydrolysing PLD activity involved in signal 
transduction, the membrane fraction was used as a source of PLD activity.
3.2 Solubilisation of the Membrane-Associated PLD,
Several groups have reported the solubilisation of membrane-associated PLD 
activities with a number of non-ionic detergents, including TX-lOO and n - octyl-P, D- 
glucopyranoside (Martin, 1988; Kanfer, 1991; Kanoh e ta l,  1991; Wang e ta l ,  1991), 
however, from these studies to date it has not been possible to assign PLD to an 
integral or peripheral membrane location. Further, it remains possible that the PLD 
exists as a cytoskeletally-asssociated protein with localisation dependent upon protein 
to protein interactions via cytoskeletal elements anchored to the plasma membrane. 
Therefore, generation of a soluble PLD activity from bovine spleen membranes was 
approached utilising a range of solubilising agents. Extraction with detergents to 
solubilise membrane-bound and associated proteins and either hypertonic 
concentrations of salt and solutions of high pH to solubilise peripheral membrane- 
associated proteins (Shariff & Luna, 1990; Shariff & Luna, 1992) were examined.
Frozen crude plasma membranes stored at -80^C were thawed and an equal 
volume of homogenisation buffer, containing the appropriate concentration of 
detergent or salt, added. The non-ionic detergents TX-lOO, Tween-20, n -octyl-(3, D- 
glucopyranoside and Thesit and the anionic detergent cholate were examined at a 
concentration equivalent to 10 x their critical micelle concentration. In parallel, salt 
extraction was performed with IM and 2M respectively. Frozen crude plasma 
membranes were also thawed, pelleted by centrifugation (100,000 x g, 1 h),
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resuspended to 2 x their original volume and exposed to high pH; in either phosphate 
or carbonate solution at 100 mM, pH 12. All samples were agitated on a rotary wheel 
for 1 hr at 4^C and solubilisation by these agents assessed as their ability to release 
PLD activity to the supernatant recovered following centrifugation (100,000 x g, 1 hr) 
of the extracted membranes (Fig 3.1).
l i?
All the agents examined released PLD activity to the supernatant, except n 
-octyl-(3, D-glucopyranoside (Fig 3.1). Extraction with IM and 2M NaCl respectively, 
each resulted in the recovery of a small percentage of the total membrane-associated 
PLD activity. Detergent extraction was also successful using Tween-20, Thesit and 
cholate, however, maximal detergent solubilisation was achieved using TX-lOO and
.allowed the recovery of approximately 85 % of the total membrane-associated PLD 
activity (Fig 3.1).
Membranes were pelleted before incubation with phosphate and carbonate 
solutions of high pH. It was apparent that up to 45% of the total membrane-associated 
PLD was present in the 100,000 x g supernatant (Fig 3.1), indicating release of PLD 
activity upon freeze-thawing and centrifugation. This was not attributed to 
contaminating cytosolic activity as successive washing of the membranes with 
homogenisation buffer removed all soluble activity without significantly altering the 
apparent specific and total PLD activity recovered in freshly prepared crude 
membranes before freezing (data not shown). Consequently, pH extraction with 
phosphate and carbonate solutions at at alkaline pH resulted in a further 40.8 ± 1.6% 
and 31.2 + 1.0% solubilisation of the total membrane-associated PLD activity 
respectively (Fig 3.1).
The recovery of soluble activity without treatment of the membranes 
questioned the ability of the previously described salt and detergent extractions to 
genuinely solubilise PLD activity. Therefore, it was concluded that TX-lOO and pH 
extraction, in combination with prior freeze-thawing and high speed centrifugation
■Ç
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Fig 3.1 Solubilisation of Membrane-Associated PLD Activity from the Crude 
Plasma Membrane Fraction of Bovine Spleen.
Crude plasma membranes from bovine spleen were prepared by homogenisation and 
differential centrifugation as described in Section 2.5.1 and stored at -80^C. Frozen 
membranes were thawed and 0.4 ml aliquots (4mg protein, 7.26 pmol/min PLD 
activity) were diluted with an equal volume of homogenisation buffer containing 
detergent or salt as appropriate. For alkaline extraction at pH 12, 0.4 ml aliquots were 
centrifuged (100,000 x g, 1 h) and resuspended in 0.8 ml of lOOmM phosphate or 
carbonate solution pH 12. Samples were then agitated on a rotary wheel for 1 hr at 
4°C, centrifuged (100,000 x g, 1 h) and the solubilised PLD recovered in the 
supernatants. 5 fxl of the post-solubilisation supernatants were assayed for PLD 
activity as described in Section 2.4 and protein determined as described in Section
2.2.1. Total PLD activity extracted, expressed as a percentage of the total membrane- 
associated PLD activity, for each condition is shown opposite. This experiment is 
representative of another identical experiment.
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of the frozen membranes, resulted in maximal release of solubilised PLD activity. For 
alkaline pH exti'action, Na2HP04  was chosen in preference to carbonate as a neutral 
pH could be re-established by direct addition of 500mM NaH2P0 4 . Further, as these 
agents would effectively solubilise differing amounts of membrane lipid, minimum 
volumes of recovered solubilised and unsolubilised material (5pl from each fraction) 
were assayed for PLD activity. This would minimise the contribution of endogenous 
lipid to the overall concentration of exogenous lipid present in the in vitro PLD assay 
and therefore have limited influence upon the measured reaction rates of each sample.
The concentration dependence of TX-100 solubilisation of membrane- 
associated PLD activity was investigated (Fig 3.2). PLD activity was released in a 
concenti'ation dependent manner with maximal solubilisation achieved at a TX-lOO 
concentration of 16mM (1% w/v). Consistent with the recovery of PLD in the soluble 
supernatant fraction, a concentration-dependent reduction of PLD activity associated 
with the pelleted insoluble membrane fraction was also observed (Fig 3.2).
Membranes that were not exposed to detergent and further centrifuged showed little 
release of PLD activity (approximately 6%; data not shown).
Similar results were obtained when the pH dependence of phosphate 
extraction was investigated (Fig 3.3). Membranes were thawed and pelleted by 
centrifugation before exposure to phosphate solutions of varying pH. Up to 45% of 
the total membrane-associated PLD activity was recovered in freeze-thaw supernatant 
generated by centrifugation as previously described. After incubation in the presence 
of phosphate and further centrifugation, additional PLD activity was recovered in the
r.'i'-soluble supernatant fraction, but in a pH dependent manner, maximal at pH 12. 
Parallel reduction of PLD activity in the insoluble membrane fraction was also 
apparent (Fig 3.3). Incubation of the remaining unsolubilised crude plasma
membranes in the presence of lOOmM phosphate pH 12 showed little further release 
(approximately 4%) of PLD activity upon centrifugation (data not shown).
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Fig 3.2 Triton X-100-Dependent Solubilisation of Membrane-Associated PLD 
Activity from the Crude Plasma Membrane Fraction of Bovine Spleen.
Crude plasma membranes stored at -80^C were thawed and 0.4 ml aliquots (4mg 
protein, 7.26 pmol/min PLD activity) were diluted with an equal volume of 
homogenisation buffer containing TX-lOO as appropriate. Samples were then agitated 
on a rotary wheel for 1 h at A-^C. The samples were centrifuged (100,000 x g, 1 h) and 
the solubilised PLD recovered in the supernatants. Pellets were resuspended in 0.8 ml 
of homogenisation buffer. An appropriate volume of the post-solubilisation 
supernatants and 5|il of each pellet were assayed for PLD activity as described in 
Section 2.4; final concentration of TX-lOO in the assay was 0.1% (w/v). Protein 
concentration of each sample was detennined as described in Section 2.2.1. Total 
PLD activity recovered in each of the supernatants and pellets, expressed as a 
percentage of the total membrane-associated PLD activity, is shown opposite[open 
squares-solubilised activity; closed squares-unsolubilised activity]. This experiment is 
representative of another identical experiment.
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Fig 3.3 pH-Dependent Solubilisation of Membrane-Associated PLD Activity 
from the Crude Plasma Membrane Fraction of Bovine Spleen.
Crude plasma membranes stored at -SO^C were thawed and 0.4 ml aliquots (4mg 
protein, 7.26 pmol/min PLD activity) were centrifuged (100,000 x g, 1 h) and 
resuspended in 0.8 ml of lOOmM phosphate solution of appropriate pH. Samples were 
then agitated at for 1 h on a rotai'y wheel at 4^C. The samples were centrifuged 
(100,000 X g, 1 h) and the solubilised PLD recovered in the supernatants. Pellets were 
resuspended in 0.8 ml of phosphate solution and 5|il of the post-solubilisation 
supernatants and pellets were assayed for PLD activity as described in Section 2.4. 
Protein concentration of each sample was detennined as described in Section 2.2.1. 
Total PLD activity recovered in each of the supernatants and pellets, expressed as a 
percentage of the total membrane-associated PLD activity, is shown opposite [open 
squares-solubilised activity; closed squares-unsolubilised activity]. This experiment is 
representative of another identical experiment.
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Therefore, maximal solubilisation could be achieved by either TX-lOO 
extraction or high pH extraction with lOOmM phosphate pH 12. Both approaches 
displayed comparible solubilisation of PLD activity, however, it was recognised that 
pH extraction after centiifugation allowed recovery of a protein solution depleted of 
membrane lipid and unlikely to have membrane bound proteins contributing to its 
heterogeneity. Subsequently, freeze-thawing, centrifugation and alkaline pH 
extraction of the bovine spleen crude plasma membranes (pH 12) was adopted for 
solubilisation of the membrane-associated PLD activity. At full preparative scale this 
solubilisation protocol routinely resulted in 70 + 14 % (n=5) recovery of the total 
membrane-associated PLD activity. Further, the absence of detergent allowed the 
investigation of ammonium sulphate fractionation as a potential means of enzyme 
concentiation and purification (see Section 3.3).
3.3 Ammonium Sulphate Precipitation of the Solubilised PLD.
A number of approaches have been taken towards precipitation of proteins for 
preparative purposes (reviewed by Englard & Seifter, 1990). These include 
pertubation or modification of solvent by changes in pH and temperature or 
introduction of miscible organic solvents or certain salts. Generation of a soluble PLD 
activity from the crude plasma membrane fraction (as described in Section 2.5.2) in 
the absence of detergent allowed the use of ammonium sulphate fractionation as a 
potential means of concentration and purification of enzyme activity.
Small scale experiments were performed using solubilised PLD preparation 
and the dissolved bulk protein was precipitated, in increasing steps of 5 or 10% (w/v) 
saturation, by the successive addition of solid ammonium sulphate at pH 7.5 and 4% . 
The salt was added with constant stirring and full equilibration of the solvent 
achieved by further mixing for 30 min. The precipitate was then collected by 
centrifugation (10,000 x g, 15 min). The supernatant was decanted for further 
fractionation and the precipitate resuspended in 25 mM Hepes pH 7.5, 2 mM EDTA. 
This procedure was repeated until a final saturation of 80 % (w/v) was achieved. A 1
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Fig 3.4 Fractionation of the Solubilised PLD Using Solid Ammonium Sulphate,
100 ml (207 mg protein) of solubiUsed PLD was prepared by freeze-thawing, 
centrifugation and alkaline extraction of crude plasma membranes and adjusted to pH 
7.5. Successive fractionations were made by addition, at 4^C with constant stirring, of 
solid ammonium sulphate. The pH was maintained at 7.5 by addition of concentrated 
NH4OH. When all the salt was added the mixture was stirred for a further 15 min.
The resultant precipitate was then recovered by centrifugation (10,000 x g, 15 min). 
The supernatant was decanted and used as the starting material for the next 
fractionation. Fractions were successively precipitated at saturations of 20, 25, 30, 35, 
40,45, 50, 60,70 and 80% (w/v) respectively. A 1 ml aliquot of each supernatant was 
retained and each precipitate was resupended in 10 ml of 25 mM Hepes pH 7.5, 2 
mM EDTA. All fractions were then dialysed overnight against two changes of 11 of 
25 mM Hepes pH 7.5 containing 2 mM EDTA. 20 pi from each fraction was then 
assayed for PLD activity as described in Section 2.4 [hatched bars-activity remaining 
in recovered supernatants; solid bars-activity present in recovered precipitates].
8 0
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saturation Total protein Total PLD activitv Specific activitv
(w/v) (mg) (pmol/min) (pmol/min/me)
0-30% 39.7 13.5 ± 1.2 0.34 ±0.03
30-50% 19.0 19.8 ±0.9 1.04 ±0.05
50-60% 8.0 8.7 ±0.5 1.08 ± 0.06
60-70% 13.8 54.1 ±1.7 3.93 ±0.12
70-80% 8.2 16.6 ± 1.0 2.04 ± 0.12
8 1
ml aliquot of supernatant and precipitate from each saturation point were dialysed 
overnight against two changes of 11 of 25 mM Hepes pH 7.0, 2 mM EDTA and 
assayed for PLD activity (Fig 3.4).
PLD activity was detected in the first precipitate recovered at a saturation of 
20% (w/v). As saturation increased to 50% (w/v) the distribution of activity between 
supernatant and precipitate did not significantly change, however, at 60% (w/v) the 
majority of the total PLD activity was recovered in the precipitate, with further 
activity recovered in the precipitates of 70 and 80% (w/v) saturation. However, under 
these conditions the changes in protein concentration throughout the fractionation 
protocol were not determined. Therefore, as a step towards full scale preparative 
fractionation, a similar experiment was perfoiTned to investigate the distribution of 
total PLD activity, specific PLD activity and protein recovered as supernatants or 
precipitates over the following range of percentage saturation; 0-30%, 30-50%, 50- 
60%, 60-70% and 70-80% (w/v). This was performed in a similar manner as above, 
except equilibration of the protem solution achieved by 30 min of constant mixing.
Again, samples from each of the recovered precipitates were dialysed overnight and 
subsequently assayed for protein content, total PLD activity and specific PLD activity 
(Table 3.2).
Table 3.2 Changes In Total Protein, Total PLD Activity and Specific PLD 
Activity During Ammonium Sulphate Fractionation of the Solubilised PLD.
' i
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The profile of total protein, total PLD activity and specific PLD activity changed 
dramatically throughout the fractionation procedure. It was evident that maximal PLD 
activity was recovered at a saturation interval of 60-70% (w/v) (Table 3.2) with 
approximately 12% of the total protein.
The specific PLD activity, in common with total PLD activity, was also 
maximal at 60-70% (w/v) saturation where substrate was hydrolysed at a rate of 3.93 
±0.12 pmol/miii/mg of protein. Therefore, PLD activity was significantly enriched in 
this fraction with respect to the original starting material which hydrolysed substrate 
at a rate of 1.04 ± 0.08 pmol/min/mg of protein. Based upon the above data, 
approximately 20 % of the total protein representing 60-65 % of the total activity was 
recovered over the saturation interval of 50-80% (w/v). Therefore, fractionation 
allowing the recovery of such a precipitate was established for full scale preparative 
purification of the solubilised PLD. Use of this protocol routinely resulted in an 
approximate 3-fold enrichment with a 30-45 % yield of PLD activity.
1
3.4 Ion-Exchange Chromatography.
As an initial purification step, ion-exchange chromatography of the solubilised 
PLD was considered suitable. Initial studies utilised Q-Sepharose FF anion-exchange 
media due to its high capacity for protein, high chromatographic flow rates, ease of 
use and economy. A preliminary mvestigation was initiated to define conditions 
required for successful anion-exchange chromatography. Q-Sepharose FF 1 ml 
columns were equilibrated over the pH range of 5.0-9.0 (in 0.5 pH unit intervals) and 
1 ml of solubilised PLD activity, equilibrated to the same pH, was applied to each 
column. The columns were washed in the absence of NaCl and then eluted with
buffer containing IM NaCl and the collected fractions assayed for PLD activity (Fig
3.5A).
The amount of solubilised PLD activity bound to the anion-exchange resin 
increased as pH increased from the 5.0 to 9.0. Optimum binding occurred at pH 8.5.
Ï
However, this represented only 33 % of total PLD activity whereas 66 % of the total
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Fig 3.5 Determination of pH Conditions Required for Ion-Exchange.
A pH Conditions Required for Anion-Exchange.
B pH Conditions Required for Cation-Exchange.
2 ml of Q-Sepharose FF anion-exchange resin or S-Sepharose FF cation-exchange 
resin were equilibrated to the desired pH (5-9 or 5-8, in 0.5 pH units) by three washes 
of 10 volumes of 250 mM Buffer of appropriate pH, containing 1 M NaCl and three 
further washes of 10 volumes of 25 mM Buffer of appropriate pH, containing 2 mM 
EDTA, 0.1% (w/v) TX-lOO. After each wash the suspended resin was allowed to 
settle and the supernatant removed by aspiration. The supernatant of the final wash 
was aspirated to generate a resin slurry of 50%. Columns of 1 ml bed volume were 
then packed in glass wool plugged 2 ml syrmges with each of the equilibrated resins.
To each column, 1 ml of solubilised PLD (prepared as described in Section 2.5.2) 
equilibrated to the appropriate pH (by overnight dialysis against 25 mM buffer, 2 mM 
EDTA, 0.1% (w/v) TX-lOO) was loaded and the following washes performed:
(i) 3 X 1 ml of final equilibration buffer; pooled as 4 ml 'load' fraction inclusive of 
loaded volume.
(ii) 4 X 1 ml of equilibration buffer; pooled as 4 ml 'non-specific wash' fraction.
(iii) 3 X 1 ml of equilibration buffer containing 1 M NaCl; pooled as 3 ml 'first 
elution' fraction.
(iv) 3 X 1 ml of equilibration buffer containing 1 M NaCl; pooled as 3 ml 'second 
elution' fraction.
For screening experiments the following buffering systems over the pH range of 5 to 
9 were used; pH 5.0-Acetate, pH 5.5/6.0/6.5-Mes, pH 7.0/7.5-Mops and pH 
8.0/8.5/9.0-Tricine.
50 jil from each pooled fraction was then assayed for PLD activity as described in 
Section 2.4 and the activity recovered in each of the collected fractions from each 
column shown opposite [hatched bars-'load' fraction; solid bars-'non-specific wash' 
traction; open bars-'first elution' fraction; stippled bars-’second elution' fraction]. 1
8 3
'PLD activity remained unbound (Fig 3.5A). Therefore, cation-exchange 
chromatography using S-Sepharose FF resin was investigated as a potential step in 
purification of the enzyme. Conditions for successful cation-exchange were 
determined by preparation of similar 1ml columns, except the pH range of 5.5 to 8.0 
was investigated. Solubilised PLD was prepared as appropriate and applied to the 
equilibrated columns. Columns were then washed and eluted and the collected 
fractions asssayed for PLD activity (Fig 3.5B).
The solubilised PLD preparation bound to the cation-exchange columns in a 
pH dependent manner and under these conditions, strength of binding increased as pH 
decreased. At pH 5.5 and 6.0 approximately 80% of the activity was eluted with a 
buffer containing IM NaCl. However, it was noted that the protein applied to the
column equilibrated to pH 5.5 contained a heavy precipitate. This loaded material was 
immobilised at the top of the column bed and was resolvated upon development with
equilibration buffer containing 1 M NaCl. Therefore, this condition was discarded and 
a pH of 6.0 was established for full scale preparative cation-exchange 
chromatography using S-Sepharose FF resin. In addition, TX-lOO (0.1% w/v) was 
included in all chromatography buffers as its exclusion resulted in lower recovery of 
applied solubilised PLD activity (data not shown).
At full scale, the solubilised PLD activity was prepared as described in 
Sections 2.5.2 and 2.5.3 and subjected to cation-exchange chromatography on S - 
Sepharose FF column with a bed volume of 10ml. (Fig 3.6). The majority of applied 
protein did not bind to the column. Co-migrating with this protein was a minor PLD 
activity and represented approximately 5 % of the total PLD activity applied to the
I
u:S;
column. The major PLD activity was recovered upon development of the column with 
a linear gradient of 0-0.5M NaCl, eluting as a single peak between 120-360 mM 
NaCl. Development of the column from 0.5-1.0 M NaCl resulted in no further elution 
of PLD activity (data not shown). Active fractions were pooled and NaCl removed by 
overnight dialysis against 5 1 of chromatography buffer in preparation for further 
chromatographic purification.
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Fig 3.6 Cation-Exchange Chromatography of the Solubihsed PLD on S- 
Sepharose FF,
A 10 ml (1.6 X 4.96 cm) column of S-Sepharose FF was prepared as described in 
Section 2.6.2 and subsequently packed with 10 column volumes of 25mM Mes pH 
6.0 containing 2mM EDTA and 0.1% (w/v) TX-lOO. Solubilised PLD was prepared 
and dialysed overnight against the same chromatography equilibration buffer as 
described in Section 2.5.3. The dialysate was clarified by centrifugation (10,000 x g, 
15min) and the supernatant (190.01 rag protein) applied to the column (fraction 1-14). 
The resin was then washed with approximately 100 ml of chromatography buffer 
(fractions 15-34) and bound protein eluted by development of a 100 ml linear gradient 
of 0-0.5 M NaCl {solid line) in chromatography buffer. Fractions of 4.0 ml were 
collected and 50 pi from each fraction assayed for PLD activity {open squares) as 
described in Section 2.4. Protein concentration {closed squares) of the eluate was 
measured by absorption at 280 nm.
Employment of cation-exchange chromatography routinely resulted in an 
approximate 2-fold purification and a recovery of 30-50 % of the total PLD activity 
applied to the column.
3.5 Heparin-Agarose Chromatography.
Chromatography using heparin-substituted agaroses consists of both an ion- 
exchange process between the applied protein and the immobilised polyanion and 
also a pseudo-affinity-like binding process (Margalit et a l, 1993). Based upon these 
interactions, immobilised heparin has been successfully utilised in the purification of 
a number of proteins, particularly kinases, lipases and phospholipases. These include 
a receptor and G-protein regulated Ptdlns-specific phospholipase C from turkey 
erythrocytes (Moms et al, 1990) and most recently the membrane-associated PLD 
activities of HL-60 cells (Brown etal., 1993) and rat brain (Massenberg et a l, 1994).
The solubilised PLD routinely bound to a 1 ml column of heparin-agarose in 
the absence of NaCl at pH 6.0 and activity was recovered upon elution of the column 
with chromatography buffer (25mM Mes pH6.0, 2mM EDTA, 0.1% (w/v)) 
containing 1 M NaCl (Fig 3.7). Therefore, the post cation-exchange PLD activity was 
subjected to full scale preparative heparin-agarose chromatography (Fig 3.8).
All the applied protein containing PLD activity bound to the column and 
subsequent to washing with 10 volumes of chromatography buffer the PLD activity 
was recovered upon development of the column with a linear gradient of 0-0.85M 
NaCl. The PLD activity eluting as a single peak between 360-500 mM NaCl, distinct 
from the major peak of eluted protein. Development of the column from 0.85-2.0 M 
NaCl resulted in elution of no further protein or PLD activity (data not shown).
Active fractions were pooled and dialysed overnight against 5 1 of 25 mM Mes pH 
6.0, 1 M NaCl, 5 mM MgCl2 in preparation for adsorption chromatography using 
hydroxyapatite.
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Fig 3.7 Determination of Conditions Required for Chromatography of the
Solubilised PLD on Heparin-agarose.
2 ml of heparin-agarose resin were each equilibrated to the desired pH (6, 7 and 8) by 
three washes of 10 volumes of 250 mM Buffer of appropriate pH, containing 1 M 
NaCl and three further washes of 10 volumes of 25 mM Buffer of appropriate pH, 
containing 2 mM EDTA, 0.1% (w/v) TX-lOO. After each wash the suspended resin 
was allowed to settle and the supernatant removed by aspiration. The supernatant of 
the final wash was aspirated to generate a resin slurry of 50%. Columns of 1 ml bed 
volume were then packed in glass wool plugged 2 ml syringes with each of the 
equilibrated resins.
To each column, 1 ml of solubilised PLD (prepared as described in Section 2.5,2) 
equilibrated to the appropriate pH (by overnight dialysis against 25 mM buffer, 2 mM 
EDTA, 0.1% (w/v) TX-lOO) was loaded and the following washes performed:
(i) 3 X 1 ml of final equilibration buffer; pooled as 4 ml 'load' fraction inclusive of 
loaded volume.
(ii) 4 X 1 ml of equilibration buffer; pooled as 4 ml 'non-specific wash’ fraction.
(iii) 3 X 1 ml of equilibration buffer containing 1 M NaCl; pooled as 3 ml 'first 
elution' fraction.
(iv) 3 X 1 ml of equilibration buffer containing 1 M NaCl; pooled as 3 ml 'second 
elution' fraction.
For screening experiments the following buffering systems over the pH range of 6 to 
8 were used; pH 6.0 & 7.0-Mes and pH 8.0-Tricine.
50 |il from each pooled fraction was then assayed for PLD activity as described in 
Section 2.4 and the activity recovered in each of the collected fractions from each 
column shown opposite [hatched bai’s-'load' fraction; solid bars-'non-specific wash' 
fraction; open bars-’first elution' fraction; stippled bars-'second elution' fraction].
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Fig 3.8 Heparin-Agarose Chromatography of the Solubilised PLD.
A 10 ml (1.6 X 4.96 cm) column of heparin-agarose prepared as described in Section 
2.6.2 was packed and equilabrated with 10 column volumes of 25mM Mes pH 6.0 
containing 2mM EDTA and 0.1% (w/v) TX-lOO. The PLD preparation (43.4 mg 
protein) pooled from cation-exchange chromatography (Fig 3.6) was desalted by 
overnight dialysis against 5 1 of chromatography buffer and applied to the column. 
The resin was washed with 100 ml of chromatography buffer and bound protein 
eluted (fractions 1-25) by development of a 100 ml linear gradient of 0-0.85M NaCl 
in chromatography buffer(j(?/W line). Fractions of 4.0 ml were collected and 50 |ul 
from each fraction assayed for PLD activity {open squares) as described in Section 
2.4. Protein concentration {closed squares) of the eluate was measured by absorption 
at 280 nm.
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Employment of heparin-agarose chromatography routinely resulted in an 
approximate 4-fold purification and a recovery of 125-170 % of the total PLD activity 
applied to the column. The recovery of a greater amount of PLD activity than loaded 
onto the column may reflect the removal of an endogenous PLD inhibitor protein or 
an endogenous factor that interferes with the assessment of PLD activity in vitro. : |
3.6 Hydroxyapatite Chromatography.
■ Proteins adsorbed to an hydroxyapatite chromatography matrix can be 
specifically eluted based upon the systematic disruption of the complex electrostatic
interaction between the amino and carboxyl groups of the proteins and the charged 
calcium and phosphate of the hydroxyapatite crystal surface. Consequently, 
procedures that allow specific elution of basic, acidic and neutral proteins were 
investigated (Gorbunoff, 1990).
Solubilised PLD bound hydroxyapatite (BioGel HTP and Bio-Rad EconoPac
cartridges) and was retained on a 1 ml column equilibrated with 25 mM Mes pH 6.0, -g
2 mM EDTA 0.1% (w/v) TX-lOO (Fig 3.9A). Activity remained bound to the column 
during washing with 5 mM MgClz and a minor activity was recovered upon washing 
with IM NaCl. The majority of activity was recovered upon elution with 0.3M 
sodium phosphate. Post heparin-agarose PLD activity was fully retained on the 
column during washing with either 5 mM MgCli or 1 M NaCl in 25 mM Mes pH 6.0 
and successful elution was achieved using 0.3 M sodium phosphate (Fig 3.9B). From 
this information, an elution protocol was constructed. This employed equilibration of 
the column in 25 mM Mes pH 6.0 containing 5 mM MgCl2 and 1 M NaCl, resulting 41
in basic and neutral proteins selectively miming through the column. A linear gradient 
of 0-0.5 M sodium phosphate eluted the bound acidic proteins and the PLD activity.
Full scale preparative chromatography of the post heparin-agarose activity 
was performed using a 10 ml hydroxyapatite column and the elution protocol oulined 4
sabove (Fig 3.10). The solubilised PLD reproducibly eluted as a single peak of activity 
associated with eluted protein at a position in the gradient equivalent to
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ïFig 3.9 Determination of Conditions Required for Chromatography of the
Solubihsed PLD on Hydroxyapatite.
A Conditions required for chromatography of solubilised PLD.
B Conditions required for chromatography of post heparin-agarose PLD.
2 ml of hydroxyapatite (BioGel HTP) were initially washed three times with 10 
volumes of distillled water to remove fines. The hydroxyapatite was then equilibrated 
to pH 6.0 by three washes of 10 volumes of 250 mM Mes pH 6.0 containing 1 M 
NaCl and three further washes of 10 volumes of 25 mM Mes pH 6.0, containing 2 
mM EDTA, 0.1% (w/v) TX-lOO. After each wash the suspended resin was allowed to "fl:
settle and the supernatant removed by aspiration. The supernatant of the final wash Iwas aspirated to generate a resin slurry of 50%. A column of 1 ml bed volume was 
then packed in a glass wool plugged 2 ml syringe with the equilibrated resin.
To the column, 1 ml of solubilised PLD (prepared as described in Section 2.5.2) or 
post heparin-agarose PLD, equilibrated to the same pH (by overnight dialysis against 
25 mM Mes pH 6.0, 2 mM EDTA, 0.1% (w/v) TX-lOO), were loaded and the 
following washes performed:
(i) 3 X 1 ml of final equilibration buffer; pooled as 4 ml 'load' fraction inclusive of 
loaded volume.
,1(ii) 4 X 1 ml of equilibration buffer; pooled as 4 ml 'non-specific wash' fraction.
(iii) 4 X 1 ml of equilibration buffer containing 5 mM MgCl2; pooled as 4 ml MgCl2 |  
fraction.
(iv) 4 X 1 ml of equilibration buffer containing 1 M NaCl; pooled as 4 ml 1 M NaCl 
fraction.
I(v) 4 X 1 ml of equilibration buffer containing 0.5 M NaH2P04  ; pooled as 4 ml %
ÆNaH2P04  fraction.
a
I50 |4l from each pooled fraction was then assayed for PLD activity as described in a
•iï'Section 2.4 and the activity recovered in each of the collected fractions from each î;
Îcolumn shown opposite.
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Fig 3.10 Hydroxyapatite Chromatography of the Solubilised PLD,
The PLD preparation (18.97 mg protein) pooled from heparin-agarose 
chromatography (Fig 3.10) was dialysed overnight against 5 1 of 25 mM Mes pH 6.0, 
1 M NaCl, 5 mM MgCl2, 0.1% (w/v) TX-lOO and applied to 10 ml column of 
hydroxyapatite, consisting of two Bio-Rad 5 ml pre-packed cartridges connected in 
series, equilibrated with 50 ml of the above buffer. The resin was washed with 
chromatography buffer until the absorbance trace returned to baseline. Bound protein 
was eluted (fractions 20-45) by development of a 100 ml linear gradient of 0-0.3 M 
NaH2P04  {solid line) in chromatography buffer. Fractions of 4.0 ml were collected 
and 50 |J.l from each fraction assayed for PLD activity {open squares ) as described in 
Section 2.4. Protein concentration {closed squares) of the eluate was measured by 
absoiption at 280 nm.
:
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approximately 85 mM sodium phosphate. Active fractions were pooled and dialysed 
overnight to remove salt and phosphate in preparation for FPLC cation-exchange
flchromatography. Typically, use of adsorption chromatography on hydroxyapatite
resulted in an approximate 1.5-fold purification and 39-42 % recovery of the activity
■Ïapplied to the column.
3.7 FPLC Cation-Exchange Chromatography.
Characterisation of conditions required for cation-exchange chromatography 
using Pharmacia ion-exchange FF resin (see Section 3.4) allowed direct loading of the I;
dialysed post hydroxyapatite preparation to a Pharmacia Mono-S FPLC cation- 
exchange column. As an intermediate manipulative step, high resolution ion- 
exchange was investigated as a means of sample concentration and detergent removal 
that is required for successful gel filtration. Detergent removal was achieved by 
washing with chromatography buffer excluding TX-100. Initial experiments using g
gradients of 0-0.5 M NaCl over a small number of column volumes allowed recovery |
of all of the applied activity as an essentially detergent free sample of 3-4 ml (data not 
shown). However, development of the column with a gradient of 0-0.5 M NaCl over 
20 column volumes, partially resolved the majority of activity from the majority of 
protein. At preparative scale, 'columm dialysis' was perfomed by washing the 
immobilised sample with detergent free buffer until the absorbance trace returned to 
baseline. Fractions were then collected following gradient elution as described above 
(Fig 3.11). Again, resolution of activity from protein was observed. Activity in 
fractions 15-20 were pooled and concentrated in preparation for gel filtration 
chromatography.
Use of this chromatographic step routinely resulted in an approximate 2-fold 
purification and a 25-30 % recovery of the total activity applied to the column.
3.8 FPLC Gel Filtration Chromatography.
The ability to further purify the solubilised PLD activity by gel filtration of the
I
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Fig 3.11 FPLC Cation-Exchange Chromatography of the Solubilised PLD,
The PLD preparation (5.15 mg protein) pooled from hydroxyapatite chromatography 
(Fig 3.11) was dialysed overnight against 5 1 of 25 mM Mes pH 6.0, 2 mM EDTA,
0.1 % (w/v) TX-100 and applied to a Pharmacia pre-packed 1 ml Mono-S HR 5/5 
cation-exchange column equilibrated with 25 mM Mes pH 6.0, 2 mM EOT A. After 
loading, the resin was washed with detergent-free chromatography buffer until the 
absorbance trace returned to baseline. Bound protein was eluted by development of a 
30 ml linear gradient of 0-0.5M NaCl {solid line) in chromatography buffer. Fractions 
of 1 ml were collected during gradient development and 10 pi from each fraction 
assayed for PLD activity {open squares) as described in Section 2.4. Protein 
concentration {closed squares) of the eluate was measured by absorption at 280 nm.
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detergent free post Mono-S preparation was investigated. Pooled post Mono-S PLD 
preparation (5 ml) was concentrated 20-fold and applied to a FPLC SR-12 pre-packed 
gel filtration column (Fig 3.12), The solubilised PLD activity eluted as a single pealc 
distinct from the major peak of protein. Typically, the activity eluted in a volume of 
approximately 13 ml of buffer (n=5). Upon the determination of the columns void 
volume (vo, equivalent to 7 ml), the elution volume (ve) of the solubilised PLD was 
calculated to coii'espond to vg/vo values ranging between 1.64 and 1.65. Comparison 
of the elution volume of the solubilised PLD to those of known standard proteins of 
determined molecular weight allowed calculation of the apparent native molecular 
weight of the PLD (Fig 3.13). The native molecular weight of the solubilised PLD 
was calculated to be 69 ± 2 kDa (mean ± SD, n=5).
As a preparative chromatography step, FPLC SR-12 gel filtration 
chromatography routinely resulted in a small enrichment of the post Mono-S 
preparation and a 82-95 % yield of activity applied to the column.
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3.9 Table of Purification of the Solubilised PLD and SDS-PAGE Analysis of 
Chromatography Fractions.
■ :Partial purification of the solubilised PLD by the above protocol has been 
performed on five separate occasions with similar results. The pooled PLD recovered 
from each step was analysed by SDS-PAGE (Fig 3.14) and a typical purification 
summary is shown in Table 3.3. Use of the above protocol resulted in the recovery of 
a significantly purified PLD preparation; 42.3-64.2 fold purification relative to the 
total solubilised PLD recovered with a 1.52-1.98% yield. The final post gel filtration 
preparation exhibited a specific activity towards substrate of 71-111.1 pmol/min/mg 
of protein.
The individual fractions recovered from gel filtration chromatography that 
contained PLD activity were also analysed by SDS-PAGE (Fig 3.15). It was not 
possible to identify any single polypeptide that co-migrating with PLD activity during 
gel filtration chromatography. However, it was apparent that polypeptides of a similar
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Fig 3.12 FPLC Gel Filtration Chromatography of the Solubilised PLD.
The PLD preparation (0.72 mg protein) pooled from FPLC cation-exchange 
chromatography (Fig 3.10) was concentrated 20-fold to a volumeof 250 |al in a 
Centriprep 10 microconcentrator as described in Section 2.7.1. 200 p.1 of the protein 
concentrate was applied to a Pharmacia pre-packed 30 ml SR-12 gel filtration column 
equilibrated with 25 mM Mes pH 6.0, 2 mM EDTA, 250 mM NaCl. Fractions of 0.5 
ml were collected and 5 pi of each fraction assayed for PLD activity {open squares) 
as described in Section 2.4. Protein concentration {closed squares) of the eluate was 
measured by absorption at 280 nm.
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Fig 3,13 Calibration Curve of the FPLC SR-12 Gel Filtration Column.
The 30 ml pre-packed FPLC SR-12 column employed in Fig 3.12 was equilibrated 
with 25 mM Mes pH 6.0, 2 mM EDTA, 250 mM NaCl. Protein standards or post 
Mono-S PLD preparation were applied to the column in a volume of 200 |il and the 
column developed in the same buffer at a flow rate of 0.5 mPmin. The void volume 
(vo) of the column was determined from the elution of Blue Dextran monitored at 280 
nm. The elution of p-amylase (200 kDa), alcohol dehydrogenase (ADH, 150 kDa), 
bovine serum albumin (BSA, 66 kDa), carbonic anhydrase (CA, 29 kDa) and 
cytochrome-c (cyt. c, 12.4 kDa) from the column were also monitored at 280 nm and 
their elution volume (ve) determined. The Ve of the solubilised PLD was determined 
for the elution of PLD activity from the column (see Fig 3.13). The apparent 
molecular weight of the solubilised PLD was calculated from the calibration curve of 
log Mr against vq/wq.
96
(üG
O) GO(OT V
eo
T
O) GO ^
T y T
E3C<UC3
O)
00
h -
(O
lO
co
#
i !
cy
I I
Fig 3.14 Purification of the Solubilised PLD; SDS-PAGE Analysis.
10 pg of the PLD preparation pooled from each stage of the purification protocol was 
analysed by SDS- PAGE on a 10 % polyacrylamide resolving gel, as described in 
Section 2.3, and silver stained as described in Section 2.3.5.
Lane 1: Membranes.
Lane 2: Freeze-thaw 100,000 x g supernatant.
Lane 3: Phosphate extracted activity.
Lane 4: Total Solubilised PLD.
Lane 5: Ammonium sulphate precipitate (50-80% fraction).
Lane 6: Clarified load to S-Sepharose FF.
Lane 7: Post S-Sepharose FF.
Lane 8: Post heparin-agarose.
Lane 9: Post hydroxyapatite.
Lane 10: Post Mono-S HR 5/5.
Lane 11 : Post SR-12 Gel Filtration.
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Table 3.3 Purification of the Membrane-Associated PLD of Bovine Spleen,
Step
ExtractedMembranes
50-80%Ammonium
SulphateFraction
S-SepharoseFF
Heparin-
Agarose
Hydroxy­
apatite
Mono-S
SR-12 Gel Filtiation (Fractions 28-32)
Protein
(mg).
1507.00
190.01
43.40
18.97
5.15
0.72
0.68
Total Specific FoldActivity Activity PurificationIpmol/minl Ipmol/min/ 
mgl
2607.11
851.24
279.50
452.81
189.67
56.56
55.76
1.73
4.48
6.44
23.87
36.83
78.55
82.00
1.00
2.60
3.72
13.80
21.29
45.40
47.40
Yield
100.00
32.65
10.72
17.37
7.28
2.17
1.82
2-10 pi of enzyme preparation from each stage of the purification protocol was 
assayed for PLD activity as described in Section 2.4. Protein concentration was 
determined as described in Section 2.2.1.
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Fig 3.15 SDS-PAGE of the Column Fractions Co-Purifying With PLD Activity 
During SR-12 Gel Filtration Chromatography.
50|l l 1 of each fraction co-eluting with PLD activity from the SR-12 gel filtration 
column (see Fig 3.12) was analysed by SDS-PAGE as described in Section 2.3 and 
silver stained as described in Section 2.3.5. The PLD activity contained in a similar 
50 jLtl aliquot is indicated on each lane as appropriate. PLD activity was measured as 
described in Section 2.4.
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molecular weight to that determined as the native molecular weight of the solubilised 
PLD (see Section 3.15) were present in the collected fractions. In conclusion, the 
solubilised PLD was substantially purified by the above protocol, though not to 
homogeneity and the polypeptide responsible for activity remains to be identified.
3.10 Identification of the Solubilised PLD.
In the absence of a homogeneous preparation of the solubilised PLD, its 
identification within the mixture of polypeptides present after gel filtration 
chromatography (illustrated in Fig 3.15) could allow protein sequencing to be 
initiated. Despite the presence of 69 kDa polypeptides, no individual polypeptide was 
identified as co-purifying with PLD activity. Therefore, alternative analytical 
approaches were initiated to identify the polypeptide responsible for PLD activity.
The ability of PLD to catalyse a transphosphatidylation reaction and in the 
presence of short chain primary aliphatic alcohols form phosphatidylalcohols at the 
expense of PtdOH formation may predict the existence of a phosphatidyl-enzyme 
intermediate during hydrolysis of PtdCho by PLD. This may occur prior to the 
consequent formation of PtdOH and choline products. By presentation of PtdCho, 
tritium labelled in the acyl chain, during the reaction process, a ^H-labelled 
intermediate should be formed. If such an intermediate was stable then it was 
proposed that it could be isolated by precipitation, electrophoresed on an SDS-PAGE 
gel and subsequently visualised by autoradiography. Further, it was concluded that if 
labelling occurred in a specific manner then it would be possible to specifically 'chase' 
the labelled phosphatidyl moeity from the PLD by addition of a large excess of 
unlabelled PtdCho. Additionally, since the formation of the supposed intermediate 
would occur via a covalent linkage, it would be expected that the unlabelled PtdCho 
would not 'chase' the labelled PtdCho from those proteins labelled in a non-specific 
manner. Unfortunately, upon employment of this approach no labelling of the 
solubilised PLD was apparent (data not shown) and as this was a single investigation
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it is difficult to predict whether the solubilised PLD can be identified in this manner 
under similar or developed conditions. This requires further investigation.
3.11 Alternative Chromatographic Approaches Taken Towards the Purification 
of the Solubilised PLD.
Despite considerable purification of the solubilised PLD it was apparent that a 
number of polypeptides co-purified with the PLD activity (Fig 3.15). To allow 
purification of the solubilised PLD to homogeneity, a number of purification 
strategies in addition to those utilised could be pursued.
The use of affinity dye matrices were considered during the early stages of 
development of this purification protocol. It was found that a series of immobilised 
dyes; Matrex Orange A, AffiGel Blue, Matrex Green A and Matrex Red A were all 
able to bind the solubilised PLD at pH 6.0 in the absence of salt (data not shown). 
Washing the gels with 300mM NaCl resulted in complete elution of PLD activity 
from the Matrex Orange A and partial elution from Affigel Blue. Increasing the NaCl 
concentration to IM allowed complete elution from AffiGel Blue and initiated the 
elution of PLD activity from both Matrex Red A and Matrex Green A. Complete 
elution from Matrex Green A was achieved by multiple washes of IM NaCl (data not 
shown). This ordered elution of PLD activity would indicate an increasing binding 
affinity of Matrex Orange A<AffiGel Blue<Matrex Green A<Matrex Red (group 1, 
group 3, group 3 and group 5 respectively, as described by Stellwagen, 1990). 
Classification of the dye matrices relies upon their individual ability to bind protein; 
group 1 binding least and group 5 most. Despite characteristic binding to and elution 
from the affinity dyes, at full preparative chromatography scale, the use of affinity 
dyes during the early stages of the chromatography protocol did not result in any 
further enrichment of the solubilised PLD (data not shown). However, it may prove 
beneficial as a chromatographic step incorporated into the latter stages of the 
established purification protocol and requires further development.
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A series of amino-linked hydrophobic resins of increasing carbon chain length 
(agarose-NH[CH2]nNH2) were investigated for potential binding of the solubilised 
PLD. It has previously been reported that co-aminopropyl-agarose chromatography
can been utilised for the successful purification of PLD from Savoy Cabbage (Allgyer 
& Wells, 1979). The immobilised O)~arainopropyl group was proposed to confer a 
mimetic for the choline headgroup of PtdCho and allowed purification by means of a 
pseudo-affinity interaction. Despite this, in the presence of IM NaCl, the solubilised 
PLD did not interact with any of the resins based upon hydrophobicity or otherwise.
In a similar manner, the use of hydrophobic interaction chromatography was 
investigated using a Phenyl-Superose FPLC column. Under varying conditions in the 
prescence of IM NaCl and TX-100 no consistent binding to and elution from the 
column was observed.
Therefore, this resin in common with the series of amino-linked hydrophobic 
resins described above did not offer any further means of purification of the 
solubilised PLD and were not further investigated.
3.12 A Number of Proteins Co-Purify with the Solubilised PLD Activity During 
Chromatography.
Partial purification of the solubilised PLD by the protocol routinely generated 
a preparation that displayed pigmentation and suggested the presence of a haem 
containing protein. This was investigated by the use of scanning spectroscopy of post 
S-Sepharose and post heparin-agarose PLD activity in the presence and absence of the 
reducing agent dithionite (Fig 3.16). This generated a maximum peak of absorption at 
412nm for the oxidised form which shifted to 428nm upon reduction with dithionite. 
This was consistent with the observed spectra generated upon scanning of purified 
cytochrome bg^g (cyt bgag) from human neutrophils under similar conditions (Harper 
et al, 1984). Therefore, this suggested a putative cyt bggg co-purified with the PLD 
activity.
102
In a number of studies of haematopoeitic type ceils a temporal relationship 
between PLD activity and superoxide generation mediated by the formation of the 
respiratory burst complex has been described (Koenderman et al, 1989; Rossi et al, 
1990; Thompson et al, 1990; Agwu et al, 1991b) placing receptor-mediated 
activation of PLD kinetically upstream of superoxide production. The active 
respiratory burst complex is foimed upon receptor-mediated assembly of multiple 
protein components (see Heyworth etal,  1992; Segal & Abo, 1993; Chanock et al,
1994) which consists of the membrane bound cyt bggg (a 22kDa a  subunit, p22f 
and a heavily glycosylated 91kDa p subunit, gp91f^^ -^  ^with two cytosolic proteins of 
4.'}phox and kDa respectively (p47P^ -^^  and ) and one or more small
molecular weight G-proteins including R ad , Rac2 and/or Rap la (Quinn et a l,  1989, 
Abo e ta l,  1991; Knaus e ta l,  1991; Benna e tal,  1994; Bromberg etal,  1994). 
Complex formation involves the movement of these cytosolic proteins to a 
cytoskeletal location, the successful interaction of p22P^^ ^^ , p61P^ ^^  ^ and the small 
molecular weight G-protein with the cyt bssg is dependent upon p47P '^‘^  ^ and its 
expressed Src homology 3 domains (Sumimoto eta l,  1994). Activation appears to be 
GTP-dependent, however, the GDP-bound form of R ad has recently been described 
as a potent activator of the complex (Bromberg et al, 1994).
Purification of p41P^^^ has been reported to occur in association with cyt bggg 
(Teahan et al, 1990) and its direct interaction with the C-terminal regions of cyt bssg 
subunits during activation of the complex has been characterised (Nakanishi e ta l,
1992). Therefore, based on the putative co-purification of a cyt bggg with PLD 
activity the possibility of co-purification of the other respiratory burst proteins with 
the bovine spleen PLD preparation. This was examined by Western blotting (Fig 
3.17) utilising polyclonal antibodies raised to the pAlP^^ and p61P^^^ proteins (kind 
gift of P. Heyworth). Initial investigations demonstrated that Western blotting of 
material from each stage of the purification protocol showed p47P^ *^ -^  to be 
immunologically detectable to the stage of post heparin agarose-chromatography and 
corresponded to the expression of p47f’^*'^  ^in HL-60 cell extracts and the lack of
103
Ab».units
0.20
+ DITHIONITE0.10
0.00
200 300 400 500 600
B W a v e le n g th  (n m )
0.10
0.08
+ DITHIONITE
0.06
A b s,
units
0.04
0.02
0.00
600300 400200 500
Wavelength (nm)
Fig 3.16 Scanning Spectroscopy of Post S-Separose and Post Heparin-agarose 
PLD Preparations.
A Scanning spectrophotometry of post S-Separose PLD preparation.
B Scanning spectrophotometry of post heparin-agarose PLD preparation. 1
.Continuous scanning spectrophotometiy of the partially purified PLD preparations 3
(200 |il) was performed between 200 and 600nm in a Shimadzu UV-2101PC UV- 
Visible scanning spectrophotometer in the presence and absence of an excess amount 
of sohd dithionite. Absorbance profiles were recorded by a Roland Sketchmate 
printer.
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Fig 3.17 Anti-p47P^ "-'^  and p67Pl*»^  Immunoblotting of Solublised PLD 
Recovered During Purification.
30jig of protein from whole cell lysates and the partially purified PLD preparations IS
recovered during chromatography (listed below) were prepared in SDS-sample buffer
.as described in Section 2,3.3 and subjected to SDS-PAGE on 10% polyacrylamide 
slab gels. Resolved proteins were transferred onto nitrocellulose and membranes
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probed with anti-p47/^^^ and antibodies, washed and developed using the
ECL detection system as described in Section 2.8. This experiment is representative 
of another identical experiment.
fs
Lane 1 : Whole-cell lysate from normal human neutrophils.
Lane 2: Whole-cell lysate from CGD-pô?#"^^ deficient human neutrophils.
Lane 3: Whole-cell lysate from CGD-p47#^^ deficient human neutrophils. I
Lane 4: Crude cytosolic fraction of HL-60 cells.
Lane 5: Crude membrane fraction of HL-60 cells.
Lane 6: Solubilised PLD.
Lane 7; Post S-Sepharose.
Lane 8 : Post heparin-agarose.
Lane 9: Post hydroxyapatite.
Lane 10: Post Mono-S cation-exchange.
il■s
expression of the p47P^ *^ -^  protein in neutrophil extracts obtained from chronic 
granulomatous disease (CGD) patients deficient in the p471^ ^^ -^  protein (Fig 3.17A). 
Cross-reactivity with the anti"p67^’^ '^^  ^antibody was also apparent in these fractions, 
however, a number of polypeptides of vaiying molecular weight were detected (Fig 
3.17B). The integrity of these polypeptides as being p671^ ^^ ^^  or p671 /^^^ -^derived 
remains questionable despite comparison to cellular extracts from HL-60 cells and 
neutrophils of CGD patients deficient in p67/^^^^.
microsomal membranes. The crude membrane fraction contained higher specific and
106
t-
3.13 Discussion.
3.13.1 Purification of Solubilised PLD from Bovine Spleen.
From initial investigations it was apparent that the membrane fraction of 
bovine spleen exhibited both a higher specific and higher total PLD activity than the 
crude cytosolic activity. It was also evident that fractionation of bovine spleen 
homogenate generated a crude plasma membrane fraction with a 10-fold increase in
the specific activity of PLD. Significant PLD activity was also recovered in the 
cytosol. However, as the cytosolic preparation represented the supernatant from the 
35,000 X g pellet, it is possible that this activity is associated with non-pelleted
total PLD activity and was adopted as the source of enzyme for purification. This 
indicated that successful solubilisation or extraction of the membrane-associated
activity from the heavy membrane fraction was necessary.
A wide range of agents solubilised PLD activity. It was recognised that these 
agents may solubilise different amounts and species of lipid to different extents from 
the particulate samples. These lipids would influence the assay conditions and 
therefore the specific activity of the recovered solubilised fractions. Since only small 
amounts of the solubilised and unsolublised fractions were assayed there was only a
'small contribution of endogenous factors in the assay. Consequently, the non-ionic 
detergent TX-100 and high pH extraction appeared to be optimal. Additionally, pH 
extraction extraction produced a lipid depleted and detergent free protein solution.
The use of TX-100 for successful solubilisation suggested the PLD to be a 
membrane-bound protein; however, the ability to recover a soluble activity after salt 
extraction suggested the activity to be membrane-associated. It was also evident that 
the freeze-thawing of the heavy membrane fraction resulted in release of PLD 
activity, again suggesting the PLD activity to be membrane-associated rather than 
membrane bound. Further, high pH extraction of the heavy membrane fraction also 
released activity in the absence of detergent. Therefore, it was evident that PLD 
activity existed as a membrane-associated protein that did not require detergent for 
successful solubilisation.
The existence of multiple membrane-associated isoforms of PLD cannot be 
discounted. No solubilising agent investigated allowed complete extraction of all the 
activity and therefore it may be that a number of distinct PLD isoforms are extracted 
by the different agents: a loosely membrane-associated activity sensitive to salt 
extraction, a tightly membrane-associated form requiring high pH extraction for 
successful solubilisation, a membrane-bound form requiring detergent solubilisation 
and a detergent insoluble form interacting with detergent insoluble elements 
associated with the plasma membrane, possibly the cytoskeleton.
Generation of a lipid depleted soluble activity, that did not require detergent 
for solubility allowed the use of ammonium sulphate precipitation in the purification 
protocol. Recovery of the majority of activity in the precipitate of 50-80 % (w/v) 
saturation suggested that the activity existed with a highly charged shell of hydration. 
It was also apparent that activity was recovered at all saturation points in the 
preliminaiy experiments. As percentage saturation increased from 0-50 % (w/v), it is 
probable that any remaining particulate material present in the solubilised preparation 
would precipitate. Therefore, the activity recovered in these fractions may represent 
the co-precipitation of any PLD activity in association with this remaining particulate- 
derived lipid. Furtlier, the solubilising conditions used allowed extraction of 
peripheral membrane proteins, likely to be predominantly hydrophilic in character. 
Any hydrophobic regions or domains expressed by these protein may associate
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specifically or non-specifically in an aqueous enviroment, such that complexes of 
proteins with a highly charged surface were formed. Under these conditions, 
perturbation of the soluble activity in its aqueous environment would require a high 
percentage of saturation.
The precipitated PLD activity was dialysed to remove salt and establish a pH 
of 6.0. Routinely, after dialysis the solubilised PLD preparation required clarification 
before initiation of cation-exchange chromatography. The recovered precipitate 
contained little (approximately 1%) or none of the total activity dialysed (data not 
shown). The precipitate was discarded and the majority of the activity, recovered in 
the clarified supernatant, utilised for further purification.
It was observed that binding of solubilised activity to anion and cation- 
exchange resms occurred at pH 8.5 and 6.0 respectively. This suggested that the 
solubilised activity existed as either a single protein with a neutral pi, with pH 
manipulation altering its electrostatic charge and hence binding to both ion-exchange 
resins, or as two separate activities, one anionic and the other cationic. Upon full- 
scale cation-exchange chromatography, the applied preparation routinely resolved as 
two separate activities, a minor activity associated with the unbound protein and the 
major activity recovered upon elution of the column. Separation of such activities 
may indicate the solubilisation of two membrane-associated PLD isoforms.
In conclusion, two PtdCho-hydrolysing PLD activities were observed to be 
present in the solubilised bovine spleen preparation, however, it may represent the 
activity of one single protein that has been partially modified or lost' a cationic region 
required for binding to the initial S-Sepharose column. As gel-riltration of the 
solubilised PLD preparation was not performed at this stage it remains speculative to 
suggest that these two activities represent individual PLD isofoims. Thus, this 
requires confirmation by biochemical characterisation of its molecular mass, true
■isoelectric point and kinetic parameters.
Initial small-scale chromatography with heparin-agarose suggested that PLD 
activity interacted in a manner similar to that observed with cation-exchange resin;
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the activity interacting in an ionic manner with the immobilised polyanion. However, i
at full preparative scale, gradient elution of the solubilised PLD required higher 
concentrations of NaCl than those utilised duiing cation-exchange chromatography, 
suggesting a more specific interaction. Such interactions have been attributed to 
distinct heparin binding sites expressed within protein sequences (Mai'galit et ai,
1993). Such a sequence may be expressed by the solubilised PLD or a protein with 
which it is in close association. Therefore, it could be suggested that the use of 
heparin-agarose chromatography results in two chromatographic processes. Firstly, 
the majority of protein interacts in a manner similar to cation-exchange and secondly 
a percentage of the post S-Sepharose preparation, including the solubilised PLD 
interact in a manner based upon affinity. f
Use of heparin-agarose chromatography routinely resulted in recovery of a 
greater amount of PLD activity than the total activity applied. This effect upon 
activity cannot simply be attributed to the loss of cellular lipid as this would have |
been removed during prior S-Sepharose cation-exchange chromatography. This 
suggested the possible existence of a PLD inhibitory protein or factor. Partial 
purification of cytosolic PLD from bovine lung also enhanced overall PLD activity by 
Up to 20-fold (Wang et al, 1991) and may further suggest the existence of a PLD
inhibitory factor. Additionally, regulation of the membrane-associated activity of HL- 
60 granulocytes may be influenced by the potential existence of a PLD inhibitory %
protein, illustrated by the fact that ARP derived from bovine brain cytosol, as opposed 
to cytosol from HL60 cells, was ineffective in stimulating PLD activity in HL-60 
membranes until it was partially fractionated by chromatography (Brown et al,
1993). Further, partial purification of an ARF-sensitive PLD activity from porcine 
brain is only detectable after cation-exchange chromatography, with no measurable 
activity present in crude fractions nor solubilised extracts prior to this fractionation 
(Brown et al, 1995). These observations also resemble the existence of an 
unidentified cytosol-derived inhibitor of soluble PtdCho-PLC from canine myocardial 
tissue (Wolf & Gross, 1985).
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Duiing hydroxyapatite chromatography the post-hepaiin PLD activity 
routinely resolved as a single peak of activity recovered by sodium phosphate elution.
According to the classification of Gorbunoff (1990), this would suggest the partially 
purified PLD to be an acidic enzyme of pi less than 7.0. Examination of the small 
scale hydroxyapatite chromatography (see Section 3.6), utilising the initial solubilised 
material, suggested that the minor PLD activity recovered upon 1 M NaCl elution 
may represent another isoform with a neutral pi (7.0-7.6), distinct from the partially 
purified activity. This may discount the suggestion that the solubilised activity that 
interacts with both anion and cation-exchange resins, at pH 8.5 and 6.0 respectively, 
is a single enzyme. Indeed, two distinct isoforms may be present in the initial 
solubilised preparation, the minor one removed by cation-exchange chromatography 
(see Section 3.4). However, the assignment of pi values suggested by 
chromatography on hydroxyapatite remains tentative.
Mono-S cation-exchange chromatography served as a rapid, high resolution 
means of detergent removal in preparation for gel-filtration chromatography.
Development of a shallow linear salt gradient also led to further purification of the 
eluted solubilised PLD.
Upon gel-filtration chromatography the solubilised PLD migrated with an 
apparent molecular weight of 69 kDa, This was different from the observed 50 kDa 
activity from human neutrophil cytosol (Bowman etal, 1993), the 30 and 80 kDa 
activities partially purified from bovine lung (Wang et ai, 1991) and the partially 
purified rat brain 200 kDa activity (Taki & Kanfer, 1979). The differences in 
obseiwed molecular weight may be accounted for by the absence or presence of 
detergents which contribute to the apparent molecular weight.
The purification protocol developed during this work shares a number of 
similarities to those utilised in the purification of other membrane-bound PLD 
activities. Ammonium sulphate precipitation has previously been reported in the |
partial purification of the oleate-activated membrane-associated PLD activity of rat 
brain (Taki & Kanfer, 1979). In common with the solubilised PLD activity described
110
here, this activity was precipitated at a saturation of 70 % (w/v). The chromatographic 
approaches used here are similar to those of published characterisations of PLD 
isozymes where ion-exchange, heparin, hydroxyapatite and gel-filtration resins have 
been exploited. These are relevant to the purification of the membrane-associated 
PLD activities from porcine brain (Brown et al, 1995), porcine lung (Okamura & 
Yamashita, 1994), rat brain (Taki & Kanfer, 1979; Massenberg et al, 1994) and HL- 
60 granulocytes (Brown e ta l,  1993). In the most recently communicated partial 
purifications of PLD activities (Brown etal,  1993; Massenberg e ta l ,  1994;
Okamura & Yamashita, 1994) it has become apparent that successful chromatography 
has been possible by the use of a number of chromatographic steps that were 
independently developed during this research. Amongst the above studies, one 
outstanding example of striking similarity to the work described in this chapter, in 
both the nature of chromatography and the elution protocols utilised, is the partial 
purification of the membrane-associated PLD activity of porcine brain (Brown et al,
1995). Within this particular protocol, partial purification utilised S-Sepharose cation- 
exchange chromatography with a lOO-lOOOmM NaCl gradient, repeated heparin 
affinity chromatography with a 300mM-1500mM NaCl gradient, hydroxapatite 
chromatography with a 0-500mM potassium phosphate gradient and gel-filtration 
resolution. The similarity of these chromatographic steps, though in a different order, 
suggests that the solubilised PLD activity partially purified in this research may be 
related to the ARF-sensitive PLD activity characterised from porcine brain. However, 
this remains to be confirmed under the assay conditions established for identification 
and characterisation of such an activity (Brown etal,  1993).
3,13,2 Does PLD Exist In A Complex With Other Proteins ?
Pertinent to the solubilised PLD described here, it was recognised that 
removal of detergent during FPLC cation-exchange chromatography and subsequent 
concenti'ation before gel-filtration may have resulted in specific or non-specific 
protein:protein interactions, contributing to the determined molecular weight of 69
1 1 1
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kDa. Therefore, the profile observed upon gel-filtration may represent that of either a 
single polypeptide or a number of interacting proteins in a protein complex.
Consistent with multiple proteins interacting in an undefined manner was the 
observed co-purification of a putative cyt bggg and immunodetectable protein
to the stage of heparin-agarose chromatography. These proteins are required for the 
formation of the agonist-stimulated respiratory burst complex in haematopoeitic cell 
types (see Section 3.12). In a number of cases the involvement of agonist-stimulated 
PLD and the formation of PtdOH have been reported to be involved in the regulation 
of the assembly of this complex (see Section 1.9.3). However, the nature of the 
interaction of PLD, or its lipid product, with these proteins during complex formation 
remains unknown. This may be by direct or indirect means. Therefore, co-purification 
of these proteins may merely reflect structural and biochemical similarities to the 
PLD activity described in this work such that they interact with chromatography 
supports in a manner independent of PLD. This requires further elucidation.
3.13.3 Additional Stratergies for the Purification of PLD.
In the absence of purification of the membrane-associated PLD to 
homogeneity a number of alternative chromatographic approaches to purification 
could be undertaken. This is highlighted by the successful binding to and elution from 
the affinity dye resins described in Section 3.11. Although no significant purification 
was observed upon chromatography of the solubilised PLD during the early stages of 
development of the purification protocol, it may represent an alternative means of 
fractionation to be included as a later step. In addition to this, affinity chromatography 
of the solubilised PLD could be investigated. This would rely upon the successful 
immobilisation of PtdCho to a suitable chromatography support. Indeed, PtdCho 
covalently immobilised via its acyl chains to an agarose support has been successfully
■if
employed in the purification of Crotalus adamanteus venom PLA2 (Rock & Snyder, 
1975). Further, polyacrylamide immobilised sn-l, 2-diacylglycerol and sn-l, 2- 
diacylglycerol in combination with PtdSer have been utilised in the purification of
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membrane-associated DAG kinase of rat brain and PKC from rabbit renal cortex 
respectively (Besterman et al, 1986b; Uchida & Filburn, 1984). It is unknown 
whether the solubilised PLD would interact with immobilised PtdCho, however, both 
techniques remain attractive alternative chromatographic approaches towards 
purification of the membrane-associated PLD.
The use of ion-exchange chromatography during the purification protocol may 
suggest that chromatofocusing could be applied towards purification of the enzyme. 
During this type of chromatography, proteins are eluted by means of a decreasing pH 
gradient developed across a weak anion-exchange column, as their net positive charge 
is lost. This would rely upon the application of the solubilised PLD to a weak anion- 
exchange medium at a pH above its pi to allow binding. It must be realised that whilst 
chromatofocusing may allow further purification of the enzyme, conditions for 
successful chromatography may require some development as it is not known whether 
the solubilised PLD will bind to an anion-exchange column at a pH above its 
suggested pi of <7(see Section 3.9) or whether significant loss of activity would be 
obseiwed upon manipulation of the pH enviroment of the enzyme subsequent to 
partial purification.
Non-chromatographic approaches towards purification of the solubilised PLD 
could be undertaken, including prepaiative non-denaturing gel electrophoresis and 
preparative SDS-PAGE analysis. It is unknown whether electrophoresis of the 
solubilised PLD can be conducted under non-denaturing conditions. Further, the 
solubilised PLD remains to be identified on SDS-PAGE analysis of the post gel- 
filtration preparation (see Section 3.9) and this has prevented the further purification 
of the enzyme by preparative SDS-PAGE. Therefore, both these techniques remain to 
be investigated.
The putative formation of a phosphatidyl-enzyme intermediate during PLD 
catalysed hydrolysis of PtdCho allowed the possible isolation of such a 
protein/substrate complex to be investigated. This was conducted with radiolabelled 
lipid substrate such that any formation of a protein/substrate complex could be
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detected; however, this was not successful in this study. Despite this, covalent 
modification of the solubilised PLD's catalytic subunit with a photo-affinity PtdCho 
analogue containing a photoreactive fatty acid may represent an alternative approach 
to the enzyme's identification. Use of a lysoPtdOH molecule containing a photo­
reactive diazirine group has been utilised in the identification of a putative membrane 4
receptor for this bioactive lipid (van der Bend et al, 1992a). Suitability of such an 
approach would rely on its characterisation as a PLD substrate and its inhibition of |
modification by PtdCho substrate. Although this technique has not as yet been 
employed for the bovine spleen membrane-associated PLD described in this work, 3
such an approach has been taken towards identifying a solubilised membrane- 
associated PLD from rat brain. Despite labelling of multiple proteins, no single
ipolypeptide was conclusively identified as the solubilised PLD (M. Liscovitch, 
personal communication).
The solubilised bovine spleen PLD protein has been partially purifed in this j
research; however, the polypeptide responsible for activity has not been 
unequivocally identified. Alternative approaches to the purification and identification 
of PLD include the possibility that a phosphatidyl-enzyme intermediate is formed 
during the catalytic reaction thereby allowing labelling of the protein and subsequent 
isolation of the protein-label complex without the preservation of enzyme activity. I
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Chapter 4
Characterisation of the Solubilised Phospholipase D.
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enzymes.
Using this methodology, the activity of the partially purified preparation was 
characterised as a distinct Phospholipase D activity and its substrate specificity within
I
4.1 Introduction.
The aim of this project was to purify the PLD activity responsible for 
receptor-stimulated PtdCho hydrolysis. Until recently, no PLD activities had been 
purified to homogeneity from a mammalian source, however, the existence of distinct 
isoforms with distinct phospholipid substrate specificities had been suggested (eg.
Taki & Kanfer, 1979; Kobayashi & Kanfer, 1987; Wang e ta l,  1991; Horwitz &
Davis, 1993; Okamura & Yamashita, 1994; see Sections 1.8 & 1.11). To facilitate the 
purification of a PtdCho-specific PLD activity, PtdCho was employed as substrate in 
the mixed micellar assay. Further, any previous kinetic and biochemical 
characterisation of PLD activity has been performed upon crude fractions of broken 
cell preparations and not a highly purified enzyme preparation in a defined mixed 
micellar assay system as described in this chapter. f
The catalytic rate towards PtdCho was investigated by the presentation of lipid 
substrate in combination with the detergent TX-lOO, as described by Dennis and 
coworkers for other lipid hydrolysing enzymes such as PLA2 (Dennis, 1974; Deems
Iet al, 1975) and the phosphatidic acid phosphohydrolase and Ptdlns 4-kinase 
activities of yeast (Lin & Carman, 1990; Buxeda et al, 1991). This model is known 
as the 'surface dilution' model for presentation of lipid substrate to lipid hydrolysing
f
the major glycerophospholipids determined. The divalent cation and pH dependence ;Si
of the solubilised PLD's activity were also examined.
4.2 Phosphatidylcholine Concentration Dependence.
4.2.1 Establishment of Mixed Micellar Conditions For Measurement of Catalytic 
Rates. «
3:The membrane-associated PLD was partially purified by S-Sepharose cation- 3
:exchange and heparin-agarose chromatography. This preparation was then utilised in %
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the kinetic analysis and characterisation of the enzyme. These studies required a 
defined assay for PLD m vitro comparable to those used for studying the detailed 
'mode of action' of other lipid hydrolysing and metabolising enzymes. These enzymes 
normally act upon substrates that are intercalated as part of complex structures such 
as mixed micelles rather than ones that are dispersed (DeHaas etal., 1971). Dennis 
and CO workers (Dennis, 1974; Deems etal., 1975) described such methodology for 
the assessment of the activity of purified PLA2 (Naja naja) towards mixed micelles of 
TX-lOO and PtdCho, establishing the 'surface dilution' kinetic model. This involved 
the preparation of lipid/detergent micelles at fixed molar ratios whereby fixed 
concentrations of lipid could be maintained at the surface of the lipid/detergent 
micelles and 'presented' at the aqueous/lipid interface for enzyme catalysed 
metabolism. Kinetic analyses of these enzymes were demonstrated to be best 
performed using mixed micelles (Dennis, 1974; Deems etal., 1975) and this 
methodology was utilised for the characterisation of the solubilised PLD.
Initial assessment of PLD activity in crude fractions was achieved using an in 
vitro assay based upon that described by Martin (1988); however, detailed 
characterisation of this assay was not detennined. Therefore, in accordance with the 
'surface dilution' kinetic model, PLD activity was measured as a function of the sura 
of the molar concentration of TX-lOO plus PtdCho at a set micellar surface 
concentration of 2.8 mole percentage (mol %), similar to that described in the original 
assay of Martin (1988) and utilised during the early development of the purification 
protocol.
At low micellar concentrations of TX-lOO, where the critical micelle 
concentration was a significant percentage of the total detergent concentration, 
activity was dependent on the bulk concentration of PtdCho (Fig 4.1). However, at 
high detergent concentration in the micelle the contribution of the the critical micelle 
concentration to the total detergent concentration became less significant and PLD 
activity was independent of the bulk concentration of PtdCho (Fig 4.1). At these 
elevated concentrations saturation kinetics were exhibited and the same percentage of
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Fig 4.1 Phospholipase D Activity Measured as a Function of the Sum of the 
Molar Concentrations Of Triton X-100 Plus Phosphatidylcholine.
PLD reaction velocity was measured as a function of the sum of the molar 
concenti’ations of TX-lOO plus PtdCho at a set micellar surface concentration of 
PtdCho (2.8 mol %). Reaction velocity was determined at the bulk concentrations 
indicated employing 10 pi of the post heparin-agarose preparation. After 60 min, 
reactions were terminated and choline generation determined as described in Section 
4.2.1. Protein concentration of the post heparin-agarose PLD preparation was 
determined as described in Section 2.2.1.
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the total lipid substrate was hydrolysed. It was apparent that the partially purified 
PLD activity catalysed the hydrolysis of PtdCho substrate in a manner predicted by 
the model for enzymes hydrolysing substrate intercalated in a lipid/detergent phase. 
This represented maximal activity at a micellar surface substrate concentration of 2.8 
raol% and TX-lOO concentrations of 1.6 mM and higher (Fig 4.1). Therefore, the 
characterisation of PLD activity and its catalytic rates towards PtdCho were examined 
at TX-lOO concentrations of 1.6mM, whereby all of the provided subsU'ate was 
assumed to be incorporated into the lipid/detergent micelles and the contribution of 
the critical micelle concentration for TX-lOO to be negligable.
1 1 9
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4.2.2 Determination of Apparent Km and Vmax Values with Phosphatidylcholine as 
Substrate.
At a fixed TX-lOO concentration of 1.6 mM (0.1% w/v), the reaction rate of 
the partially purified PLD was examined over a range of PtdCho concentiations 
expressed as a mole percentage of the TX-lOO/PtdCho mixed micellar phase. The rate
of reaction increased as a linear function of micellar surface PtdCho concentration 
(Fig 4.2). Saturation of activity with respect to substrate did not occur and a maximal 
rate was not measured. This was in part due to the inability of TX-lOO to maintain 
lipid solubilisation above 40-50 mol % PtdCho. Lipid substrate was visibly insoluble 
at these high concentrations. Fitting of the data to the Enzfitter Version 1.05 non­
linear regression data analysis computer programme revealed that the observed 
kinetics were typically first order. This was consistent with the mixed miceUe 'surface 
diluton' model in that PLD activity was dependent upon increasing PtdCho 
concenti'ation, however, the lack of observed saturation of activity with respect to 
substrate did not allow Vmax and Km values to be estimated and suggested the 
enzyme did not conform to Michaelis -Menten kinetics. Therefore, high mol% 
concenti'ations of substrate may allow zero order kinetics to be observed, however 
this appears to be beyond the solubilisation capabilities of TX-lOO (see above).
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Fig 4.2 Phospholipase D Reaction Velocity; Concentration Dependence on 
Phosphatidylcholine.
The reaction velocity of the solubilised PLD was determined as outlined in Section
4.1 in the presence of 1.6 mM (0,1% w/v) TX-lOO except at the indicated increasing 
mol% micellar surfaceconcentrations of PtdCho using 10 pi of the post heparin- 
agarose enzyme preparation. After 60 min, reactions were terminated and choline 
generation determined as described in Section 2.4. Protein concentration of the post 
heparin-agarose PLD preparation was determined as described in Section 2.2.1.
I
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Since saturation of activity with respect to substrate could not be achieved in 
this assay system, all further assays were performed at 1.6 mM TX-lOO and 2.8 mol% 
PtdCho under conditions of pseudo first-order kinetics. These conditions displayed 
linear choline generation with respect to protein (50 pg partially purified enzyme) and
time (60 min) (data not shown).
4.3 Dependence on Divalent Cations for Activity,
The effect of divalent cations, Ca^+ and Mg^+, upon the rate of reaction of the 
solubilised PLD was investigated over the concentration range of 10"l^-lCf^M and 
10"^-10‘^ M respectively. This was performed using the standard assay conditions 
desciibed in Section 4.2 with free divalent cation concentrations buffered by means of 
EGTA/cation buffering calculated by a chelation computer programme.
In each of these investigations, under conditions of no free divalent 
cation/lmM EGTA, the specific activities of the partially purified PLD preparations 
were 20.1±0.8 and 22.3+1.8 pmol/min/mg respectively. Subsequently, the activity of 
the partially purified enzyme was unaltered at physiological Ca^ "^  concentrations 
(0.1 pM). However, at higher concentrations of Ca^+ a small inhibition of activity was 
observed (Fig 4.3A). In contrast, the partially purified enzyme appeared insensitive to 
modulation of free Mg^+ concentration (Fig 4.3B) and no modulation of reaction rate 
was observed over tlie Mg2+ concentration range when assayed in the presence of 10' 
free Ca^+ (data not shown).
4.4 pH Dependence of Activity.
The effect of pH upon the rate of reaction of the solubilised PLD was 
investigated over the pH range of 5.0 to 9.0. This was performed using the standard 
assay conditions (Section 4.2) and a multicomponent buffering system consisting of 
50 mM Acetate/Mes/Mops/Tricine; pH was fixed by addition of HCl of NaOH as 
appropriate. At pH 7.5, use of this buffering system to replace the customary 50 mM
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Fig 4.3 Effect of Calcium and Magnesium Upon Solubilised Phospholipase D 
Reaction Velocity.
A Effect of calcium upon solubilised PLD reaction velocity.
B Effect of magnesium upon solubilised PLD reaction velocity.
PLD reaction velocity was detennined with 10 pi of the post heparin-agarose 
preparation using the standard assay conditions described in Section 4.2.1 except free 
divalent cation concentrations, as indicated, were established by means of computer 
calculated EGTA/cation buffering. Protein concentration of the post heparin-agarose 
PLD preparation was determined as desciibed in Section 2.2.1.
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Fig 4.4 pH Dependence of Solubilised PLD Reaction Velocity.
PLD reaction velocity was deteimined with 10 pi of tlie post heparin-agarose 
preparation using the standard assay conditions described in Section 4.2.1 except pH 
conditions, as indicated, were established using a multicomponent buffering system 
of 50 mM Acetate/Mes/Mops/Tricine, adjusted by addition of HCl or NaOH 
respectively. Protein concentration of the post heparin-agarose PLD preparation was 
determined as described in Section 2.2.1.
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Hepes in the standard assay protocol (Section 2.4) showed no significant alteration of 
the observed catalytic rate of the solubilised PLD (data not shown).
Increasing the pH of the reaction mixture from 5.0 to 9.0 resulted in the 
reaction velocity proceeding as a parabolic function of pH, maximal activity observed 
at pH 7.0 (Fig 4.4). Therefore, it would appear that the reaction rate of the solubilised 
PLD does not significantly fluctuate in the physiological pH range and does not alter 
significantly at the extremes of pH examined here.
4.5 Hydrolytic Activity: Identification of a Distinct Phospholipase D Activity,
The hydrolysis of membrane phospholipids by PLD activities results in the 
concomitant generation of PtdOH and free base. Therefore, in pursuit of the 
purification of a membrane-associated PtdCho-PLD activity, choline generation was 
utilised as a means of monitoring PLD hydrolytic activity. However, it was 
recognised that this did not unequivocally identify a PtdCho-PLD activity. A number 
of enzymes could potentially account for the liberation of free choline from a PtdCho 
substrate: firstly sequential PtdCho-PLC activity and a non-specific 
dephosphoiylation of the produced phosphocholine, secondly the sequential action of 
PtdCho-PLC activity and the specific dephosphorylation of phosphocholine to choline 
by means of a phosphocholine phosphatase and thirdly the direct generation of free 
choline may occur by means of base-exchange activity upon PtdCho.
These enzymatic events can be partly dispelled due to the lack of evidence in 
support of the existence of a specific phosphocholine phosphatase (Pelech & Vance,
’1989). Further, phospholipid base-exchange enzymes rely upon the provision of 
appropriate free base and are markedly stimulated by millimolar Ca^ "*' concentrations 
(Saito & Kanfer, 1975; Mori e ta l ,  1989). However, it was apparent from previous 
studies (see Section 4.3) that millimolar concentrations of Ca^+ appeared to partially
inhibit the hydrolytic activity of the partially purified PLD preparation (Fig 4.3A). 
To further address the potential contribution of these enzymatic pathways to
the generation of free choline, the reaction velocity of the solubilised PLD was
" i .
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assessed in the presence of free base and various concentrations of the general 
phosphatase inhibitor, sodium fluoride. When the reaction velocity of the solubilised 
PLD was measured utilising the standard assay conditions (Section 2.4) in the 
presence of 5 mM free choline, ethanolamine, inositol or serine, no significant 
alteration in specific activity was observed (Table 4.1). Further, in the combined 
presence of 0.1 mM Ca^+ no further modulation of the reaction velocity was observed 
(data not shown). This suggested that choline generation was not a consequence of 
phospholipid base-exchange activity. Inclusion of NaF, at concentrations of 1, 3 and 
10 mM was without effect (Table 4.1) and suggested that dephosphorylation of
Table 4.1 Hydrolytic Activity of Solubilised PLD in the Presence of 
Free Base and NaF.
Specific Activitv
Addition rpmol/min/mg)
None 22.85 ±1.9
5 mM choline 23.23 ±3.1
5 mM ethanolamine 21.70 ±2.4
5 mM inositol 21.98 ±3.0
5 mM serine 23.87 ± 1.4
1 mM NaF 22.98 ±1.7
3 mM NaF 23.68 ± 1.5
10 mM NaF 21.88 ±3.2
10 111 of post heparin-agarose preparation was assayed for PLD activity as outlined in 
Section 2.4, except the above additions were made to the incubation mixture. Protein 
concentration was determined as described in Section 2.2.1.
phosphocholine, if formed, played no role in the generation of free choline from the 
PtdCho substrate. Further, inclusion of l^C-labelled phosphocholine in the reaction
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did not alter the reaction velocity of the solubilised PLD and did not result in the 
generation of ^"^C-labelled choline (data not shown), discounting the possibility of 
dephosphorylation of phosphocholine, subsequent to PtdCho-PLC activity.
The unique ability of PLD activities to catalyse a transphosphatidylation 
reaction and in the presence of short chain aliphatic alcohols form 
phosphatidylalcohols (Dawson, 1967), has been ubiquitously utilised as a marker for 
receptor-activated PLD activity in whole cell studies (eg. Bocckino et al, 1987a & b; 
Liscovitch, 1989; Cook e ta l,  1991). Therefore, the possible formation of 
phosphatidylalcohols by the purified preparation was investigated. Presentation of 
substrate to the enzyme was approached in a number of ways utilising aqueous 
dispersions of tritium labelled or unlabelled PtdCho substrate in 2 mM EDTA pH 7.5 
or as mixed micelles with TX-lOO or n -octyl-p, D-glucoside, incubated in the 
presence of unlabelled ethanol or unlabelled butanol as appropriate. These conditions 
are summarised in Table 4.2.
Table 4.2 Summary of in vitro Assay Conditions Utilised for Observation of Cell 
Free PLD-catalysed Transphosphatidylation.
Assav Substrateform Lipid substrate Alcohol
1 Aqueous labelled unlabelled
dispersion PtdCho ethanol/butanol
2 Aqueous unlabelled labelled
dispersion PtdCho ethanol/butanol
3 Mixed micelles labelled unlabelled
(TX-lOO) PtdCho ethanol/butanol
4 Mixed micelles unlabelled labelled
(TX-lOO) PtdCho ethanol/butanol
5 Mixed micelles labelled unlabelled
(OG) PtdCho ethanol/butanol
6 Mixed micelles unlabelled labelled
(OG) PtdCho ethanol/butanol
(OG-/î-octyl-p, D-glucopyranoside)
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rate than that for PtdSer (Table 4.3).
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sUnder all of these conditions, the partially purified preparation failed to 
catalyse a transphosphatidylation reaction and no phosphatidylalcohol formation was 
observed. However, in the presence of TX-lOO the membrane-associated activity of 
bovine spleen catalysed PtdOH formation in the absence of catalysed 
transphosphatidylation, indicating a PLD reaction (M. Wakelam, personal 
communication). Similar results have also been observed with membrane-associated 
PLD from both rat brain and spleen (M. Wakelam, personal communication).
4.6 Phospholipid Substrate Specificity : Identification of a Distinct 
Phosphatidylcholine Specific Phospholipase D.
Whole cell studies have suggested the main substrate for PLD catalysed 
phospholipid hydrolysis is PtdCho. However, the hydrolysis of both PtdEtn and 
Ptdlns have been documented (see Section 1.8). In the context of purifying a PtdCho- 
specific PLD activity, the major phospholipid substrate specificity was determined. 
All the potential substrates, PtdCho, PtdEtn, Ptdlns and PtdSer, were prepared as 
mixed micelles of labelled and unlabeUed phospholipid with TX-lOO (0.1% w/v) at a 
fixed concentration (2.8 mol%) in a similar manner to that described in Section 2.4.
Recovery of total tritium labelled water soluble metabolites was utilised as an 
indication of phospholipase activity. The partially purified preparation from each 
stage of the purification protocol outlined in Chapter 3 was examined for hydrolytic
activity (Table 4.3). Material from the final gel filtration chromatographic step |i
exhibited activity towards PtdCho, PtdEtn and PtdSer and none towards Ptdlns. This 
final preparation appeared to be specific for PtdCho as substrate, exhibiting an 
approximate 20-fold higher rate of hydrolysis than that for PtdEtn and a 4-fold higher 3
I
Table 4.3 Phospholipid Hydrolysis by the Solubilised PLD.
Specific Activity ('pmol/min/mgl
Preparation PtdCho PtdEtn Ptdlns PtdSer
S - Sepharose 9.82+0.26 0.35+0.01 2.16+0.20 4.24+0.54
Heparin 25.32+2.76 0.55+0.02 4.17+0.40 9.22+0.23
HA 28.45±1.21 1.36+0.15 4.79+0.96 5.70+0.23
Mono - S 71.55+1.87 1.56+032 n.d. 30.90+11.36
Gel - filtration 74.40±5.19 4.00±0.96 n.d. 17.76±0.98
2-10 jil of enzyme preparation from each stage of the purification protocol was 
assayed for phospholipid hydrolysis in a similar manner to that described in Section 
2.4 except water soluble metabolites in the total aqueous phase were recovered as an 
indication of phospholipid hydrolysis. Protein concentration was determined as 
described in Section 2.2.1.(/î.t/.-none detected, HA-hydroxyapatite)
Further, the specific hydrolytic activity of total water soluble metabolite generation 
from PtdCho was comparable to the determined specific PLD activity of the post gel- 
filtration preparation as assessed by ^H-choline generation (see Table 3.3). Further 
characterisation of the water soluble metabolites formed upon catalysed PtdCho 
hydrolysis were assessed by ion-pair extraction as routinely utilised for determination 
of PLD catalysed ^H-choline formation during purification (Table 4.4). 
lon-pair extraction of the total aqueous products generated following hydrolysis of 
PtdCho by the post gel-filtration preparation confirmed choline to be the only 
aqueous soluble metabolite formed, neither phosphorylcholine nor 
glycerophosphocholine were formed (Table 4.4). However, the identification of the 
individual water soluble metabolites produced upon catalysed hydrolysis of the other 
major phospholipids was not determined and may represent not only a PLD catalysed 
mechanism, but other lipid hydrolysing activities. This may be consistent with the
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changing ratios of PtdCho: PtdEtn, PtdCho: Ptdlns and PtdCho: PtdSer hydrolysis 
observed throughout the purification protocols (see Table 4.5). Indeed, the maintained 
ratio of PtdCho: PtdEtn (approximately 1:0.04) may suggest that hydrolysis of both 
PtdCho and PtdEtn was catalysed by the same activity whilst that of PtdSer was by a 
different activity, distinct from the solubilised PLD as the ratio of PtdCho:PtdSer was 
observed to vary throughout the purification protocol.
Table 4.4 Recovery of Water Soluble Metabolites Generated Following 
Catalysed Hydrolysis of PtdCho.
Enzyme preparation 
Control 
post gel-filtration
dpm recovered in water 
soluble PtdCho metabolites.
dpm in 
glvcerophosphocholine 
/phosphocholine fraction dpm in choline fraction
4012+123 778+28
4342+345 5543+156
20 |ll1 of post-gel filtration enzyme or buffer were assayed for PtdCho hydrolysis in a 
similar manner to that described in Section 2.4 except following 
heptanone/tetraphenylboron ion-pair extraction of the total aqueous soluble products 
radioactivity recovered in the glycerphosphocholine/phosphocholine and choline 
fraction was determined by liquid scintillation counting.
3'
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Table 4.5 Ratio of Major Phospholipid Hydrolysis Relative to that of PtdCho.
Preparation PtdCho PtdEtn Ptdlns PtdSer
S-Sepharose 1 0.03 0.22 0.43
Heparin 1 0.02 0.16 0.36
HA 1 0.05 0.17 0.20
Mono-S 1 0.02 N.A. 0.43
Gel-filtration 1 0.05 N.A. 0.23
In conclusion, the partially purified preparation from each stage of the 
purification protocol displayed hydrolytic activity towards all of the major 
glycerophospholipids with differing and changing specificities. However, the final 
post gel filtration enzyme exhibited hydrolytic activity and distinct specificity 
towards PtdCho, observed as an apparent PLD activity.
4.7 Is The Membrane-Associated PLD of Bovine Spleen Regulated By a Small 
Molecular Weight G-protein ?
During the completion of the work towards this thesis it was reported that the 
small molecular weight G-protein, ARF was identified as a putative PLD activator 
(Brown et al, 1993; Cockcroft et al, 1994). Further studies also revealed the 
apparent involvement of other small molecular weight G-proteins of the Rho family 
in the regulation of PLD activity (Bowman et al.j 1993; Malcolm etaL, 1994). This 
questioned whether the bovine spleen enzyme described in this work could be 
activated in a similar manner. Experiments addressing this were initiated after SDS- 
PAGE analysis of fractions recovered during column chromatography showed they 
contained polypeptides of approximately 15-25 kDa (see Figs 3.14 & 3.15), the 
relevant molecular weight for members of the Ras superfamily of small molecular 
weight G-proteins (Downward, 1990; Hall, 1992).
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IInitial experiments conducted with post heparin-agarose material showed no J
sensitivity to ImM Mg^^-GTPyS in incubations under standard assay conditions with i
%or without bovine spleen cytosolic fraction as a potential source of small molecular 
weight G-proteins protein (Fig 4.5). This was attributed to the detergent conditions 
(0.1% (w/v) TX-lOO), known to be inhibitory to ARF activity and GTP binding by 
ARF (Bobak e ta l ,  1990). Incubation of detergent free post Mono-S PLD activity in 
the presence of detergent/lipid conditions known to be optimal for the ADP- 
ribosylation activity of ARF (0.2% (w/v) cholate, 2mM PtdCho; Bobak et a/., 1990) 
resulted in enhanced specific activity of the post Mono-S preparation relative to the 
same material assayed under standard conditions in the presence of TX-lOO (Fig 4.6).
Further, a modest 2-3 fold Mg^+-GTPyS dependent activation of PLD activity in the
;absence of cytosolic protein or in the presence of boiled cytosolic extract was 
observed (Fig 4.6). The inhibition of Mg-GTPyS-dependent activation of the post 
Mono-S preparation in the presence of crude cytosol may suggest the presence of an 
inhibitoi-y factor, active against the mediator of GTPyS-dependent activation. This 
suggested that the PLD preparation may potentially be regulated in a manner 
dependent upon small monomeric G-proteins.
4.8 Characterisation of the Solubilised Phospholipase D: Discussion and 
Summary.
The detergent/phosphatidylcholine mixed micelle may provide an artificial 
lipid/water interface resembling the surface of mammalian plasma membranes and 
therefore be applicable to the characterisation of cell free PLD activity. Based upon 
the kinetic and physical characteristics described by Dennis (1974), the 'surface 
dilution' kinetic scheme for lipid hydrolysing enzymes appeared appropriate for the 
solubilised PLD. Consequently, PLD activity was observed to be dependent on both 
the bulk and the surface concentration of PtdCho. Studies of both rat (Martin, 1988) 
and rabbit tissues (Kanoh et ai, 1991) utilising PtdCho/TX-100 micelles also
I
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Fig 4.5 Effect of Mg^+ GTPyS Upon Catalysed PtdCho Hydrolysis by the Post 
Heparin-agarose Preparation.
PLD reaction velocity was detemiined with 10 |il of the post heparin-agarose 
preparation under standard assay conditions as described in Section 4.2 in the 
presence and absence of 10 pg of crude cytosolic protein, 1 mM Mg^+, 1 mM Mg^" -^ 
GTPyS and 10 pg of denatured cmde cytosolic protein (boiled at lOO^C for 5 min) as 
indicated. Protein concentration of the post heparin-agarose PLD preparation was 
determined as described in Section 2.2.1.
Abbreviations used: Hep-post heparin-agarose PLD preparation; cyt-crude cytosolic 
fraction; GTP-GTPyS.
132
1
PMS(TX- 100)+MgGTP 
PMS (TX-lOO) 
PMS+boiled cyt+MgGTP 
PMS+boiled cyt+Mg 
PMS+boiled cyt 
boiled cyti PMS+cyt+MgGTP 
^  PMS+cyt+Mg 
PMS+cyt 
PMS+MgGTP 
PMS+Mg 
cyt 
PMS
100 200
— I—
300 400 500
Specific Activity (pmol/min/mg)
Fig 4.6 Effect of Mg^+ GTPyS Upon Catalysed PtdCho Hydrolysis by the Post 
Mono-S Preparation,
Substrate was prepared as mixed micelles of 0.1% (w/v) TX-100/2.8 mol% PtdCho 
under standard assay conditions as described in Section 2.4 or as a detergent/lipid 
dispersion of 0.2% (w/v) cholate/2 mM PtdCho. PLD reaction velocity was then 
determined with 10 pi of the post Mono-S preparation in the presence and absence of 
10 pg of crude cytosolic protein, 1 mM Mg^+, 1 mM Mg2+~GTPyS and 10 pg of 
denatured cmde cytosolic protein (boiled at 100°C for 5 min) as indicated. Protein 
concentration of the post Mono-S PLD preparation was determined as described in 
Section 2.2.1.
Abbreviations used: PMS-post Mono-S PLD preparation; cyt-cmde cytosolic 
fraction; GTP-GTPyS.
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described maximal PLD activity at a TX-lOO concentration of 0.05-0.1% (w/v); 
however, at higher concentrations of detergent activity was observed to decline. This 
may reflect dilution of substrate, which was not maintained at a fixed surface 
concentration as detergent concentration was increased. Therefore, the membrane- 
associated PLD activities of both rat and rabbit tissues appear to hydrolyse PtdCho in 
a similar manner to the partially puiified enzyme described here, though a potentially 
greater maximal hydrolytic activity may have been observed if the surface 
concentration was maintained in a similar manner to that proposed by Dennis (1974).
Application of Michaelis-Menten kinetics within this 'surface dilution' model 
did not allow estimation of both Vmax and Km values for the partially purified 
enzyme. Saturation 'zero order' kinetics were not obseiwed as TX-lOO could not 
maintain PtdCho substrate solubility above 50 mol% concentrations. In conclusion, 
the kinetics of the solubilised PLD were not extensively characterised within the 
'surface dilution' model. However, it may seiwe as a useful means of more thoroughly 
characterising the enzyme with regard to defined kinetic parameters (eg inteifacial 
Michaelis constant, dissociation constant for the mixed micelle binding site etc.), 
substrate specificity towards PtdCho of vaiying acyl chain structure and modulation 
of reaction velocity by lipid molecules (discussed further in Chapter 5) or putative 
inhibitor compounds. The lack of saturation kinetics may reinforce the proposed 
existence of an inhibitory modulator of the PLD activity present during cation- 
exchange and heparin-agarose chromatography as suggested in Section 3.5. Further, 
the recent identification of the small molecular weight G-protein, ARF, as a putative 
PLD activator (Brown et al, 1994, Cockcroft et al, 1994) may indicate a requirement 
for a GTP-dependent in vitro activation of the enzyme, potentially resulting in 
elevated in vitro specific activity.
The partially purified PLD was insensitive to the modulation of both free Ca^ "^  
and Mg2+ ions at physiologically relevant concentrations (0.1 |iM & 1 mM 
respectively). This is consistent with the similar reported insensitivity of the 
membrane-associated PLD activities of rat lung (Martin, 1988), rat brain (Kanoh et
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al, 1991) and canine brain (Qian et al, 1990). At high concentrations of Ca^+, 
inhibition of PLD reaction velocity was observed. In a similar manner, both Ca^+ and 
Mg2+ inhibited the membrane-associated activity of rat brain, but in a concentration 
dependent manner (Kanoh et al, 1991) and high millimolar concentrations of both 
Ca^+ and Mg^+ slightly inhibited the membrane-associated activities of canine brain 
and endothelial cells (Qian et al, 1990, Martin, 1988). Therefore, it would appear that 
a number of membrane-associated activities from various mammalian tissues display 
similar insensitivity to the modulation of divalent cations when reaction velocity is |
monitored by means of a mixed micellar assay utilising PtdCho and the non-ionic 
detergent TX-lOO and can be regarded as divalent cation-independent activities.
In contrast to the partially purified preparation, a number of other partially 
purified PLD activities display different sensitivity to the modulation of free divalent 
cation concentration. The partially purified cytosolic and membrane-associated 
activities of bovine lung were reported to be activated by Ca^+ in a concentration
%dependent manner, being maximal at 10 mM, however Mg^+ did not effect the £
activity of the cytosolic enzyme but inhibited the membrane-associated form in a yi
concentiation dependent manner (Wang et al, 1991). This difference may be :
?reconciled by the fact that the investigation of Wang and coworkers (Wang et a l ,
1991) relied upon the assessment of PLD activity by means of an
' - i ;
octylglucoside/PtdCho dispersion assay. Independent studies examining membrane- 
associated PLD activities of rat brain by means of similar PtdCho/oleate dispersion 
assays reported differing sensitivities to divalent cations. Kobayashi and Kanfer |
(1987) reported that under their assay conditions Ca^+ (up to 5 mM) and Mg^+ (up to
■10 mM) had no effect upon PLD reaction velocity whilst Chalifa et a l  (1990)
,■1’described a Mg^+ induced stimulation of PLD activity in vitro. Under the conditions
of this assay, inclusion of Mg^+ prolonged linear PLD activation which may suggest '
that divalent cation stabilizes enzyme activity or affects enzyme-substrate interaction.
Similarly, Okamura & Yamashita (1994) described in the recent purification 
of a 190kDa membrane-associated PLD of pig lung that PLD activity showed no
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absolute requirement for divalent cations yet their stimulatoiy effects were dependent 
upon the presence of fatty acid and may further suggest that interaction of lipid/fatty 
acid and divalent cation stabilizes enzyme activity as described by Chalifa et al 
(1990). It may be concluded that a number of different PLD activities exist in a 
number of tissues yet this may be influenced by the differing assay methodologies 
utilised for monitoring PLD activity in each of these studies. Indeed, the en virement 
within which the PtdCho substrate is presented to the enzyme may reflect the 
observed sensitivities to divalent cation modulation. Consequently, the mechanisms 
of activation or inhibition and whether these effects are upon the assay system or the 
enzyme itself remain to be clarified.
The partially purified bovine spleen enzyme displayed a pH optimum of 7.0. 
This was similar to the membrane-associated activities from various tissues described 
above, where PLD activity was monitored using a PtdCho/TX-100 mixed micellar 
assay in rat lung (Martin, 1988), rat brain (Kanoh et al, 1991) and canine brain (Qian 
et al, 1990) respectively. Chalifa e ta l  (1990) also described the membrane- 
associated PLD of rat synaptic membranes to display a neutral pH optimum (7.2). 
Despite the use of a similar PtdCho/oleate dispersion assay, this contrasted with the 
reports of Kobayashi & Kanfer (1987) and Okamura & Yamashita (1994) whereby 
similar investigation utilising rat brain and pig lung extracts displayed an acidic pH 
optimum (6.5). However, in the investigations of Chalifa and coworkers it was 
apparent that different buffering agents were utilised. Consequently, description of 
both acidic (Kobayashi & Kanfer, 1987) and neutial PLD activities (Chalifa et al.
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1990) of rat brain may reflect this and further evidence is required to address whether 
this represents the same or distinguishable enzymic entities.
Hydrolysis of L-3-phosphatidyl [N-methyl-^H] choline by the partially
purified preparation showed ^H-choline to be the only water soluble metabolite 
generated. Further, this was not secondary to glycerophosphocholine or :S
phosphocholine formation and was not as a result of phospholipid base-exchange 
activity. This suggested the partially purified preparation to be a distinct PLD activity.
A unique feature of PLD enzymatic activity is the ability to catalyse a 
transphosphatidylation reaction and in the presence of primary aliphatic alcohols the 
formation of phosphatidylalcohols. The ability of the partially purified preparation to 
catalyse such a reaction was examined. However, under all of the assay conditions 
utilised no formation of phosphatidylalcohols was observed. This questioned the 
integrity of the partially purified preparation as a PLD enzyme, however, the ability 
of lipid free partially purified preparations to catalyse transphosphatidylation requires 
specific assay conditions. The conditions of substrate presentation, ionic strength, 
buffering systems, pH and presence of a membrane-like enviroment subtly influence 
the observation of in vitro transphosphatidylation (J. N. Kanfer, personal 
communication). Additionally, the competition of short chain primaiy alcohols with 
water in the transphosphatidylation reaction in an in vivo situation relative to that in 
an in vitro assay system may be more favourable to phosphatidylalcohol formation 
and consequently indicate the potential requirement for an intact membrane lipid 
environment to allow intercalation of alcohols and accesss to the enzyme active site. 
Hence these factors may reflect the inability of the partially purified preparation to 
catalyse ti’ansphosphatidylation in this study.
In examining the activity of the partially purified PLD towards different 
phospholipids, specificity towards PtdCho was obseiwed. Hydrolysis of both PtdEtn 
and PtdSer were apparent though to a much lesser extent. Ptdlns was not a substrate 
for the partially purified PLD. This is consistent with the observed profile of 
phospholipid hydrolysis in rat microsomes, where PtdCho appeared to be the 
prefened substrate for PLD and both PtdEtn and PtdSer gave relatively small 
activities (Horwitz & Davis, 1993), Despite partially purified PLD from rat brain 
microsomes (Taki & Kanfer, 1979; Kobayashi & Kanfer, 1987) and purified pig lung 
PLD (Okamura & Yamashita, 1994) displaying similar characteristics in divalent 
cation sensitivity, pH optima and detergent effects in a PtdCho/oleate dispersion 
assay the profile of phospholipid hydrolysis was inconsistent. Absolute PtdCho 
specificity was observed for the microsomal PLD purified from pig lung (Okamura &
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Yamashita, 1994) whereas the enzyme preparation described by Taki & Kanfer 
utilised both PtdCho and PtdEtn, with PtdEtn giving a higher enzymatic V^ax than 
PtdCho. This discrepancy remains to be clarified though confirmation of absolute 
PtdCho specificity has been reported for octylglucoside solubilised membrane PLD of 
bovine lung (Wang et al, 1991). A cytosolic PLD activity from bovine lung was also 
described by Wang et al, (1991) and displayed broader phospholipid substrate 
specificity, hydrolysing PtdEtn> PtdCho > Ptdlns. This may represent the existence of 
multiple PLD isoforms though how this relates to other activities in other tissues 
assayed under vaiying conditions remains unclear. Whole cell studies have described 
PLD catalysed hydrolysis of phospholipids in response to agonists. This has included 
the stimulated hydrolysis of PtdCho, PtdEtn and Ptdlns (see Section 1.8). Direct 
comparison of these activities and the ones described above awaits purification to 
homogeneity of each of these individual activities, assessment of their substrate 
specificity and elucidation of their regulation upon reconstitution. Purification of 
microsomal PLD from pig lung (Okamura & Yamashita, 1994) has allowed 
confirmation of a PtdCho-specific PLD activity while purification of further PLD 
activities will allow assignation of PtdCho-specific, Ptdlns-specific, PtdEtn-specific 
or general phospholipid-PLD nomenclature.
In addition to the characterisation of the kinetics of PLD activity under 
defined detergent/substrate conditions it was also evident that the partially purified 
preparation recovered during Mono-S cation-exchange chromatography appeared 
sensitive to incubation in the presence of Mg^+-GTPyS . Under modified 
detergent/substrate conditions PLD hydrolytic activity was enhanced approximately 
2-fold. This suggested that a small molecular weight G-protein was present in the post 
Mono-S preparation and the modified assay conditions may reflect the desired 
protein/üpid/detergent conformational requirements for effective GTP binding of a 
small molecular weight G-protein, its activation of PLD or its interaction with an 
unidentified intermediate protein required for activation of PLD. This may be 
consistent with the reported activation of PLD activities by ARF and members of the
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weight G-proteins, however, this remains tentative as further development of initial
Rho subclass of the Ras superfamily of small molecular weight G-proteins (Brown et 
ai, 1993; Bowman e ta l,  1993; Cockcroft etal,  1994; Malcolm et ai,  1994). 
Inhibition of enhanced in vitro activity was also evident in the presence of crude 
cytosol and may suggest that the crude cytosolic fraction of bovine spleen contains an 
inhibitory factor relevant to the regulation of in vitro PLD hydrolytic activity. Similar 
reports of cytosol-mediated inhibition of m vitro activity of membrane-associated 
PLD partially purified from HL-60 cells and porcine brain have been described 
(Brown e ta l ,  1993; Brown et al,  1995). However, the data described above 
represent the results from successive purification protocols and requires further 
investigation and characterisation. Additionally, the presence of a small molecular 
weight G-protein in the post Mono-S preparation requires confirmation by Western 
blotting techniques or GTP-binding experiments and therefore the activation of the 
bovine spleen PLD in a GTP-dependent manner remains speculative.
In summary, the solubilised PLD appeared to conform to the 'surface dilution' 
kinetic model proposed by Dennis and coworkers, however, the Vmax and hence Km 
for the enzyme could not be determined from the observed pseudo-first order kinetics 
despite the enzyme exhibiting concentration dependence upon PtdCho. This 
characteristic has yet to be reconciled with other PLD and lipid metabolising enzymes 
but may represent the kinetics of a partially active or inhibited enzyme (discussed 
further in Chapter 5). The reaction rate showed no dependence upon the presence of 
divalent cations and remained insensitive to any alteration over physiological 
concenti'ation ranges and a pH optima of 7.0. In addition, the partially purified 
preparation displayed distinct PLD activity with specificity to PtdCho hydrolysis in 
accordance with the original aims of the work conducted towards this thesis. Finally, 
the partially purified preparation may be subject to regulation by small molecular
s
studies are required.
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Chapter 5 
Final Discussion.
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5.1 Existence of Multiple PLD Isoenzymes.
Cation-exchange chromatography performed during the purification protocol 
described in this thesis routinely resulted in the separation of two PtdCho-hydrolysing 
enzymes (see Section 3.4) and may suggest the presence of two related PLD isoforms 
in bovine spleen. However, the additional activity was recovered as unbound material 
during cation-exchange chromatography and was not biochemically characterised |
further. It remains unclear as to whether this activity represents an additional PtdCho- 
specific PLD, a general glycerophospholipid-hydrolysing PLD activity or a physically : £
modified but related form of the PLD activity. The existence of two independent PLD 
isoenzymes in rat brain was suggested by Kanoh et al. (1991) and multiple PLD 
activities, active against various phospholipids are apparent, though their inter­
relationship and similarities remain unclear. Plasma membrane PLD preparations J
have been shown to preferentially metabolise PtdCho presented in detergent micelles, 
while microsomal preparations have been shown to preferentially hydrolyse PtdCho |
presented as a dispersion with fatty acid (eg. Kanoh et at, 1991). This suggested i
existence of distinct PLD isoforms has been clarified by the separation and
4identification of two distinguishable PLD activities in TX-lOO-solubilised rat brain 
membranes chromatographed on heparin-5PW (Massenberg et al,  1994). One PLD 
form was completely dependent upon sodium oleate for activity and similar to the 
190kDa PLD subsequently purified to homogeneity from pig lung (Okamura &
Yamashita, 1994) and the other was markedly activated by the addition of purified 
ARF protein and GTPyS in the presence of Ptdlns(4, 5)P2 (Massenburg et al,  1994). 
Identification of distinguishable PLD activities from the same tissue may allow 
subsequent purification and characterisation of members of a putative PLD isoenzyme 
family. Clearly the relationship between the isoforms of PLD would be clarified by 
understanding the role of these enzymes within cells.
5.2 Functional Significance of PLD Activity.
The identification and characterisation of at least two PLD isoforms may 
reflect the cell's use of PtdCho in multiple metabolic processes. PtdCho represents 
approximately 50% of the total cellular phospholipid and within it there may be
the generation of PtdOH for second messenger functions such as the control of the 
cytoskeleton and the respiratory burst (see Section 1.9) but also in the maintenance 
and metabolism of cellular PtdCho as part of the Kennedy pathway. However, which 
of the PLD isoforms is involved in signalling and which is involved in general 
biosynthesis of PtdCho remains unclear. Whether, for example, it is the ARF 
activated, Ptdlns(4, 5)P2 sensitive PLD that is responsible for PtdCho turnover in 
response to agonists is not known since further molecular details are required to relate 
structure to function amongst PLD isoforms.
Recently a model for the co-ordinate regulation of PLD activity with that of 
ARF and the phosphoinositide kinases has been proposed to regulate cellular 
membrane trafficking events (see Section 1.11.4), This may not only reflect 
movement of cellular lipids by means of lipid vesicle trafficking but also cellular 
proteins. However, it remains uncleai* as to whether such an integrated transport 
model is relevant in vivo and sensitivity to agonist stimulation remains to be 
demonstrated.
Ptdlns(4, 5)P2 would appear to function as a PLD cofactor and now questions 
the role of Ptdlns(4, 5)P2, its synthesis and its degradation in regulating PLD 
activation. The requirement for successful interaction of PLD with Ptdlns(4, 5)P2, 
whether direct or indirect, may further suggest the potential involvement of 
cy to skeletal proteins such as gelsolin and profilin, known to bind Ptdlns(4, 5)P2 
(Goldschmidt-Clermont et al, 1990), in the regulation of PLD activity. Additionally, 
a 100 amino acid module within the cytoskeletal protein pleckstrin, defined as a 
pleckstrin homology (PH) domain, that is conserved in a number of proteins involved 
in signal transduction has been implicated in their membrane localisation. Within this
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metabolic compartmentation. PLD activities may therefore not only be involved in
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6domain is a lipid binding site confeiiing interaction with membrane Ptdlns(4, 5)P2 
(Harlan et a l, 1994). Such a domain structure may be present in PLD and 
consequently influence its cellular localisation. However, it is also apparent that ARF, 
in common with other known signal transduction and cytoskeletal proteins such as 
cPLA2, PLCs, the catalytic subunit of Ptdlns 3-kinase, gelsolin and villin contains an 
amino acid sequence (-R/KXKK-) that apparently confers Ptdlns(4, 5)P2 binding (M, 
Hodgkin & P. Hughes, personal communication). Therefore, the cofactor requirement 
of Ptdlns(4, 5)P2 in the activation of ARF-sensitive PLD may indeed reflect direct 
lipid regulation of ARF activity and consequently activation of PLD.
The sensitivity of the bovine spleen PLD described in this work to other 
phospholipids including Ptdlns(4, 5)P2 has not been investigated, however, the 
micellar conditions described in the characterisation of this hydrolytic activity (see 
Section 4.2) would easily allow its assessment as a potential activator.
5.3 A Reappraisal of the Regulation of Receptor-mediated PLD Activation.
Although a number of the signalling mechanisms involved in the regulation of 
receptor-stimulated PLD activiation, including GTP-binding proteins, 
phosphoinositide hydrolysis, and PKC activation, have been identified and 
extensively characterised, it is apparent that other potential mechanisms of regulation 
of PLD activities may exist. This has been illustrated by recent cell free studies. In 
particular, a number of anomalies have arisen between the considered established 
mechanisms of PLD regulation in whole cells studies and observations in cell free 
assays. This has questioned the nature of the regulation of agonist-stimulated PLD 
activation and highlighted an alternative interpretation for the observations made in 
whole cells.
In a number of cell types it has been extensively reported that PKC activation 
plays a major role in the regulation of agonist-stimulated PLD activation. The ability 
of tumour promoting phorbol esters to activate PLD-catalysed phospholipid 
hydrolysis, the use of PKC inhibitors and phorbol ester-mediated down regulation of
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PKC expression has confirmed PKC involvement in PLD regulation in a number of 
cell types. This may be mediated by PKC catalysed phosphorylation of either PLD 
itself or an intermediate protein required for PLD activation. Despite this, phorbol 
ester-stimulated activation of PLD in membranes of hamster lung fibroblasts has been 
suggested to occur in an ATP-independent manner (Conricode et al, 1992). This 
contrasts with studies utilising PKC inhibitors, which are generally active against the 
ATP binding site of PKC isoforms, that block PLD activation. This may suggest that 
phorbol ester-stimulated activation of PLD may be mediated by alternative protein 
targets for phorbol esters that are not protein kinases. A number of proteins have high 
amino acid sequence identity with the cysteine-rich lipid/phorbol ester binding 
domain of PKC isoforms and therefore represent novel functional receptors for 
phorbol esters (Ahmed et a l, 1991). This includes 7%-chimaerin (Ahmed et a l, 1993) 
which functions as a Rac-GTPase activating protein and Vav, a potential GDP/GTP 
exchange factor (GEF) for the Ras-related Rho subfamily of small molecular weight 
G-proteins (Feig, 1994). The relative contribution or involvement of these proteins to 
the activation of PLD in stimulated cells remains to be assessed, but may represent an 
alternative mechanism of regulation. However, it is interesting to note that Rho has 
been suggested to be upstream of PLD (Bowman et a l, 1993; Malcolm et al, 1994), |
thereby providing a possible link between phorbol ester regulated PLD in vivo and 
small molecular weight G-proteins.
The in vitro activation of PLD by ARF is now well established. The
.-«Îinvolvement of this monomeric G-protein would suggest that, in common with other
5small molecular weight G-proteins of the Ras superfamüy such as Rho (Feig, 1994), 
the exchange of GDP for GTP upon ARF, catalysed by a guanine-nucleotide 
exchange factor (GEF), is required for ARF activation. A golgi membrane-bound 
GEF for ARF derived from CHO cells (Donaldson et a l, 1992) and rat liver (Helms 
& Rothman, 1992) has been described and this activity is sensitive to the fungal 
metabolite Brefeldin A (Donaldson et a l, 1992; Helms & Rothman, 1992). Brefeldin
I
A has been a powerful tool for investigating membrane trafficking, however, its effect
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upon the regulation of PLD activity in whole cells has not been determined. The 
contribution of ARF activation to agonist-stimulated PLD activation in a wide range 
of cell types would need to be ascertained to assess whether this represents a universal 
regulatory mechanism common to a number of receptor agonists.
5.4 Is The Membrane-Associated PLD of Bovine Spleen Regulated By a Small 
Molecular Weight G-protein ?
During the completion of the work towards this thesis it was reported that the 
small molecular weight G-proteins, ARF and Rho were identified as putative PLD 
activators (Brown et al, 1993; Bowman et a l, 1993; Cockcroft e ta l, 1994; Malcolm 
et a l, 1994). However, whether the bovine spleen enzyme described in this work 
could be activated in a similar manner remains an open question. SDS-PAGE analysis 
of fractions recovered during column chromatography showed they contained 
polypeptides of approximately 15-25 kDa (see Fig 3.14 & 3.15), the relevant 
molecular weight for members of the Ras superfamily of small molecular weight G- 
proteins (Downwaid, 1990; Hall, 1992).
5.5 A Number of Proteins Co-purify with PLD Activity ?
Partial purification of the solubilised PLD routinely generated a preparation 
that also contained a haem binding protein. The absorption spectra of this preparation 
was similar to the spectra generated upon scanning of purified cytochrome bsss (cyt 
b558) from human neutrophils under similar conditions (Harper et a l, 1984). 
Therefore, a putative cyt bg^g appeared to co-purify with PLD activity. In a number of 
studies of haematopoetic type cells a temporal relationship between PLD activity and 
superoxide generation mediated by the formation of the respiratoi*y burst complex has 
been described (Koenderman et a l, 1989; Rossi et al, 1990; Thompson et ai, 1990; 
Agwu et al, 1991b) placing receptor-mediated activation of PLD kinetically 
upstream of superoxide production.
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Although further studies are required in support of these initial observations it 
remains intriguing to speculate about the relationship of the respiratory burst proteins 
and their apparent co-purification with the partially purified PLD. Further, with the 
recent description of PLD activation by small molecular weight G-proteins of the Rho 
sub-class in human neutrophils and hepatocytes (Bowman et al, 1993; Malcolm et 
a l, 1994), the nature of small molecular weight G-protein-mediated signalling events 
may require reappraisal. This may represent a divergence in their activation of 
multiple effector molecules or their required involvement in PLD activation with a 
potentially causal role in the assembly and activation of the respiratoiy burst complex. 
Additionally, this may be indirectly related to the potential activation of the partially 
purified PLD in a GTP-dependent manner.
5.6 An Alternative Strategy to the Purification of the Phosphatidylcholine- 
Specific Phospholipase D.
Purification of mammalian PLDs has relied primarily upon effective 
solubilisation of membrane-associated activities, by means of detergent treatment or 
hypotonic salt washing and subsequent chromatography. Whilst this approach has 
allowed the partial purification of membrane-associated activities from a number of 
rat and bovine tissues and the purification to homogeneity of a microsomal PLD of 
pig lung (Okamura & Yamashita, 1994) a number of alternative approaches to 
identification and purification of PLD isofonns could be investigated. As described in 
Chapter 3, a more direct means of PLD isolation could be initiated by substrate 
photoaffinity labelling and substrate affinity chromatography. However, the general 
hydrophobicity of an immobilised lipid substrate, such as PtdCho, possesses 
particular problems for aqueous chromatography (M.Hodgkin, personal 
communication). Further, crude or partially purified extracts may be detrimental to 
the formation of specific substrate-enzyme interactions and therefore requires careful 
appraisal.
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The identification of the small molecular weight G-protein, ARF as a putative 
PLD activator in HL-60 granulocytes (Brown et a i, 1994; Cockcroft et al, 1994) and 
the potential involvement of other small molecular weight G-proteins of the Rho 
subclass in PLD activation (Bowman e ta l, 1993; Malcolm eta l, 1994) have allowed 
partial elucidation of the mechanisms regulating in vitro PLD activity. However, it 
remains to be established whether the activation of PLD by small monomeric 
GTPases is mediated by direct interaction with PLD or via interaction with another 
intermediate protein. If the interaction is indeed a direct one then a number of 
chromatographic approaches could be taken towards the purification of the PLD. The 
immobilisation of purified small molecular weight G-proteins on a suitable 
chromatographic support and exposure to solubilised par tially purified PLD has been 
attempted. Extracts from HL-60 granulocytes, were passed through a column of 
recombinant ARF in the presence of GTPyS. However, there was no detectable loss of 
PLD activity from the loaded extracts or recovery of PLD activity following a number 
of elution protocols (A. Martin; G. Thomas, personal communications). This data 
highlights the possibility that the ARF activation of PLD is indirect and successful 
affinity chromatography may require the presence of other factors eg. Ptdlns(4, 5)P2 
or an appropriate guanine-nucleotide exchange protein to catalyse GDP/GTP 
exchange upon ARF. Recently it has been observed that a PLD activity prepared from 
HL-60 membranes is insenstive to activation by ARF (and GTP) unless a cytosolic 
fraction prepared by anion-exchange is present. This data implies that ARF activation 
of PLD requires at least one more component found in cytosol and possibly 
membranes (M. Hodgkin, personal communication). This is an important 
consideration since the ARF activated PLD has only been partially purified (Brown et 
a l, 1993; 1995). Several recent reports have identified a 50kDa protein that also 
activates PLD and synergy between ARF and other cytosolic PLD activators has been 
suggested (Lambeth et a l, 1995; Bourgoin et a l, 1995). Clearly the exact nature of 
the GTP dependent step in the regulation of PLD remains contentious.
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If ARF-mediated activation of PLD is indirect, then the use of 
chromatography of this nature in combination with the pseudo-reconstitution assay 
utilised for the initial identification of ARF as a PLD activator in HL-60 granulocytes 
(Cockcroft et a l, 1994) may serve as a means of purifying activators or enhancers of 
PLD activity. It is not known whether this approach could be taken towards 
purification of the PtdCho-specific PLD described in this work, though it would 
appear from initial investigations that the partially purified enzyme from bovine 
spleen may be activated in a GTP-dependent fashion, potentially mediated by a small 
molecular weight G-protein.
5.7 Purification of the Phosphatidylcholine-Specific Phospholipase D: Long- 
Term Aims of the Project.
The aim of purifying the PtdCho-specific PLD to homogeneity was to provide 
protein sequence data that would ultimately allow the construction of oligonucleotide 
probes to screen a bovine spleen cDNA libraiy. Subsequent screening would allow 
the isolation and sequencing of a full length cDNA for PLD. Currently, sequences 
from PLD activities from species such as yeast are being utilised to screen human 
cDNA libraries for mammalian PLD enzymes (M.Wakelam, personal 
communication).
Comparison of the sequence generated for the PtdCho-specific PLD to those 
generated for other phospholipases and lipid hydrolysing enzymes may also allow the 
initiation of stracture/function studies and the possible elucidation of protein motifs or 
domains expressed by the PLD in common with these enzymes. The possiblity of a 
PLD family could also be investigated using PLD specific DNA sequences.
In addition to molecular biological studies, the purification of the PtdCho- 
specific PLD would allow the production of antisera. The development of activating, 
neutralising or identifying antisera would allow the initiation of cellular experiments 
to examine the role, function and localisation of the PtdCho-specific PLD in quiescent 
and agonist-stimulated cells.
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